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Abbreviations 
 
BL:  Bioluminescence 
BLI:  Bioluminescence Imaging 
ca-MRSA: Community-acquired Meticillin resistant Staphylococcus aureus 
CCD:  Charge coupled device 
CFU:  Colony forming units 
CLIO:  Cross-linked iron oxide nanoparticles 
CSI:  Chemical Shift Imaging (MRI Sequence) 
d:  day 
DOPE:  1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine 
FL:  Fluorescence 
FLI:  Fluorescence Imaging 
ha-MRSA: Hospital-acquired Meticillin resistant Staphylococcus aureus 
HE:  Hematoxylin – Eosin staining 
IVIS:  In Vivo Imaging System (Bioluminescence and Fluorescence Imaging platform) 
la-MRSA: Livestock-associated Meticillin resistant Staphylococcus aureus 
MR:  Magnetic Resonance 
MRI:  Magnetic Resonance Imaging 
MRSA:  Meticillin resistant Staphylococcus aureus 
NaCl:  Sodium chloride solution 
p.a.:  post administration 
PFC:  Perfluorocarbon emulsion 
p.i.:  post infection 
S. aureus:  Staphylococcus aureus 
SSFP:  Steady-state free precession 
TSE:  Turbo Spin Echo (MRI Sequence) 
USPIO:  Ultrasmall paramagnetic iron oxide nanoparticles 
VISA:  Vancomycin intermediate Staphylococcus aureus 
VRSA:  Vancomycin resistant Staphylococcus aureus 
 
  
2 Abstract 
Abstract 
 
Staphylococcus aureus is a major threat to public health systems all over the globe. This 
second most cause of nosocomial infections is able to provoke a wide variety of different 
types of infection in humans and animals, ranging from superficial skin and skin structure 
infections to invasive disease like sepsis or pneumonia. But not enough, this pathogen is also 
notorious in acquiring and/or developing resistance to antimicrobial compounds, thus 
limiting available treatment options severely. Therefore, development of new compounds 
and strategies to fight S. aureus is of paramount importance. But since only 1 out of 5 
compounds, which entered clinical trials, becomes a drug, the preclinical evaluation of 
promising compounds has to be reconsidered, too. The aim of this thesis was to address 
both sides of this problem: first, to improve preclinical testing by incorporating in vivo 
imaging technologies to the preclinical testing procedure in order to acquire additional and 
clearer data about efficacy of promising compounds and second, by evaluating lysostaphin, 
which is a promising, new option to fight S. aureus infections. 
The first aim of this thesis focused on the establishment of a dual modality in vivo imaging 
platform, consisting of Bioluminescence Imaging (BLI) and Magnetic Resonance Imaging 
(MRI), to offer detailed insights into the course and gravity of S. aureus infection in the 
murine thigh infection model. Since luciferase-expressing S. aureus strains were generated in 
former studies and enabled thus bioluminescence imaging of bacterial infection, this 
technology should be implemented into the compound evaluation platform in order to non-
invasively track the bacterial burden over time. MRI, in contrast, was only rarely used in 
earlier studies to visualize and measure the course of infection or efficacy of anti-bacterial 
therapy. Thus, the first set of experiments was performed to identify benefits and drawbacks 
of visualizing S. aureus infections in the mouse model by different MR methods. Native, 
proton-based MR imaging showed in this regard increased T2 relaxation times in the infected 
thigh muscles, but it was not possible to define a clear border between infected and 
uninfected tissue. Iron oxide nanoparticles and perfluorocarbon emulsions, two MR contrast 
agents or tracer, in contrast, offered this distinction. Iron oxide particles were detected in 
this regard by their distortion of 1H signal in proton-based MRI, while perfluorocarbon 
emulsion was identified by 19F MRI. Mammals do not harbor sufficient intrinsic amounts of 
19F to deliver specific signal and therefore, 19F MR imaging visualizes only the signal of 
administered perfluorocarbon emulsion. The in vivo accumulation of perfluorocarbon 
emulsion can be imaged by 19F MRI and overlayed on a simultaneously acquired 1H MR 
image, which shows the anatomical context in clear detail. Since this is advantageous 
compared to contrast agent based MR methods like iron oxide particle-based MRI, further 
experiments were performed with perfluorocarbon emulsions and 19F MRI. 
Experimental studies to elucidate the accumulation of perfluorocarbon emulsion at the site 
of infection showed robust 19F MR signals after administration between day 2 and at least 
day 8 p.i.. Perfluorocarbon emulsion accumulated in all investigated mice in the shape of a 
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‘hollow sphere’ at the rim of the abscess area and the signal remained stable as long as the 
infection prevailed. In order to identify the mechanism of accumulation, flow cytometry, cell 
sorting and histology studies were performed. Flow cytometry and cell sorting analysis of 
immune cells at the site of infection showed that neutrophils, monocytes, macrophages and 
dendritic cells carried contrast media at the site of infection with neutrophils accounting for 
the overwhelming portion of perfluorocarbon signal. In general, most of the signal was 
associated with immune cells, thus indicating specific immune cell dependent accumulation. 
Histology supported this observation since perfluorocarbon emulsion related fluorescence 
could only be visualized in close proximity to immune cell nuclei. 
After establishing and testing of 19F MRI with perfluorocarbon emulsions as infection imaging 
modality, the effects of antibiotic therapy upon MR signal was investigated in order to 
evaluate the capability of this modality for preclinical testing procedure. Thus, the efficacy of 
vancomycin and linezolid, two clinically highly relevant anti - S. aureus compounds, were 
tested in the murine thigh infection model. Both of them showed reduction of the colony 
forming units and bioluminescence signal, but also of perfluorocarbon emulsion 
accumulation strength and volume at the site of infection, which was visualized and 
quantified by 19F MRI. The efficacy pattern with linezolid being more efficient in clearing 
bacterial infection was shown similarly by all three methods. In consequence, 19F MRI with 
perfluorocarbon emulsion as MR tracer proved to be capable to visualize antibacterial 
therapy in preclinical testing models. 
The next step was consequently to evaluate a promising new compound against S. aureus 
infections. Thus, lysostaphin, an endo-peptidase that cleaves the cell wall of S. aureus, was 
tested in different concentrations alone or in combination with oxacillin for efficacy in 
murine thigh and catheter associated infection models. Lysostaphin only in the 
concentration of 5 mg/kg body weight or combined with oxacillin in the concentration of 2 
mg/kg showed strong reduction of bacterial burden by colony forming unit determination 
and bioluminescence imaging in both models. The perfluorocarbon accumulation was 
investigated in the thigh infection model by 19F MRI and was strongly reduced in terms of 
volume and signal strength in both above-mentioned groups. In general, lysostaphin showed 
comparable or superior efficacy than vancomycin or oxacillin alone. Therefore, further 
development of lysostaphin for the treatment of S. aureus infections is recommended by 
these experiments. Overall, the antibiotic efficacy pattern of all applied antibiotic regimens 
was similar with all three applied methods, demonstrating the usefulness of MRI for 
antibiotic efficacy testing. Importantly, treatment with oxacillin either alone or in 
combination with lysostaphin resulted in stronger perfluorocarbon emulsion accumulation 
at the site of infection than expected compared to the results from bioluminescence imaging 
and colony forming unit determination. This might be an indication for immunomodulatory 
properties of oxacillin. 
Further murine infection experiments demonstrated in this context a differential release of 
cytokine and chemokines in the infected thigh muscle in dependence of the applied 
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antibacterial therapy. Especially treatment with oxacillin, but to a less degree with 
minocycline or linezolid, too, exhibited high levels of various cytokines and chemokines, 
although they reduced the bacterial burden efficiently. In consequence, possible 
immunomodulatory effects of antibacterial compounds have to be taken into account for 
future applications of imaging platforms relying on the visualization of the immune 
response. However, this observation opens a new field for these imaging modalities since it 
might be extraordinary interesting to study the immunomodulatory effects of compounds or 
even bacterial factors in vivo. And finally, a two modality imaging platform which combines 
methods to visualize on the one hand the bacterial burden and on the other hand the 
immune response offers an innovative, new platform to study host-pathogen interaction in 
vivo in a non-invasive fashion. 
In summary, it could be shown that perfluorocarbon emulsions accumulate in immune cells 
at the site of infection in the murine S. aureus thigh infection model. The accumulation 
pattern shapes a ‘hollow sphere’ at the rim of the abscess area and its size and 
perfluorocarbon content is dependent on the severity of disease and/or efficacy of antibiotic 
therapy. Thus, 19F MRI with perfluorocarbon emulsions is a useful imaging modality to 
visualize sites and course of infection as well as to evaluate promising antibacterial drug 
candidates. Furthermore, since the accumulation of tracer depends on immune cells, it 
might be additionally interesting for studies regarding the immune response to infections, 
auto-immune diseases or cancer, but also to investigate the efficacy of immunomodulatory 
compounds and immunization. 
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Zusammenfassung 
 
Staphylococcus aureus ist als zweithäufigste Ursache nosokomialer Infektionen eine ernste 
Bedrohung für Gesundheitssysteme weltweit. Dieses Pathogen ist in der Lage eine Vielzahl 
verschiedener Krankheitsformen, von oberflächlichen Wund- und Gewebsinfektionen bis hin 
zu invasiven Erkrankungen wie Bakteriämie oder Pneumonie, in Mensch und Tier zu 
verursachen. Zudem erwies sich dieser Krankheitserreger in der Vergangenheit als höchst 
anpassungsfähig durch den Erwerb oder die Entwicklung von Resistenzen gegenüber 
antibakterieller Substanzen, wodurch die Verfügbarkeit wirksamer Therapiemöglichkeiten 
drastisch eingeschränkt wurde. Aus diesem Grund ist die Entwicklung neuer Antibiotika und 
Behandlungsstrategien gegen S. aureus Infektionen von enormem gesellschaftlichem 
Interesse. Da aber lediglich eine von fünf Substanzen, die in klinische Studien eintreten, 
später als Medikament zugelassen wird, sollte die präklinische Evaluierung neuer, 
vielversprechender Therapeutika ebenso verbessert und überdacht werden. Diese 
Doktorarbeit addressiert in diesem Zusammenhang beide Facetten: zum einen wurde durch 
Einbeziehung von in vivo Bildgebungstechnologien ein deutlicheres Bild von der Effizienz 
neuer Substanzen während der präklinischen Evaluierung ermöglicht, zum anderen wurde 
mit Lysostaphin eine neuartige Substanzklasse zur Behandlung von S. aureus Infektionen 
getestet. 
Primärziel dieser Arbeit war deshalb die Entwicklung und Etablierung einer dualen 
Bildgebungsplattform bestehend aus Biolumineszenz- (BLI) und Kernspintomografischer 
(MRI) Bildgebung, um detaillierte Einblicke in Verlauf und Schwere von S. aureus Infektionen 
im Muskelinfektionsmodell der Maus zu ermöglichen. Die Biolumineszenzbildgebung 
bakterieller Infektionen wurde durch die Entwicklung von Luziferase-exprimierenden S. 
aureus Stämmen bereits in früheren Arbeiten ermöglicht und wurde in die 
Bildgebungsplatform integriert, um die Entwicklung der Bakterienlast nicht-invasiv verfolgen 
zu können. Kernspintomografie wurde in früheren Arbeiten hingegen kaum zur Darstellung 
der Effizienz anti-bakterieller Therapien während der Präklinik verwendet. Aus diesem Grund 
dienten die ersten Experimente zur Erkennung von Vor- und Nachteilen der Darstellung von 
S. aureus Infektionen im Tiermodell durch verschiedene Kernspintomografische 
Bildgebungsmethoden. Native, Protonen-basierte Kernspintomografie wies verlängerte T2 
Relaxationszeiten im infizierten Muskelgewebe nach, doch eine klare Eingrenzung des 
infizierten Bereiches war nicht möglich. Die Anwendung von Eisenoxid und Perfluorcarbon 
Nanopartikeln, zwei Kontrastmittel zur Kernspintomografie, ermöglichte ebendiese. 
Eisenoxid Nanopartikel wurden durch ihren Signalstöreffekt auf das MR Protonensignal 
detektiert, während Perfluorcarbon Emulsionen durch 19F basierte Kernspintomografie 
nachgewiesen wurden. Säugetiere verfügen nicht über ausreichende Mengen von 19F 
Atomen, um ein spezifisches Signal zu liefern, weshalb 19F Kernspintomografie lediglich 
applizierte Perfluorcarbon Emulsion in vivo abbilden kann. Dieses Bild kann dann über ein 
zugleich aufgenommenes Protonen MR Bild gelegt werden, wodurch die Akkumulation des 
Kontrastmittels im Detail in anatomischer Umgebung dargestellt werden kann. Da es sich 
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hierbei um einen Vorteil gegenüber anderen Kontrastmittel-basierten MR 
Bildgebungsmethoden wie Eisenoxid Nanopartikel gestützter Kernspintomografie handelt, 
wurden nachfolgende Experimente mit Perfluorcarbon Emulsionen durchgeführt. Studien 
zur Bildgebung der Perfluorcarbon Akkumulation am Infektionsherd des 
Muskelabszessmodels von S. aureus in der Maus zeigten deutliches 19F MR Signal nach Gabe 
zwischen Tag 2 und Tag 8 p.i.. In allen untersuchten Tieren zeigte sich eine Ansammlung des 
Kontrastmittels in Form einer Hohlkugel um den Abszessbereich, wobei das Signal während 
der gesamten Infektion stabil war. Um den Akkumulationsmechanismus zu identifizieren, 
wurden Durchflusszytometrie-, Zellseparations- und histologische Experimente 
durchgeführt. In diesem Zusammenhang erwiesen sich Neutrophile, Makrophagen, 
Monozyten und Dendritische Zellen als Perfluorcarbon-tragende Immunzelltypen, wobei das 
Gros an Kontrastmittel in Neutrophilen nachgewiesen werden konnte. Im Allgemeinen war 
der Großteil des Perfluorcarbonsignals mit Immunzellen assoziert, weshalb eine spezifische 
Immunzell-abhängige Akkumulation wahrscheinlich erscheint. Die histologischen 
Untersuchungen stützten diese Beobachtung, da die Kontrastmittel assoziierten 
Fluoreszenzmarker nur in der Nähe von Immunzellnuclei gefunden werden konnten. 
Die Etablierung von 19F Kernspintomografie mit Perfluorcarbon Emulsionen als 
Infektionsbildgebungsmethode ermöglichte im nächsten Schritt die Untersuchung von 
antibakterieller Therapie auf das MR Signal, um die Eignung dieser Methode für die Präklinik 
zu evaluieren. Deshalb wurden die Wirksamkeit von Vancomycin und Linezolid, zweier 
klinisch höchst relevanter Antibiotika zur Behandlung von S. aureus Infektionen, im 
Muskelabszessmodel der Maus untersucht. Beide erwiesen sich als effizient in der 
Verringerung der bakteriellen Last im infizierten Muskel und des Bakterien-
Biolumineszenzsignals, aber auch bei der Reduktion der Stärke und des Volumens der 
Perfluorcarbon Akkumulation am Infektionsherd, die durch 19F Kernspintomografie 
dargestellt und vermessen wurde. Alle drei Methoden zeigten dabei das gleiche 
Effizienzmuster nach dem Linezolid wirksamer bei der Bekämpfung der Infektion war. 
Folglich erwies sich 19F Kernspintomografie mit Perfluorcarbon Emulsionen als effektiv um 
den antibakteriellen Effekt von Antibiotika in präklinischen Modellen zu untersuchen. 
Konsequenterweise wurde im nächsten Schritt eine neuartige Substanz zur Behandlung von 
S. aureus Infektionen mit Hilfe der Bildgebungsplattform untersucht: Lyostaphin. Diese 
Endopeptidase schneidet spezifisch die Zellwand von S. aureus und wurde in verschiedenen 
Konzentrationen oder in Kombination mit Oxacillin im Muskelabszess- oder 
Katheterinfektionsmodell der Maus gestestet. Lysostaphin in der Konzentration von 5 mg/kg 
Körpergewicht (Maus) oder Lysostaphin in der Konzentration von 2 mg/kg in Kombination 
mit Oxacillin führten zu einer starken Verringerung der Bakterienlast und des 
Biolumineszenzsignals in beiden Modellen. Die Ansammlung von Perfluorcarbon 
Kontrastmittel war zudem in diesen beiden Gruppen stark reduziert im Vergleich zur 
Negativkontrolle und den mit Vancomycin und Oxacillin behandelten Tieren. 
Zusammenfassend kann festgestellt werden, dass Lysostaphin eine vergleichbare oder 
bessere Wirksamkeit als Vancomycin oder Oxacillin alleine lieferte. Aus diesem Grund 
 Zusammenfassung 7 
scheint eine Weiterentwicklung dieser Substanz zur Behandlung von S. aureus empfohlen. 
Der Nutzen der Bildgebungsplattform wurde in diesen Experimenten zudem dadurch 
deutlich, dass alle drei Methoden zur Bestimmung der Schwere der Erkrankung ähnliche 
Wirksamkeiten der Antibiotika anzeigten. Dennoch muss festgestellt werden, dass die 
Gruppen, die Oxacillin entweder alleine oder in Kombination mit Lysostaphin erhielten, 
stärkere Perfluorocarbon Akkumulation am Infektionsherd aufwiesen als von den 
Bakterienlast- oder Biolumineszenz-Ergebnissen zu erwarten gewesen wäre. Ein Grund 
hierfür könnten mögliche immunomodulatorischen Effekte von Oxacillin sein. Tatsächlich 
zeigten weitere Experimente Variationen in den Konzentrationen von Cytokinen und 
Chemokinen im infizierten Muskel in Abhängigkeit der verwendeten Antibiotikatherapie. 
Besonders die Behandlung mit Oxacillin, in geringerem Maße aber auch mit Minocyclin oder 
Linezolid, führte zu erhöhten Konzentrationen, wenngleich die Bakterienlast deutlich 
reduziert werden konnte. Folglich sollten mögliche immuno-modulatorischen Effekte 
antibakterieller Substanzen bei zukünftiger Anwendung von Bildgebungsplattform, die auf 
dem Markieren von Immunzellen basieren, mit ins Kalkül gezogen werden. Auf der anderen 
Seite eröffnet diese Beobachtung ein neues Anwendungsfeld für diese 
Bildgebungsmethoden, da es außerordentlich interessant erscheint, damit immuno-
modulatorische Substanzen oder bakterielle Faktoren in vivo zu untersuchen. Zu guter Letzt, 
ermöglicht diese Bildgebungsplattform, die Methoden zur Darstellung der bakteriellen Last 
auf der einen und des Immunsystems auf der anderen Seite verknüpft, eine innovative, neue 
Möglichkeit Wirt-Pathogen Interaktionen nicht-invasiv und in vivo studieren zu können. 
Zusammenfassend konnte gezeigt werden, dass Perfluorcarbon Emulsionen in Immunzellen 
am Infektionsherd des S. aureus Muskelabszessmodells der Maus akkumulieren. Die 
Ansammlung formt eine Hohlkugel am Rand des Abszessbereiches, deren Größe und 
Fluorgehalt von der Schwere der Erkrankung und/oder der Wirksamkeit der angewandten 
Antibiotikatherapie abhängt. Aus diesem Grund erwies sich 19F Kernspintomografie mit 
Perfluorcarbon Emulsionen als Kontrastmittel als nützliche Platform zur präklinischen 
Evaluierung antibakterieller Substanzen. Weiterhin erscheint diese Methode wegen der 
Akkumulation des Kontrastmittels in Immunzellen, als interessant zum Studium der 
Immunantwort gegenüber Infektionen, aber auch Krebs oder Autoimmunerkrankungen 
sowie zur Erforschung von immuno-modulatorischen Substanzen und Impfansätzen. 
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1. Introduction 
1.1. Infectious diseases in the 21st century 
 
Infectious diseases, a scourge of humanity since its beginning, seemed to become 
overpowered in the middle of the last century. The development of antibiotics and vaccines 
promised the eradication and curing of infectious diseases for all mankind. And indeed, in 
the golden age of antibiotics, which started in the early 1950s, a large variety of different 
drugs and compound classes were developed and introduced to the clinics, leading to a 
strong reduction of deaths caused by infectious diseases, especially in developed countries. 
In the United States, for example, among the major causes of death in the year 1900 were 
smallpox, cholera, diphtheria, typhoid fever, plague, tuberculosis, typhus, pertussis, syphilis, 
and other infectious diseases. In addition, many of these diseases caused, if the patient 
survived, complications leading to severe disabilities, like paralysis from polio or neurological 
deficits and heart disease from syphilis (Yoshikawa TT. 2002). In contrast to this, in 2010 only 
pneumonia and influenza, as well as septicemia were among the top 15 causes of death in 
the United States (Murphy SL et al. 2013). Vaccination efforts led at the same time to large 
populations immune against several, in earlier times, life-threatening infectious diseases. 
The climax of vaccination approaches is, without doubt, the eradication of smallpox in 1979, 
a disease which was responsible for an estimated 300 to 500 million deaths in the 20th 
century (Koplow DA. 2003, ScienceDaily. 2008). 
Nonetheless, the WHO estimated that in 2002 about 25.9 % or 14.7 million of all deaths 
worldwide were attributed to infectious diseases (The World Health report 2004. Annex 
Table 2). In consequence, it has to be stated, that infectious disease are not eradicated or 
overwhelmed at the beginning of the 21st century. Public health systems are struggling with 
emerging or spreading infectious diseases like human immunodeficiency virus (HIV), severe 
acute respiratory syndrome (SARS) or reemerging pathogens like tuberculosis (Fauci AS. 
2005). In addition, bioterrorism, like the 2001 anthrax attacks in the United States, has now 
to be recognized as a significant threat to public health (Christian MD. 2013).  
Furthermore, we have to face in our days a variety of problems that emerged, at least in 
parts, with the introduction of anti-infective therapy itself. Within these, two big trends are 
of special interest due to their gravity: the development of antibiotic resistance and the 
aging of the human population. 
Humankind has encountered a strong increase of life expectancy during its evolution, 
especially after sedentarization and development of culture (Caspari R, Lee SH. 2004, Caspari 
R, Lee SH. 2006). The most prominent increase took place after the ‘Industrial Revolution’. 
This was mostly caused by massive improvements of public health and was connected to a 
strong decrease of deaths in childhood (Centers for Disease Control and Prevention (CDC). 
1999). Nonetheless, human longevity is unequally distributed over the globe with developed 
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countries featuring much higher life expectancy, than developing countries. Moreover, it is 
estimated that life expectancy is further increasing (Oeppen J, Vaupel JW. 2002). 
This increase in life expectancy and the expected increase of human longevity will lead to 
massive challenges for health care systems in future. Besides the general adaptations which 
are necessary to treat elderly people, it is of special interest, that infections are more 
prevalent in elderly people than in young adults (Dhawan VK. 2002, Fein AM. 1999, Leibovici 
L. 1995, Reacher MH et al. 2000). Furthermore, this is not only due to higher hospitalization 
rates but also to increased risk of infection per hospitalization day and there is a change of 
pathogens and greater diversity of pathogens in elderly people than in young adults (Emori 
TG et al. 1991). At the moment, infectious diseases (pneumonia, influenza and complications 
during bacteremia) are among the 10 major causes of death in elderly people (Yoshikawa TT. 
2000). Thus, infectious diseases have a revival simply because of a larger population of 
human elderly people which are more prone to infections than younger ones. 
The second big challenge for the treatment of infectious diseases in future will be antibiotic 
resistance. Although genes conferring resistance to antibiotic compounds can be found in 
30.000 year old permafrost samples (D'Costa VM et al. 2011), most of the pathogenic 
bacteria were sensitive to antibiotics when they were introduced to the clinics. Nonetheless, 
since the first application of penicillin, pathogenic bacteria have evolved or acquired 
resistance mechanisms against virtually all available antibiotics (Alanis AJ. 2005). Moreover, 
several factors reinforce the emergence and spreading of antimicrobial resistance, namely 
increasing levels of antibiotic usage (in human but also animal medicine), the greater 
movement of people and the increase of industrialization and urbanization (Hawkey PM and 
Jones AM. 2009). 
Most importantly, both developments, aging of human populations and the development of 
antibiotic resistance, can reinforce their individual danger, since the increased 
hospitalization rates and the elevated risk of infection per hospitalization day for elderly 
people offer pathogens a higher chance to develop or acquire antibiotic resistance 
mechanisms (Yoshikawa TT. 2002). 
A number of bacterial pathogens has developed or acquired antibiotic resistance during the 
last 70 years and lead in our days to massive problems in health care worldwide (Alanis AJ. 
2005, Hawkey PM and Jones AM. 2009). Infections with gram-negative pathogens like 
Pseudomonas aeruginosa and Acinetobacter spp. as well as Escherichia coli, Klebsiella spp. or 
gram-positive bacteria like Staphylococcus aureus, Enterococcus faecium and Clostridium 
difficile are often associated with a high degree of bacterial resistance, sometimes resulting 
in only one or none remaining compound to treat disease (Hawkey PM. 2008, 
Theuretzbacher U. 2012). 
Thus, new approaches and compounds are necessary to ensure treatment of infections with 
above-mentioned pathogens in future. Although a number of novel promising antibiotics are 
in development at the moment (Ohlsen K. 2009, Theuretzbacher U. 2011), in 2004 only 1.6 % 
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of all drugs in clinical development by the 15 biggest pharmaceutical companies were 
antibiotics (Jabes D. 2011). It has to be stated, that although antibiotic resistance among 
pathogenic bacteria increased strongly during the last decades, while development of novel 
compounds diminished (Spellberg B et al. 2004). Many pharmaceutical companies left the 
field of antibiotic discovery or cut their expenses, since it seemed to be more interesting to 
develop therapies for chronic diseases (Projan SJ. 2003, Thomson CJ et al. 2004). 
Nevertheless, the stopping of emergence and spread of antibiotic resistance and the need 
for new antibiotics are now recognized as predominant aims of infectious disease societies, 
nations and companies (Boucher HW et al. 2009). It is regarded in our days as a public 
problem that has to be solved and countries and the EU are trying to address this problem 
with big initiatives (Theuretzbacher U. 2012). 
In this context, the DFG (Deutsche Forschungsgemeinschaft) decided to establish and fund 
the SFB630 (Sonderforschungsbereich 630) with the aim to identify, develop and evaluate 
novel compounds to fight infectious diseases. Embedded in this scientific setting, this thesis 
was initiated to establish a non-invasive in vivo imaging platform to evaluate the efficacy of 
novel compounds to treat S. aureus infections in preclinical murine models. 
 
1.2. Staphylococcus aureus – a versatile pathogen 
 
Staphylococcus aureus causes a wide variety of different diseases in humans and animals. 
They include various life-threatening invasive infections, such as sepsis, bacteraemia, 
endocarditis, pneumonia, osteomyelitis and meningitis (Lowy FD. 1998), but also the 
majority of skin and soft tissue infections in humans like impetigo, folliculitis, cellulitis and 
infected wounds and ulcers (McCaig LF et al. 2006, Talan DA et al. 2011). Overall, MRSA only, 
without meticillin-sensitive S. aureus, caused more than 80.000 invasive infections in 2011 in 
the USA (Dantes R et al. 2013). Interestingly, another study showed in addition that incident 
rates for invasive MRSA infections for persons 65 years or older (127.7 per 100,000) are very 
high, higher than for younger adults, suggesting increased susceptibility to MRSA infection 
with aging (Klevens RM et al. 2007). To get an impression about the impact of S. aureus on 
public health: the number of deaths by invasive MRSA disease outnumbered in the United 
States in 2005 the deaths caused by tuberculosis, viral hepatitis and AIDS combined 
(Boucher HW, Corey GR. 2008). 
In Europe, healthcare associated MRSA infections are estimated to affect more than 170.000 
patients per year, causing more than EUR 380 million extra in-hospital costs for the health 
care systems (Köck R et al. 2010). Interestingly, the prevalence of MRSA among S. aureus 
bacteraemia samples are highly diverse among the different countries in Europe, ranging 
from less than 1 % in Scandinavian countries to 25 – 50 % in Italy (European Antimicrobial 
Resistance Surveillance Network (EARS-net) data, Fig. 1.1). And although the percentage of 
MRSA among bacteraemia declined in the last years, the overall numbers of blood-stream 
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infections with S. aureus increased between 2002 and 2009 in Europe (Gagliotti C et al. 
2011). MRSA infections are today endemic in hospitals world-wide, requiring laborious and 
expensive methods to prevent further spread of antibiotic resistant strains. 
Above all, in the 1990s, the epidemiology of MRSA changed. While MRSA was limited to 
hospitals and other long-term care facilities prior this time, first cases about community-
acquired MRSA infections reported the emergence and spread of MRSA in the healthy 
population (Chambers HF. 2001). The first isolated strains showed the pulse-field gel 
electrophoresis pattern of USA400, but these strains were quickly replaced by USA300, 
which is now epidemic in the United States (Kennedy AD et al. 2008, DeLeo F et al. 2009). 
Although it has to be stated that the success of USA300 is object of ongoing discussion, the 
high virulence might be associated with its ability to prevent killing by neutrophils and by the 
increased production of virulence factors (Voyich JM et al. 2005). 
Ca-MRSA, especially the strain USA300, was reported in several studies in Europe, too, but 
the cases were associated mostly with small outbreaks or single cases and the overall 
problem, at least at the moment, seems thus to be rather limited (Johnson AP. 2011). A 
further big threat in Europe is the spread of MRSA among livestock (LA-MRSA) and the 
associated transmission to humans in close contact to colonized or infected animals 
(Graveland H et al. 2011). Most of the LA-MRSA strains in Europe and Northern America are 
members of the clonal complex 398 (CC398), while sequence type 9 (ST9) is most prevalent 
in Asia. Although S. aureus CC398 seems to be a poor persistent colonizer of humans, it 
accounts for an increasing number of invasive infections in humans (Schaumburg F et al. 
2012, Köck R et al. 2011). 
 
12 Chapter 1. Introduction 
 
Fig. 1.1: Prevalence of MRSA among S. aureus bacteraemia in Europe in 2012. Figure derived from 
http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/map_reports
.aspx 
 
In Germany, around 132.000 cases of MRSA are registered each year, counting for ca. 20 % 
of all S. aureus cases (Köck R et al. 2011). Most of these cases are associated with 
hospitalization. 
In conclusion, we have to face a very successful pathogen that has adapted to man-made 
countermeasures to fight infections. The spectrum of diseases that can be caused by S. 
aureus is wide-ranged, but the un-symptomatic colonization of skin and nares in humans is 
very frequent, too. A survey of carriage in the United States between 2001 and 2004 showed 
S. aureus in nasal samples of about 28.6 % of all tested persons, and 1.5 % of all tested 
persons carried MRSA (Gorwitz RJ et al. 2008). Similarly, S. aureus was found in the nasal 
swaps of 152 out of 627 patients in an outpatient study in southern Germany (Lietzau S et al. 
2004). 
To enable survival and growth in such different niches, a diversified genome and flexible 
gene expression is inevitable. This might be an explanation for the big arsenal of virulence or 
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virulence-associated genes that are harbored by S. aureus. This gram-positive pathogen 
produces a variety of different microcapsules, although its importance in pathogenesis is still 
subject of discussion. It was shown that the capsule interferes with complement binding and 
phagocytic killing (Thakker M et al. 1998, Cunnion KM et al. 2001), while other studies 
showed either no effect of capsule knock-out or even attenuation of capsule expressing 
strains in murine models (Albus A et al. 1991, Baddour LM et al. 1992). 
As gram-positive bacterium, S. aureus has a thick cell wall, which consists to 50 % by weight 
of peptidoglycan, and no outer membrane. The peptidoglycan consists of alternating 
subunits of N-acetylglucosamine and N-acetylmuramic acid. The chains are connected by S. 
aureus specific pentaglycine bridges between tetrapeptide chains bound to the N-
acetylmuramic acid subunits (Lowy FD. 1998). Further major constituents of the cell wall are 
ribitol teichoic acids, covalently bound to peptidoglycan, and lipoteichoic acids, which are 
anchored in the membrane. Interestingly, to reduce susceptibility against antimicrobial 
peptides, which are produced in tissues and by cells such as neutrophils and platelets, S. 
aureus reduces the negative charge of its surface by the action of Dlt and MprF proteins 
(Peschel A et al. 1999, Peschel A et al. 2001). Another strategy to neutralize cationic peptides 
is the secretion of staphylokinase and aureolysin, since both of them bind host derived 
antimicrobial peptides (Jin T et al. 2004, Sieprawska-Lupa M et al. 2004). 
Up to 24 cell-wall anchored proteins can be expressed by S. aureus, dependent on the 
growth phase and condition (Foster TJ et al. 2014). Foster and colleagues proposed to 
classify the cell-wall anchored proteins into four categories: the microbial surface 
component recognizing adhesive matrix molecules family (MSCRAMMs), the near iron 
transporter motif family (NEAT), protein A and the G5-E repeat family. The most abundant 
family in this context is the MSCRAMM family, which is characterized by at least two 
subdomains containing adjacent IgG-like folds (Deivanayagam CC et al. 2002). This group of 
proteins was originally thought to bind extracellular matrix components of the host, but 
there are members of this family with other functions than adhesion (Foster TJ et al. 2014). 
The archetype of this family is clumping factor A (clfA), which binds efficiently fibrinogen and 
thereby on hand promotes adhesion but on the other also hides the bacterium from the 
immune system (Ganesh VK et al. 2008). The NEAT motif family members participate in 
capturing haem from haemoglobin and thus help to supply S. aureus with iron (Hammer ND 
and Skaar EP. 2011). Protein A will be described and discussed later in this chapter, while the 
G5-E repeat family seems to be necessary for biofilm formation, but participates in adhesion, 
too (Gruszka DT et al. 2012). 
Foreign body associated infections with S. aureus are prone to biofilm formation. In 
principle, S. aureus biofilms are either polysaccharide intercellular antigen (PIA) dependent 
or independent (Archer NK et al. 2011). PIA is produced by the proteins of the ica operon 
and anaerobic conditions strongly induce PIA production and biofilm formation (Cramton SE 
et al. 2001). Nonetheless, the depletion of the ica operon did not diminish biofilm formation 
in S. aureus, but PIA-independent biofilm did not longer consist of polysaccharides but of 
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proteinaceous compounds (Lasa I and Penadés JR. 2006, Merino N et al. 2009). Composition 
of PIA-independent biofilm seems to be strain specific and not all strains produce this type of 
biofilm (O'Neill E et al. 2007). Extracellular DNA (eDNA) is another important component of 
S. aureus biofilms and might give structural support (Archer NK et al. 2011). 
After entering the host, adhesion and attachment, S. aureus has to face the host’s immune 
response and the first line of cellular defense against S. aureus infections are neutrophils 
which migrate in large numbers to sites of infection (DeLeo F et al. 2009). Therefore, S. 
aureus has evolved several proteins which are targeted against neutrophils and their 
mechanisms to fight bacterial infection. Important for the recognition of invading bacteria by 
neutrophils are the complement peptide fragments C3a and C5a as well as formylated 
peptides from growing bacteria. S. aureus harbors several proteins to inhibit the detection of 
these messenger molecules to hinder neutrophil activation and migration to the site of 
infection. Chemotaxis inhibitory protein of staphylococci (CHIPS) is, for example, one of 
these proteins and binds specifically to the formyl peptide receptor (FPR) and the C5a 
receptor (C5aR) on neutrophils and blocks thereby chemotaxis (de Haas CJ et al. 2004). 
Similar activity was demonstrated for the proteins FLIPr (FPRL1 inhibitory protein) and FLIPr-
like. FLIPr binds in this context the formyl peptide receptor-like 1, while FLIPr-like binds this 
receptor and additionally the formyl peptide receptor, but nonetheless, binding led for both 
of them to inhibition of neutrophil chemotaxis towards gradients of compounds that are 
detected by these receptors (Prat C et al. 2006, Prat C et al. 2009). Extracellular adherence 
protein (Eap or Map) binds to the intercellular adhesion molecule-1 (ICAM-1) on endothelial 
cells and thus blocks binding of neutrophils to this surface molecule, what in turn prevents 
extravasation to the site of infection (Chavakis T et al. 2002). If neutrophils enter the site of 
infection and phagocytose S. aureus, this pathogen evolved several strategies to circumvent 
killing. It expresses two superoxide dismutases to remove O2
- and even the yellow 
carotenoid pigment of S. aureus contributes to survival in phagolysosoms by scavenging free 
radicals (Foster TJ et al. 2009). 
Despite its action against phagocytes and especially against neutrophils, S. aureus inhibits 
the complement system, too, the first line of humoral defense against invading pathogens. 
The complement consists of various proteins which on one hand are able to kill bacteria 
directly in interplay but on the other hand play an important role in activating or regulating 
other effectors of the host’s immune response (Zipfel PF and Skerka C. 2009). S. aureus 
interferes with the complement cascade at virtually every level utilizing a large arsenal of 
proteins like SSL7, SSL10, Sbi, CHIPS, SCIN, Spa, Efb and others (Zipfel PF and Skerka C. 2013).  
But besides inhibiting the host’s innate immune response, S. aureus is in addition well 
stocked with proteins to interfere with adaptive immune response. Both essential parts of 
adaptive immune response, namely T and B cells, are attacked or manipulated, but that’s not 
all, S. aureus is furthermore counteracting the antibody response (Bröker BM et al. 2013). 
Protein A (Spa), a well studied surface associated and released protein, binds efficiently the 
Fc part of antibodies, thereby preventing Fcγ receptor mediated uptake of bacteria into 
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professional phagocytes (Parcina M et al. 2008). Further proteins which are able to bind 
antibodies are Sbi, SSL7 and SSL10. They seem to be predominantly secreted and enable 
neutralization of antibodies, thus facilitating extracellular lifestyle of S. aureus (Langley R et 
al. 2010, Smith EJ et al. 2011). Alongside to binding and neutralizing antibodies, S. aureus 
expresses serine proteases to cleave and digest antibodies (Prokesová L et al. 1995, 
Fernandez Falcon MF et al. 2011). 
Protein A possesses in addition to its Fc binding domain a Fab’ binding domain, which offers 
direct binding to B cell receptors, which are membrane-bound immunoglobulins that define 
the antigen specificity of the individual B cell (Graille M et al. 2000). The binding results 
either in B cell death if soluble Spa has bound or in strong activation of B cells without the 
otherwise necessary induction by T cells. This leads to short lived differentiated B cells with 
accompanying release of the anti-inflammatory cytokine IL-10 (Parcina M et al. 2013). Spa is 
on account of this regarded as ‘B cell superantigen’ (Bröker BM et al. 2013). 
Nonetheless, more attention of the scientific community was attracted by staphylococcal T 
cell superantigens. The genome of S. aureus encodes for no less than 23 superantigens 
encompassing enterotoxins (SEs) and enterotoxin-like proteins (SEls) (Fraser JD and Proft T. 
2008, Bröker BM et al. 2013). These toxins are of special interest since they are the causative 
agent of staphylococcal food poisoning and toxic shock syndrome. They are able to bypass 
the conventional antigen recognition of T cells by directly crosslinking the T cell receptor 
with MHC II molecules. This results in simultaneous, unspecific activation of a large portion 
of the total T cell population, causing a life-threatening cytokine storm (Xu SX and 
McCormick JK. 2012). 
In addition to the aforementioned immune avoidance strategies, S. aureus harbors several 
leukotoxins to attack and kill immune cells directly (Grumann D et al. 2013). The most 
prominent member is α-toxin or α-hemolysin. This toxin is secreted as monomer, but forms 
heptamers in the target’s membrane which leads to a 14-stranded β-barrel pore and deaths 
of the target cell (Montoya M and Gouaux E. 2003). Another group of toxins, the 
biocomponent leukotoxins, in contrast, consist of two separately secreted subunits that 
assemble into oligomers with strong affinity for leukocytes. Four types have been identified 
in S. aureus so far: the γ-toxin or γ-hemolysin, the Panton-Valentine leukocidin (PVL), 
leukocidin E/D and leukocidin M/F-PV-like (Foster TJ. 2005). Of special interest is PVL, since it 
was suggested to be an important factor in promoting the success of ca-MRSA strains (Gillet 
Y et al. 2002). But this observation is still topic of ongoing discussion, since other studies 
showed that PVL is a poor marker for ca-MRSA identification and therefore not necessarily 
present in ca-MRSA strains (Rossney AS et al. 2007). 
Recently, a further group of molecules with cytolytic activity have been identified in S. 
aureus: the phenol-soluble modulins (PSMs). These are short peptides and S. aureus harbors 
four α-type PSMs, two β-type PSMs and δ-toxin (Wang R et al. 2007). Interestingly, ha-MRSA 
strains lack in contrast to ca-MRSA strains considerable production of PSMs, thus PSMs are 
suggested to promote ca-MRSA survival and success in healthy population (Wang R et al. 
16 Chapter 1. Introduction 
2007). Alongside to their cytolytic activity, PSMs are detected by neutrophils through the 
formyl peptide receptor 2 which leads in turn to chemotaxis to the site of infection 
(Kretschmer D et al. 2010). 
Another group of toxins produced by S. aureus are exfoliative toxins (Ladhani S. 2003). Four 
serogroups of this family have been identified so far: exfoliative toxin A, B, C and D. They are 
responsible for the staphylococcal scalded skin syndrome, a blistering skin disorder, which is 
caused by cleavage of desmoglein-1, an intercellular adhesion molecule (Amagai M et al. 
2000). 
Besides this plethora of virulence factors, S. aureus is able to invade the host’s non-
professional phagocytes (Fraunholz M, Sinha B. 2012). This mechanism is mainly promoted 
by the action of fibronectin-binding proteins (Sinha B et al. 2000). This intracellular lifestyle 
might help to evade the immune system and might open up new nutrient sources. 
All these factors or strategies to promote lifestyle as a pathogen but also, not to forget, as a 
colonizer can be regarded as threat in the case of infection, but the most dangerous factor 
or mechanism developed or acquired by S. aureus is without doubt antibiotic resistance. The 
lack of adequate therapy during invasive infection due to the resistance of S. aureus to 
various antibiotic compounds endangers patients worldwide. S. aureus, naturally susceptible 
to almost every antibiotic compound developed so far, proved to be a master of antibiotic 
resistance acquisition or development (Pantosti A et al. 2007). 
Only a few years after introduction of penicillin to the clinics in the 1940s, the first penicillin-
resistant strains of S. aureus emerged. This resistance was facilitated by the action of the 
extracellular enzyme penicillinase, which inactivated the first β-lactam antibiotics. In the 
following years a spread of resistant S. aureus strains could be seen, leading to a pandemic 
situation, which made the development of penicillinase-resistant penicillins necessary, with 
the first and most prominent member being meticillin (Chambers HF and Deleo FR. 2009). 
Nevertheless, the introduction of meticillin resulted in a similar development than after 
introduction of penicillin. Soon after introduction of meticillin, the first resistant clones of S. 
aureus could be detected. But in contrast to penicillin resistance, the pattern was this time 
not narrow as with penicillinase, but broad, providing resistance to all β-lactam antibiotics. 
Nonetheless, this second generation of resistant strains was called meticillin-resistant S. 
aureus (MRSA). The resistance was supplied by a genetic element called staphylococcal 
chromosomal cassette (SCC) mec, which harbors the resistance gene cluster mec, which 
encodes for the additional penicillin-binding protein PBP2a and accompanying regulatory 
proteins, and the ccr genes, which enable excision and integration of the genetic element in 
the orfX gene on the S. aureus chromosome (Katayama Y et al. 2000). To date, eight 
variations of the SCCmec element have been identified, each of them comprising of at least 
mecA and the ccr genes, but some of them harbor additional resistance or virulence 
associated genes (Chambers HF and Deleo FR. 2009). Interestingly, both types of resistance, 
against penicillin or meticillin, rely on mobile genetic elements, either the aforementioned 
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SCCmec elements or plasmids. In this regard, it was shown recently, that biofilm formation 
and/or the expression of the alternative sigma factor H (SigH) promote natural transfer of 
antibiotic resistance genes on mobile genetic elements, thereby offering S. aureus the 
opportunity to acquire antibiotic resistance, developed in other species (Morikawa K et al. 
2012, Savage VJ et al. 2013). This might be an explanation for the rather quick development 
of resistance, but on the other hand also demonstrates the high adaptability of S. aureus 
when facing new challenges. 
After emergence and spread of MRSA in hospitals all over the globe, physicians confided in 
vancomycin to treat infections (Hiramatsu K. 2001). In 1997, the first case of vancomycin-
intermediate S. aureus (VISA) phenotype was described and shortly after that the first 
vancomycin-resistant strains (VRSA) (Appelbaum PC. 2006). Cell wall thickening seems to be 
a possible origin of vancomycin resistance in S. aureus (Hiramatsu K. 2001). Another 
resistance mechanism was mediated by the transfer of vanA from Enterococcus sp., although 
this seems to be associated with a loss of fitness (Foucault ML et al. 2009). Besides this, it 
was reported that MRSA developed reduced susceptibility against vancomycin, although 
they are classified by laboratory techniques as vancomycin sensitive (Sakoulas G and 
Moellering RC Jr. 2008). This development was accompanied by an increasing number of 
vancomycin treatment failures (Sakoulas G et al. 2004, Moise PA et al. 2007). 
Parallel to the development of vancomycin resistance or insusceptibility, MRSA spread into 
healthy population. Formerly, MRSA infections were almost exclusively limited to hospitals, 
thus S. aureus was seen as nosocomial pathogen. This pattern changed significantly in the 
1990s, when first infections with MRSA, later called community-acquired MRSA (ca-MRSA), 
in healthy population were reported (Chambers HF and Deleo FR. 2009). Today ca-MRSA has 
spread worldwide and is even reentering hospital settings again (Seybold U et al. 2006). 
Although ca-MRSA strains are thought to harbor less many antibiotic resistances than ha-
MRSA strains, they seem to be more virulent (Voyich JM et al. 2005). 
In conclusion, these developments made it necessary to search for new compounds to fight 
S. aureus infections. Currently, there are linezolid, daptomycin, telavancin, ceftaroline and 
tigecycline approved as anti-MRSA antibiotics by the US Food and Drug Administration 
besides vancomycin (Sakoulas G and Moellering RC Jr. 2008, Snyder J et al. 2012). Recently, 
the FDA has approved another new compound against MRSA, dalbavancin (FDA News 
Release, May 23, 2014). As with penicillin, first cases of daptomycin treatment failure due to 
resistance could be described shortly after introduction (Hayden MK et al. 2005, Hirschwerk 
D et al. 2006). Furthermore, two different mechanisms, namely by the presence of the cfr 
gene or by mutations in the V domain of 23S rRNA, lead to resistance of S. aureus against 
linezolid and resulted in linezolid treatment failures in several cases (Meka VG et al. 2004 , 
Morales G et al. 2010). In conclusion, S. aureus has developed strategies to resist or endure 
treatment with virually every antibiotic currently available (Stryjewski ME and Corey GR. 
2014). Not all of the resistance mechanisms are widespread, but it can be stated nonetheless 
that S. aureus has mastered every challenge faced by man so far. Moreover, emergence of 
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ca-MRSA strains, that seem to have acquired or developed further strategies to invade, 
colonize and damage, sometimes even kill the human host, are cause of constant worry 
today. Therefore, it is inevitable to search for new ways to fight S. aureus infections and to 
prevent the emergence of a S. aureus ‘superbug’. 
Efforts to develop new antibacterial compounds after the emergence and spreading of 
resistant bacteria, especially of MRSA, has led to the introduction of three new classes of 
antibiotics: lipopeptides, oxazolidinones and streptogramins (Parisien A et al. 2007), 
however most efforts were focused on the generation of new compounds based on well-
known antibiotic structures (Theuretzbacher U. 2009). In consequence, S. aureus and 
especially MRSA is challenged with new weapons but an old strategy. Maybe, it is time to try 
something new! And indeed, several new ideas or methods to fight bacterial infections are in 
preclinical development. 
Most importantly, a classical approach has gained renewed attention in the last decades: 
vaccination. This old approach promises the access to a weapon suitable to eradicate an 
infectious disease or simply to prevent disease in the immunized population. Vaccines 
against other pathogens like Haemophilus influenzae type b, Streptococcus pneumoniae and 
Neiserria meningitides have led to significant reduction of serious infections after their 
introduction to the clinics (Seale A and Finn A. 2011). Nonetheless, although a vaccine 
against S. aureus is very appealing to pharmaceutical companies and scientists, every 
candidate has failed so far, leaving us behind with the question: why did all of them fail, 
although preclinical data was promising (Proctor RA. 2012a, Proctor RA. 2012b, Spellberg B 
and Daum R. 2012)? It was supposed that the lack of understanding of the human immune 
response against S. aureus infection has hindered the generation of a protective immune 
response (Proctor RA. 2012a, Proctor RA. 2012b). Nevertheless, there are further vaccine 
candidates in different phases of clinical trials and new ideas for a S. aureus vaccine in 
preclinical evaluation. 
Besides active immunization with a vaccine, passive immunization with antibodies came into 
focus of scientists and pharmaceutical companies since advances in the fields of 
recombinant DNA technology and genetics made production of large amounts of endotoxin-
free monoclonal antibodies possible. In principle, several antigens have been proposed as 
suitable targets for passive immunization, for example MSCRAMMs, lipoteichoic acid, 
capsule, surface proteins or secreted virulence factors (Ohlsen K and Lorenz U. 2010, Verkaik 
NJ et al. 2011). One big advantage of passive immunization in comparison to active 
immunization might be the efficacy of this approach in infants, elderly or immune-
compromised patients, who otherwise might lack sufficient immune response (Projan SJ et 
al. 2006). Some approaches have failed to date, but more monoclonal antibodies are in 
preclinical or clinical testing for treatment of various diseases caused by S. aureus (Ohlsen K 
and Lorenz U. 2010, Proctor RA. 2012b, Oesterreich B et al. 2014). 
Immunomodulators are another new approach to fight bacterial infections. They are based 
on stimulation or guidance of the host’s immune response to fight the infection more 
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efficiently (Masihi KN. 2000, Pirofski LA and Casadevall A. 2006). Passive immunization with 
antibodies might, as a matter of principle, classified as immunomodulatory, too, due to the 
fact that their mode of action depends on the action of the immune system, maybe with the 
exception of neutralizing antibodies. But there are further approaches to modulate the 
immune response to fight infection more efficiently. Antimicrobial peptides, for example, 
have been proposed as promising candidates to fight bacterial infection by their activity 
upon the immune system (Mookherjee N et al. 2007). Synthetic variants of these peptides 
with no direct antimicrobial activity are also under investigation as new therapeutics against 
S. aureus (Scott MG et al. 2007, Nijnik A et al. 2010). 
Besides these aforementioned approaches which rely on the immune system in one way or 
another, there are of course further compounds under investigation that act on the 
bacterium itself. A number of novel compounds targeting similar compartments or 
structures of/on the bacteria than currently available antibiotics are in preclinical or clinical 
evaluation including members of the well-known β-lactam class (Fitzgerald-Hughes D et al. 
2012). New approaches contain lipoproteins, bacteriophages, enzymes, cationic 
antimicrobial peptides and novel compounds from natural sources (Ohlsen K et al. 2008). 
One novel compound with different mode of action than currently available antibiotics is 
lysostaphin. It is of special interest for this thesis since it was applied as experimental, novel 
compound to treat murine S. aureus infections in chapter 6. It was originally identified and 
described in 1964 as an extracellular protein produced by S. simulans biovar staphylolyticus 
(Schindler CA and Schuhardt VT. 1964). This zinc metalloprotease gylcyl-glycine 
endopeptidase cleaves specifically the pentaglycine interpeptide crossbridge of S. aureus 
and, to a lesser extent, of S. epidermidis (Sloan GL et al. 1977). The species specificity defines 
lysostaphin as a narrow spectrum anti-infective compound and is therefore different to 
currently used antibiotics to treat S. aureus infection. In vitro tests demonstrated high 
activity against a broad range of clinical S. aureus isolates including antibiotic resistant 
strains (Harrison EF and Cropp CB. 1965, Zygmunt WA et al. 1965, Schindler CA. 1966) and 
first in vivo tests, performed shortly after identification, showed increased survival and 
reduced bacterial burden of treated mice compared to mock treated controls (Harrison EF 
and Zygmunt WA. 1967, Schaffner W et al. 1967). However, the purification of endotoxin-
free lysostaphin formulations remained challenging and thus development was stopped until 
recombinant lysostaphin formulations became available and renewed interest in this 
compound (Climo MW et al. 1998, Patron RL et al. 1999, Kokai-Kun JF et al. 2007, Kokai-Kun 
JF et al. 2009). Interestingly, it was demonstrated that lysostaphin acts synergistic with β-
lactam antibiotics in vivo (Climo MW et al. 2001). 
To sum up, some novel compounds are currently in different stages of preclinical and clinical 
development and thus it is possible that some of those new compounds against antibiotic 
resistant S. aureus will reach the clinics sooner or later. Unfortunately, considering the 
numbers of approvals of novel compounds in the past and comparing this number with the 
number of compounds that have failed during preclinics or clinical trials, we have to state, 
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that the probability for new therapies against S. aureus in near future is not that high. In 
consequence, the preclinical evaluation of novel therapeutics has to be reconsidered to 
reduce the risk of failure. 
 
1.3. Preclinical testing and In Vivo Imaging? 
 
Depending on the author, only 5 out of 5,000 or 10,000 compounds enter clinical trials and 
in the end just one of these 5 is approved by the FDA (Preziosi P. 2004, Willmann JK et al. 
2008, DiMasi JA et al. 2010). Importantly, an evaluation of reasons for terminating drug 
development between 1987 and 1992 showed that more than 50 % of all terminations were 
related to problems with efficacy (37.6 %) or safety (19.6 %), but further 33.6 % were related 
to economic reasons (Dimasi JA. 2001). In consequence, more than 50 % of the compounds 
showed promising results in first evaluations but then failed in subsequent tests. Moreover, 
80 % of all drugs that entered clinical trials failed, suggesting insufficient preclinical 
evaluation. In principle, preclinical testing is limited by the use of the evaluation models, 
which should mimic the human manifestation of disease, independently of their in vitro or in 
vivo nature. Animal models play in this context an important role in preclinical evaluation of 
new promising compounds. 
Nonetheless, it is important to note, that the value of animal models is under ongoing 
discussion. A study that investigated the differences and similarities of the inflammatory 
response to trauma between mice and humans showed, for example, strong differences in 
the genomic response and the authors suggested that this differences might be the cause of 
extensive failure of inflammation blocking agents for critical-ill patients during clinical 
studies (Seok J et al. 2013). This observation led to strong interest in the public, e.g., even an 
article in ‘The New York Times’ (Kolata G. 2013), that insinuated uselessness of animal 
experiments for all diseases linked to inflammation, including sepsis and trauma. But other 
scientists stated that the comparison of genetically heterogenous human data with 
homogenous mouse data (the inbred strain C57BL/6J was used for this study) might not 
reflect the real benefit of mice in medicinal research (Wanner M. 2013; Hagan CE. 2013). 
Additionally, the careful selection of animal models for the evaluation of drugs to treat 
inflammatory diseases has been shown to deliver preclinical results that were predictive for 
their clinical outcome (Arnett HA and Viney JL. 2007). 
But although inflammation and immune response play a very important role in S. aureus 
animal models, there is not necessarily a link to the efficacy of new promising anti-infective 
agents. It is important, of course, for the evaluation of vaccines to prevent infection and it 
was indeed a puzzling observation that various S. aureus vaccines failed during clinical trials, 
whereas they have shown protective capacity in murine models (Proctor RA. 2012b). But all 
other approaches to combat S. aureus infections, which are in preclinical or clinical 
investigation with the exception of antibodies and immune-modulators, have modes-of-
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action that do not depend on the immune response and therefore, they should not be 
affected by differences between mice and humans. A further limitation of mouse models to 
study S. aureus infections is the insusceptibility of mice to human pathogenic S. aureus 
strains, but there are approaches underway to design or identify strains with infectious and 
pathogenic capacities that are similar to human ones (Holtfreter S et al. 2013). 
Besides this experimental design debate, there is also a heated and complex discussion 
about ethics of animal experiments underway. While opponents of animal experimentation 
argue either that humans do not have the right to experiment with animals or that animal 
experiments are not predictive enough for human outcome, supporters argue that animal 
experiments are vitally important to evaluate efficacy and adverse effects of novel 
compounds prior to clinical trials and that there are no other methods to achieve this goal 
(Ellen Frankel, P and Jeffrey, P. 2001, Shaw, WH. 2001, Greaves P et al. 2004). Nonetheless, 
animal models are at the moment widely used in the preclinical testing of new drugs 
(Preziosi P. 2004, Beckmann N et al. 2007). 
Despite this debate, animal experiments are today subject to the principle of the three Rs: 
replacement, refinement and reduction. An interesting approach to achieve replacement 
and reduction of animal experiments might be the application of in vivo imaging 
technologies (Beckmann N et al. 2007, Willmann JK et al. 2008). In principle, in vivo imaging 
technologies might be interesting during four out of five phases of drug development, 
namely target identification and evaluation, profiling during disease models, safety 
evaluation and clinical studies, only during the phase of lead finding and optimization in vivo 
imaging technologies cannot have any function (Beckmann N et al. 2007). In principle, 
several in vivo imaging techniques are available to evaluate efficacy and safety of novel, 
promising compounds to cure disease, namely ultrasound, positron-emission tomography 
(PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging 
(MRI), computed tomography (CT), luminescence and fluorescence imaging (see Tab 1.1). 
They offer different possibilities and suffer different disadvantages and therefore a careful 
decision is necessary to decide for one platform or another. 
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Tab. 1.1: Different imaging modalities for preclinical evaluation of novel drug candidates, but also 
for clinical imaging of disease. The imaging methods have different disadvantages and advantages 
that have to be considered when chosen. Further methods than the indicated ones suitable for 
infection imaging in preclinical and clinical approaches are available. The table is sought to give only a 
glance about interesting techniques for this field of science. Abbreviations: FDG: 2-deoxy-2-
[(18)F]fluoro-D-glucose, USPIO: ultrasmall paramagnetic ironoxide particles, *: Francis KP et al. 2000, 
**: Gross S et al. 2009, +: Leevy WM et al. 2006, #: Love C et al. 2005 , §: Fowler JS et al. 1999,Δ: Niska 
JA et al 2012, †: Marzola P et al. 1999, ¥: Kaim AH et al. 2002. 
Technique Disadvantages Advantages Infection Imaging 
applications 
(examples) 
Bioluminescence 
imaging 
signal loss due to tissue 
depths 
good sensitivity, high 
through-put 
luminescent 
pathogens*, luminol 
imaging** 
Fluorescence imaging signal loss due to tissue 
depths 
good sensitivity, high 
through-put 
fluorescently tagged 
probes+ 
PET (positron 
emission 
tomography) 
costly, radiation high sensitivity FDG#, drug labeling§ 
SPECT (single photon 
emission computed 
tomography) 
limited spatial resolution good sensitivity  
CT (Computed 
tomography) 
poor soft tissue contrast, 
radiation 
high spatial resolution infections of bonesΔ 
Ultrasound imaging imaging through bones 
and lung difficult 
fast, good spatial 
resolution 
 
MRI (magnetic 
resonance imaging) 
expensive, time-
consuming 
high spatial resolution, 
good soft tissue 
contrast 
soft tissue 
infection†, USPIO¥ 
 
 
Optical (luminescence and fluorescence) as well as magnetic resonance imaging were of 
special interest for this thesis since the aim of this work was to establish a multimodal 
imaging platform consisting of this two methods to evaluate antibiotic drug candidates in 
murine models of S. aureus infection. 
Bioluminescence imaging is based on the activity of luciferases in vivo. Luciferases are 
enzymes that catalyze oxidative reactions which lead to emission of photons. The bacterial 
luciferase is most suitable for infection imaging due the organization of the luxABCDE 
operon, which does not only encode for the luciferase but also for the enzymes necessary 
for luciferase compound synthesis (Meighen EA. 1993). In consequence, the introduction of 
the luxABCDE operon enables the bacterial cell to produce all components which are 
necessary for generation of luminescence signal. This cannot be achieved by other 
luciferases since they are depended on the additional administration of compounds to emit 
photons. The heterodimeric bacterial luciferase (encoded by luxAB) catalyzes the oxidation 
 1.3. Preclinical testing and In Vivo Imaging? 23 
of flavin mononucleotide (FMNH2) and a long-chain fatty aldehyde (synthesized by a 
complex consisting of luxCDE), thereby emitting blue-green light (peak at 490 nm). The 
introduction of this operon into S. aureus led to stable expression of luciferase and 
correlating photon emission (Francis KP et al. 2000). This enabled in turn imaging of bacterial 
burden in various models of S. aureus infection (Kuklin NA et al. 2003, Kadurugamuwa JL et 
al. 2003b, Engelsman AF et al. 2009, Funao H et al. 2012). This technique was furthermore 
applied to investigate the efficacy of antibiotics (Kadurugamuwa JL et al. 2003a, Xiong YQ et 
al. 2005) or to determine promoter activity in vivo (Steinhuber A et al. 2008). Due to the 
broad published data about bioluminescence imaging of genetically modified luxABCDE-
expressing S. aureus strains, we decided to include this modality into our two modality 
platform for antibiotic drug candidate evaluation. 
In contrast, much less publications about magnetic resonance imaging (MRI) as infection 
imaging modality, especially for S. aureus infections, in preclinical setting were available at 
the beginning of this thesis. Regarding native, proton based MRI, few studies demonstrated 
an increase in T2 relaxation times in the infected thigh muscle of a murine thigh infection 
model of S. aureus (Marzola P et al. 1999, Kaim AH et al. 2002, Kaim AH et al. 2003). One of 
these studies demonstrated moreover differences in signal pattern after antibiotic therapy 
(Marzola P et al. 1999). Furthermore, ultrasmall paramagnetic ironoxide nanoparticles 
accumulated after intravenous administration at the rim of the abscess area in this model, as 
shown in a different study (Kaim AH et al. 2002). This could be visualized best by either T2 or 
T2
* weighted MR methods. The accumulation was facilitated by uptake of contrast agent in 
the bloodstream by phagocytes which then migrated to the site of inflammation (Kaim AH et 
al. 2002, Kaim AH et al. 2003). 
In principle, a similar accumulation mechanism was shown for perfluorocarbon emulsions in 
murine models of stroke, ischemia and pulmonary inflammation (Flögel U et al. 2008, Janjic 
JM et al. 2008, Ebner B et al. 2010). These perfluorocarbon emulsions could be visualized at 
the site of inflammation by 19MRI. Since mammals do inherently not harbor sufficient 
amounts of 19F to deliver signal in 19F MR images, perfluorocarbon emulsion could be 
visualized background-free and overlayed upon 1H MR images to determine accumulation in 
anatomical context. 
Nonetheless, at the beginning of this thesis, no studies about accumulation of 
perfluorocarbon emulsions at sites of infection were available. Thus, the capability of 19F MRI 
with perfluorocarbon emulsions as MR tracer had to be evaluated first. It was furthermore 
necessary to compare the accumulation and MR visualization of perfluorocarbon emulsions 
with those of USPIOs in order to decide which method of both should be part of our two 
modality imaging platform for the evaluation of promising novel antibiotic drug candidates. 
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1.4.  Aim of this thesis 
 
The central goal of this thesis was to establish and evaluate a two-modality imaging 
platform, consisting of bioluminescence and magnetic resonance imaging, for preclinical 
testing of novel antibiotic drug candidates in small animal models. Bioluminescence imaging 
was chosen, since the application of luciferase-expressing pathogens offers in vivo and non-
invasive monitoring of bacterial burden throughout the course of infection, while magnetic 
resonance imaging should visualize anatomical changes caused by infection and immune 
response. Although this imaging platform should be pathogen-independent, S. aureus was 
chosen as model pathogen to establish and test the imaging modalities, due to the 
enormous clinical importance and the need for novel antibiotics to treat infections caused by 
this bacterium. 
In a second step after establishment, the two-modality platform should be applied to 
visualize and measure the efficacy of well-known antibiotics against S. aureus. And finally, in 
a third step, if the platform visualizes and indicates differences in the efficacy pattern of 
antibiotics, a promising novel compound to fight S. aureus infections should be evaluated 
with this system: lysostaphin. 
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2. Materials 
 
2.1.  Chemicals and consumables 
 
Chemicals and consumables used in this study were purchased from Alfa Aesar (Karlsruhe), 
BD Biosciences (Heidelberg), Bio-Rad (München), eBioscience (Frankurt), Eppendorf 
(Hamburg), Life Technologies (Darmstadt), Merck Millipore (Schwalbach), Miltenyi Biotech 
(Bergisch Gladbach), Oxoid (Wesel), Pluriselect (Leipzig), Roth (Karlsruhe), Sarstedt 
(Nürnbrecht), Sigma-Aldrich (Taufkirchen), ThermoFisher Scientific (Erlangen), VWR 
(Ismaning). Antibodies used for flow cytometry were supplied by Miltenyi Biotech (Bergisch 
Gladbach) and eBioscience (Frankfurt). 
 
2.2.  Kits 
 
Table 2.1: Kits used in this thesis.  
Kit Supplier 
Anti-Ly6G MicroBead Kit (mouse) 
Miltenyi Biotech (Bergisch Gladbach) Anti-CD11b MicroBead Kit (mouse) 
Anti-FITC MicroBead Kit 
CD4 S-pluriBeads Kit anti-ms 
Pluriselect (Leipzig) 
CD11b M-pluriBeads Kit anti-ms 
CD19 S-pluriBeads Kit anti-ms 
Ly6G M-pluriBeads Kit anti-ms 
Mouse Chemokine 6plex FlowCytomix Multiplex 
eBioscience (Frankfurt) 
Mouse CCL2 (MCP-1) ELISA Ready-SET-Go! 
Mouse IFN gamma ELISA Ready-SET-Go! 
Mouse Th1/Th2 10plex FlowCytomix Multiplex 
Mouse Th1/Th2 10plex Ready-to-Use 
FlowCytomix Multiplex 
 
2.3.  Antibacterial compounds 
 
Table 2.2: Antibiotics used in this study. 
Compound Supplier Stock 
Linezolid Sigma-Aldrich (Taufkirchen) 15 mg/ml in PBS or 0.9 % NaCl 
Lysostaphin Bharat Biotech (Hyderabad, India) 2 mg/ml in PBS or 0.9 % NaCl 
Minocycline 
Sigma-Aldrich (Taufkirchen) 
20 mg/ml in PBS or 0.9 % NaCl 
Oxacillin 200 mg/ml in PBS or 0.9 % NaCl 
Vancomycin 30 mg/ml in PBS or 0.9 % NaCl 
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All antibiotics were solved in sterile 0.9 % NaCl or PBS and then filtered through 0.22 µm 
syringe filters (Merck Millipore, Schwalbach) to receive sterile antibiotic solution. Stock 
solution was then further diluted in either sterile 0.9 % NaCl or PBS in order to receive 
working solution. Recombinant Lysostaphin was kindly provided by Bharat Biotech as ready-
to-use solution. Lysostaphin was expressed as mature lysostaphin in Escherichia coli, with no 
traces of prepro-lysostaphin or pro-lysostaphin (Khatri GS, Sharma R. 2005). The formulation 
was produced under ‘Good Manufactoring Practice’ with > 99 % purity and was constituted 
in 10 mM phosphate buffer (pH 6.9) with 154 mM NaCl. 
 
2.4. Instruments 
 
Table 2.3: Instruments used in this study. 
 
Instrument Model Manufacturer 
Centrifuge Pico 17 Heraeus (Hanau) 
Biofuge 13R Heraeus (Hanau) 
Multifuge X3R Heraeus (Hanau) 
Multifuge 1 L-R Heraeus (Hanau) 
Confocal Laser Scanning 
Microscope 
TCS SP5 Leica (Mannheim) 
Enzyme linked immunosorbent 
assay (ELISA) reader 
Multiskan Ascent Thermo Fisher Scientific 
(Erlangen) 
Flow Cytometer MACSQuant Analyzer Miltenyi Biotech (Bergisch 
Gladbach) 
Incubator Tv40b Memmert (Schwabach) 
BB16 Heraeus (Hanau) 
Mini10 Hybaid (Heidelberg) 
Innova 4300 New Brunswick Scientific 
(Hamburg) 
Luminescence / Fluorescence 
In vivo Imaging System 
FACSCalipur BD Biosciences (Heidelberg) 
IVIS Lumina II Caliper Life Sciences 
(Hopkinton, MA, USA) 
Magnetic Resonance Scanner Biospec, 7 Tesla Bruker Biospin (Reinstetten) 
pH meter pH720 Inolab (Weilheim) 
Photometer ultraspec 3100 pro Amershan Biosciences 
(Nürnberg) 
Vortex Biovortex V1 Lab4you (Berlin) 
Sonifier Sonifier 250 Branson Ultrasonics (Danbury, 
CT, USA) 
Surgical microscope OPMI Zeiss (Oberkochen) 
Tissue homogenizer Dispomix BioLabProducts (Gödenstorf) 
Water bath 1002 GFL (Burgwedel) 
1092 GFL (Burgwedel) 
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2.5. Culture media and plates 
 
Table 2.4: Media used in this study. 
Media Ingredient g/l 
B medium tryptone 
yeast extract 
NaCl 
K2HPO4 
10 
5 
10 
1 
BHI medium Brain Heart Infusion Broth (Oxoid, Wesel)  37 
Luria Bertani medium (LB) tryptone 
yeast extract 
NaCl 
10 
5 
10 
Mueller Hinton medium Mueller Hinton Broth (Sigma Aldrich, 
Taufkirchen) 
23 
TSB medium Difco Tryptic Soy Broth (BD Biosciences, 
Heidelberg)  
30 
 
All media were solved in distilled water and then autoclaved prior to use at 121 °C and 1 bar 
for 20 min. To receive agar plates, 15 g/l agarose was added to the respective medium prior 
autoclaving. Sterile filtered antibiotic solutions were added after cooling of medium or agar 
to 50 °C. 
 
2.6.  Bacteria 
 
Table 2.5: Bacterial strains used in this thesis. 
Strain Source 
S. aureus LAC (USA300) Clinical Isolate, Tübingen, (now in IMIB strain 
collection) 
S. aureus NCTC8325 National Collection of Type Cultures, United 
Kingdom 
S. aureus HG001 Herbert S et al. 2010 
S. aureus Xen29 Caliper Life Sciences (Hopkinton, MA, USA) 
 
All strains were stored at – 80 °C in glycerin stocks and plated on B or LB agar plates prior 
cultivation for experimental application. 
 
2.7.  Buffers and solutions 
 
Buffers and solutions supplied with the kits were used according to the manufacturer’s 
instructions. Home-made buffers and solutions are either mentioned in materials or 
methods chapters 2 and 3. Only distilled water was used for buffers and solutions. 
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2.8. Contrast agents and tracer 
 
In principle, magnetic resonance imaging contrast agents/tracer and luminol for 
luminescence imaging were applied in this study. Luminol sodium salt was purchased from 
Alfa Aesar (Karlsruhe) and dissolved in sterile 0.9 % NaCl solution to achieve a working 
solution of 40 mg/ml. Thus, an injection of 100 µl i.p. resulted in 200 mg Luminol/kg body 
weight (average mouse weight of 20 g). 
Two different types of contrast agents/tracer for magnetic resonance imaging were used 
throughout this study: ironoxide nanoparticles and perfluorocarbon emulsions. 
The cross-linked ironoxide nanoparticles (CLIO) were kindly provided by the group of Prof. 
Dr. Schenk (Department of Inorganic Chemistry, University of Würzburg). They had a 
diameter of 30 nm with a central ironoxide core of 2 – 3 nm and were dextran coated. 
Emulgated in phosphate buffered saline, 16.8 mg Fe/kg bodyweight were injected 
intravenously. 
Regarding perfluorocarbon emulsions, two different sources of particles were used in this 
study: commercially available ready-to-use and home-made emulsions. The commercially 
available emulsion was used for the experiments in the chapters 5 and 6 and for all 
experiments in chapter 4 with the exception of flow cytometry, fluorescence microscopy and 
cell sorting experiments. The commercially available particles consisted of a 20 % v/v 
perfluoropolyether emulsion for direct intravenous administration (VS1000H or VSdmGreen, 
both from Celsense, Pittsburgh, PA, USA). 
At the beginning of this thesis, no fluorescently labeled perfluorocarbon emulsion was 
commercially available. But the fluorescent label was necessary to uncover the mechanism 
of accumulation and to identify participating immune cells by flow cytometry, fluorescence 
microscopy and cell sorting approaches. Therefore home-made fluorescently labeled 
perfluorocarbon emulsion was used in some indicated experiments in chapter 4. The 
emulsification protocol is described in chapter 3.7. 
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2.9.  Software 
 
Table 2.5: Software used during this thesis. 
 
Software Manufacturer 
Adobe Acrobat Pro 9 Adobe (San Jose, CA, USA) 
Flow Cytomix Pro eBioscience (Frankfurt) 
Flowing Software 2.5.0 Perrttu Terho, University of Turku, Finland 
GIMP 2 The GIMP Team, Freeware, www.gimp.org 
Graph Pad Prism 5 GraphPad (La Jolla, CA, USA) 
Living Image 3.2 Caliper Life Science (Hopkinton, MA ,USA) 
MACSQuantify 2.4 Miltenyi Biotech (Bergisch Gladbach) 
MS Office 2007 Microsoft (Redmond, WA, USA) 
Windows XP and Windows 7 Microsoft (Redmont, WA, USA) 
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3. Methods 
 
3.1.  General methods 
 
All media and solutions were sterilized prior use either by autoclaving (20 min, 121 °C and 1 
bar) or filtered through 0.22 µm syringe filters. 
Staphylococcus aureus was cultured, if not otherwise stated, in liquid B or LB medium in 
shaking cultures at 37°C. For storage, 15 ml of liquid cultures (18 h) were centrifuged (10 
min, 4000 g/min), the pellet resuspended in 1 ml fresh medium and mixed with 1 ml of 
sterile glycerin. The resulting culture was then stored at – 80°C. 
To generate infectious doses, frozen bacteria (- 80°C) were thawed at room temperature and 
then plated on B agar plates. After overnight incubation at 37°C, single colonies were picked 
and incubated in 50 ml shaking cultures of B medium for 18 h at 37°C. 15 ml of the culture 
were then centrifuged for 5 min at 4000 rpm/min at room temperature, the supernatant 
discarded and the pellet resuspended in 15 ml 0.9 % NaCl solution. After another 
centrifugation step (RT, 5 min at 4000 rpm/min) and discarding of the supernatant, the 
pellet was resuspended in 1 ml 0.9 % NaCl solution. The OD600 value of this bacterial solution 
was now measured and the solution diluted to reach the final concentration of bacteria for 
the animal or in vitro experiments (following the assumption that 1 OD600 unit equals 7.5 x 
108 bacteria/ml). 
 
3.2. Minimal inhibitory concentration testing (MIC) 
 
The minimal inhibitory concentration is defined as the lowest compound concentration in 
solution that inhibits bacterial growth completely. To determine this concentration, the 
experiments followed in principle the recommendations of the CLSI (CLSI. 2012). 
The bacteria were incubated overnight in liquid Mueller Hinton medium (MH) at 37°C for at 
least 18 h. 15 ml of the culture was centrifuged (4000 rpm, 10 min at room temperature) 
and the pellet resuspended in 1ml MH medium. The OD600 was measured and the bacterial 
solution diluted to reach a final concentration of 5 x 107 bacteria/ml. Antibacterial 
substances were diluted serially in MH medium to receive different concentrations and 
pipetted into different wells of a 96 well plate. 100 µl of the bacterial solution was then 
administered to each well and the plate incubated for 18 h at 37°C. Each 96 well plate 
included positive (only bacteria, no antibacterial substance) and negative (only antibacterial 
substance, no bacteria) controls. The lowest concentration of antibacterial substance 
resulting in no visible turbidity was defined as MIC value of this compound. 
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3.3.  Animal models 
 
3.3.1. Ethics statement 
All animal experiments in this thesis were approved by the Committee on the Ethics of 
Animal Experiments of the government of Lower Franconia (54-2531.01-42/06 and 55.2-
2531.01-06/12). All experiments were performed in strict accordance with the German 
animal protection law. The animals were housed in cages under standardized lighting 
conditions and had ad libitum access to food and water. All in vivo imaging was performed 
under isoflurane anesthesia and all efforts were made to minimize suffering. Animals were 
sacrificed at the end of the experiment by CO2 inhalation. 
 
3.3.2. Thigh infection model 
The standard model of this thesis was the S. aureus thigh infection model. It was applied in 
all experimental chapters of this thesis, especially for magnetic resonance imaging. The S. 
aureus infection in this model is provoked by an intramuscularly injection of bacteria into the 
thigh muscles of mice. This resulted in localized infection and inflammation and finally in 
abscess formation in the muscle tissue of the mouse. The bacteria remained in the thigh 
muscle and did not, as in other S. aureus infection models, spread throughout the animal’s 
body and cause systemic infection. Importantly, both acute and chronic phase of 
inflammation were covered in this rather long-term model, since the infection and immune 
response did not kill the mouse. These features and the formation of large abscesses (thus 
loci of infection) seemed to be very interesting and promising to investigate differences in 
magnetic resonance images and methods as well as the accumulation of contrast agents. 
The infection model 
In principle, female Balb/c mice (Charles River, Sulzfeld) were housed at least for 7 days in 
the animal facility prior to experimentation. They had ad libitum access to food and water. 
Animals were around 6 to 8 weeks old, when acquired and reached a body weight of 18 to 
22 g at the beginning of experimentation. Before bacteria were administered, animals were 
shaved at both thigh muscles in order to enable efficient photon imaging and to offer a clear 
sight onto the site of injection. Animals received inhalation anesthesia (1.5 % isoflurane in 
O2) while bacteria were injected intramuscularly into the left thigh muscle. Bacterial 
suspension was generated following general methods in B medium, washed and 
resuspended in 0.9 % NaCl solution or PBS. A variable number of bacteria was administered 
in the experiments of this thesis, but in all cases, bacteria were in a volume of 50 µl. In 
principle, only two different S. aureus strains were applied in this thesis: the luciferase 
expressing strain Xen29 and the ca-MRSA strain LAC (or USA300). The S. aureus Xen29 strain 
was in this context a derivative of the strain ATCC 12600 with a chromosomally integrated 
luxABCDE operon from Photorhabdus luminescencs (Francis KP et al. 2000). The exact 
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number of administered bacteria and the strain is stated in the corresponding results 
section. 
Antibiotic treatment 
Some groups of mice in chapters 5, 6 and 7 received antibiotic treatment during the course 
of infection. In principle, treatment started, if not otherwise stated, at 2 hours p.i. and was 
resumed two times a day. The antibiotic concentrations mentioned in the corresponding 
results section were calculated as mass (antibiotic) per body weight per day. Vancomycin 
was administered in a dose of 30 mg/kg/day, linezolid in 15 or 20 mg/kg/d, oxacillin in 200 
mg/kg/d, minocycline in 20 mg/kg/d, and lysostaphin in either 2 or 5 mg/kg/d. All antibiotics 
were administered intraperitoneally with the exception of lysostaphin which was injected 
intravenously. The solvent of the antibiotics is stated in the methods section. The last 
antibiotic treatment was applied 12 hours prior the end of the experiment and organ 
recovery. 
Contrast agents and tracer 
In chapters 4, 5 and 6, perfluorocarbon emulsions were applied as MR tracer. The emulsions 
were either acquired (Celsense, Pittsburgh, PA, USA) or home made (see chapter 3.7). The 
applied perfluorocarbon emulsion for each experiment is stated in the corresponding results 
section. Independent of their origin, 100 µl of ready-to-inject emulsion was applied 
intravenously through one of the tail veins. Mice were therefore anesthetized with 1.5 % 
isoflurane in oxygen and placed on the warming platform of the IVIS system, which is heated 
to 37 °C (Lumina II, Caliper Life Sciences, Hopkinton, MA, USA). 
The iron oxide nanoparticles (CLIO), which were used in MR imaging experiments in chapter 
4, were applied in a similar fashion than perfluorocarbon emulsion. The home made contrast 
agent (AG Schenk, Department of Inorganic Chemistry, University of Würzburg) was 
dissolved in a final volume of 100 µl and infected into one of the tail veins during anesthesia 
and after warming of mice. 
In chapter 7, mice infected with S. aureus LAC received luminol solution in order to visualize 
myeloperoxidase activity non-invasively and in vivo at the site of infection with luminescence 
imaging. Therefore, mice received intra-peritoneal administrations of luminol at a 
concentration of 200 mg/kg body weight in a final volume of 100 µl. The luminol sodium salt 
(Alfa Aesar) was dissolved in sterile 0.9 % NaCl solution and filtered through 0.22 µm syringe 
filters to achieve final solution. 
Tissue and blood recovery 
At the end of the experiment, mice were sacrificed by administration of inhalable pure CO2. 
The infected thigh muscles were then removed aseptically and either processed immediately 
after recovery or frozen at – 80°C until processing. In some experiments of chapter 4, inner 
organs like liver, kidneys, spleen, lungs and heart were removed aseptically and frozen at – 
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80 °C until processing. The blood was, if necessary, recovered after death of the animal by 
removing the heart and collecting the leaking blood. Blood samples were immediately after 
recovery imaged for fluorescence signal with the IVIS system (Lumina II, Caliper Life 
Sciences), then allowed to coagulate, centrifuged and the resulting serum samples collected 
and frozen at – 80 °C until the levels of cytokines or chemokines were measured. 
 
3.3.3. Catheter related infection model 
For evaluation of lysostaphin efficacy in chapter 6, a second animal model besides thigh 
infection was applied: the catheter-associated infection model. In principle, a catheter was 
placed in this model in the jugular vein of mice and S. aureus was administered into its inner 
lumen. Bacteria formed a biofilm in the catheter and then spread via the bloodstream to 
colonize inner organs. This resulted in systemic infection. In general, the model was 
performed according to a prior study (Lorenz U et al. 2008). 
The infection model 
Female Naval Medical Research Institute (NMRI) mice (Charles River, Sulzfeld) with a weight 
of 30 to 35 g were house for at least one week in the animal facility. Prior experimentation, 
the thorax and neck region of the mice was shaved to enable unobstructed luminescence 
imaging and surgery. Regarding surgery, mice received an intraperitoneal injection of 
xylazine (8 mg/kg body weight) and ketamine (100 mg/kg body weight) for anesthesia and a 
minimal horizontal incision was made into the skin of the left side of the neck. The 
submaxillary gland was isolated to expose the bifurcation of the anterior and posterior facial 
veins using a surgery microscope (Zeiss). Next, a venotomy on the anterior facial was 
performed between loose ligatures and the catheter (polyurethane catheter, Instech 
Salomon, Plymouth Meeting, PA, USA) was inserted through the incision. After advancing 
the catheter towards the superior vena cava, the ligatures were tied and the catheter 
subcutaneously tunneled and exteriorized through a midline scapular incision. The catheter 
lumen was washed once with sterile 0.9 % NaCl solution and sealed with a plug. 
Animals were allowed to recover for 24 hours before the start of the infection experiment. 
Mice were then anesthetized by inhalation of isoflurane (1.0 to 1.5 % in oxygen). The plug of 
the catheter was removed and 30 µl bacterial suspension with 3.7 x 107 cfu S. aureus Xen29 
was administered into the catheter lumen. Bacteria were allowed to adhere to the catheter 
surface for 15 min, before the catheter was flushed with 0.2 ml sterile 0.9 % NaCl solution. 
Animals were now and at several time points after start of infection imaged for emergence 
and development of luminescence signal. 
Antibiotic treatment 
Two hours post infection, the antibiotic treatment started. Animals received either sterile 
0.9 % NaCl solution (control group, intraperitoneally), 30 mg/kg/d vancomycin 
(intraperitoneally), 200 mg/kg/d oxacillin (intraperitoneally), lysostaphin in the dosing of 2 or 
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5 mg/kg/d (intravenously) or a combination of 200 mg/kg/d oxacillin and 2 mg/kg/d 
lysostaphin. Antibiotics were administered twice a day.  
Tissue and catheter recovery 
At the end of the experiment (day 4 p.i.), mice were sacrificed by administration of inhalable 
pure CO2. The location of the catheter in the vena cava was then surgically confirmed and 
only mice with correctly placed catheter were included in the analysis. The catheter, kidneys, 
liver, heart and lung were then removed aseptically, their luminescence signal measured ex 
vivo and either processed immediately after recovery or frozen at – 80°C until processing.  
 
3.3.4. Determination of colony forming units 
Two different murine models of S. aureus infection were applied in this study: the thigh 
infection model and the catheter-associated infection model. Main and primary site of 
infection in the thigh infection model was the thigh muscle of the mouse, while major 
bacterial communities in the catheter-associated infection model were found in the kidneys 
and catheter of infected mice. Besides these primary sites of infection, the bacterial burden 
of other organs was in some other experiments of interest, too. In chapter 6, the heart and 
lung of mice of the catheter-associated infection experiment were recovered in addition to 
kidneys since bioluminescent imaging indicated infection at these sites. In chapter 4, the 
bacterial burden in liver, kidneys and spleen of mice of the thigh infection model was 
determined in order to evaluate whether the infection is localized in this model and whether 
perfluorocarbon emulsion alters the course of infection or not. 
Nonetheless, the colony-forming units and thus bacterial burden in all of these organs was 
measured, in principle, in the same way. After recovery at the end of the experiment, the 
organ was placed in a tissue homogenization tube (gentleMACS M tube, Miltenyi Biotech) 
with 2 ml sterile 0.9 % NaCl solution or PBS. The organ was then homogenized with a tissue 
homogenizer (DispoMix, BioLabProducts, Gödenstorf) and the resulting cell suspension 
serially diluted in sterile 0.9 % NaCl solution or PBS. The catheters of the catheter-associated 
infection (chapter 6) model were sonicated with low-energy, but high frequency sound in 2 
ml sterile 0.9 % NaCl solution. Several dilutions of tissue or catheter samples were then 
plated on B agar plates and incubated for 18 – 24 hours at 37°C. The colonies were counted 
and multiplied with the dilution factor to determine the number of colony-forming units in 
the respective organ.  
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3.4. In vivo Bioluminescence and Fluorescence Imaging 
 
In vivo bioluminescence and fluorescence imaging was performed in all experiments with 
the help of an ‘In Vivo Imaging System’ (IVIS Lumina II, Caliper Life Sciences). 
Bioluminescence imaging of bacterial burden 
Luciferase-expressing S. aureus Xen29 was applied in many of the experiments in order to 
visualize bacterial burden non-invasively in vivo. This strain harbors a chromosomally 
integrated luxABCDE operon from Photorhabdus luminescencs (Francis KP et al. 2000). This 
operon is sufficient for the generation of luciferase protein and compound to emit photons 
in the presence of oxygen and energy in the cell. S. aureus Xen29 was applied in the murine 
thigh infection model in chapters 4, 5, 6 and 7, and in the catheter-associated infection 
model in chapter 6. Regarding the thigh infection model, bacteria were injected into the left 
thigh muscle of mice. As a negative control, sterile 0.9 % NaCl solution was injected into the 
right thigh muscle. The bioluminescence signal was then detected at different time points 
(indicated in the corresponding results section) pre or post start of infection by the IVIS 
system. Therefore, mice received inhalation anesthesia (1.5 % isoflurane in oxygen). When 
asleep, mice were placed on the imaging platform of the IVIS system, which is heated to 37 
°C in order to sustain body temperature of the animals during experimentation. Inhalation 
anesthesia (1.0 % isoflurane in oxygen) was continued until the end of the imaging session. 
The bioluminescence imaging was performed with following parameters: exposure: 120 s; 
FStop: 1; excitation: block; emission: open; field of view (FOV): D; and height: 1.5 cm. Images 
were analyzed with Living Image 3.2 software (Caliper Life Sciences). To determine 
bioluminescence emission values, an oval area of interest was manually defined at the site of 
interest and applied with same geometry and size to images of all mice at all time points (of 
the individual chapter) in order to offer comparability. 
Bioluminescence imaging of myeloperoxidase activity with luminol 
In chapter 7, the experiments focused on the influence of antibiotic treatment on the 
immune response. Since some of the mice were infected in these experiments with S. aureus 
LAC, which does not harbor a luciferase in its genome and thus does not emit 
bioluminescence signal, it became possible to administer luminol solution into these mice in 
order to visualize processing of this compound by neutrophilic myeloperoxidase (Gross S et 
al. 2009). The reaction results in the emission of blue to green photons that could be 
detected in principle with same settings than the bioluminescence signal derived from S. 
aureus Xen29. 
In general, mice received inhalation anesthesia (1.5 % isoflurane in oxygen) and when 
asleep, luminol sodium salt (Alfa Aesar), in sterile 0.9 % NaCl solved, in a concentration of 
200 mg/kg body weight was administered intraperitoneally. Immediately after injection, 
mice were placed on the imaging platform of the IVIS system and bioluminescence signal 
36 Chapter 3. Methods 
measured in a series of images (5 to 10), each with following parameters: exposure: 120 s; 
FStop: 1; excitation: block; emission: open; field of view (FOV): D; and height: 1.5 cm. Images 
were generated with Living Image 3.2 software (Caliper Life Sciences) and bioluminescence 
signal was then calculated, similar to S. aureus Xen29 derived signal quantification, by 
defining manually an oval area of interest at the site of infection and applied to all mice and 
time points. 
Fluorescence imaging of perfluorocarbon emulsions 
In chapter 4, home-made perfluorocarbon emulsions were labeled with fluorescence dyes in 
order to investigate the accumulation at the site of infection by flow cytometry, cell sorting 
and fluorescence microscopy of tissue sections. The fluorescence labeling offered on the 
other hand the visualization of the tracer in vivo or in tissue homogenization samples, too. 
Thus, the accumulation of perfluorocarbon emulsion in mice was studied by in vivo 
fluorescence imaging, as well as in blood and tissue homogenization or cell sorted samples. 
For in vivo imaging, mice received either fluorescently labeled perfluorocarbon emulsion 
(labeled with either Atto550 or Atto647N, as stated in the corresponding results section) or, 
as a control, non-fluorescent perfluorocarbon emulsion and fluorescence signal was 
determined at various time points prior or post administration. Therefore, mice were 
anesthetized with gaseous isoflurane (1.5 % in oxygen) and placed on the imaging platform 
of the IVIS system. In the first set of experiments, a large number of different excitation (500 
nm, 535 nm, 570 nm, 605 nm, 640 nm, 675 nm) and emission filter (DsRed (575 - 650 nm), 
Cy5.5 (695 – 770 nm) settings was tested for specific visualization of perfluorocarbon 
derived fluorescence. Best ratios of fluorescence signal at site of infection compared to 
signal of control treated mice were achieved with excitation filter: 535 nm and emission 
filter DsRed for Atto550-labeled perfluorocarbon emulsions and excitation filter: 640 nm and 
emission filter: Cy5.5 for Atto647N-labeled perfluorocarbon emulsions. Hence, all following 
imaging sessions were performed with these filter settings and following parameters: 
exposure: 120 (or 60) s; FStop: 1; excitation: block; emission: open; field of view (FOV): D; 
and height: 1.5 cm. The area of interest was defined manually in the images generated with 
the help of Living Image 3.2 software (Caliper Life Sciences) and applied to all mice in the 
same geometry and size. 
The fluorescence signal of blood and tissue homogenization or sorting samples were imaged 
in equal volumes in 1.5 ml Eppendorf caps. They were placed in racks on the imaging 
platform of the IVIS system and the imaging was performed with the 535 nm excitation filter 
and DsRed emission filter for the Atto550-labeled perfluorocarbon samples or with the 640 
nm excitation and the Cy5.5 emission filter for the Atto647N-labeled perfluorocarbon 
emulsion samples. The imaging parameters were: exposure: 120 (60 or 30) s; FStop: 2; 
excitation: block; emission: open; field of view (FOV): D; and height: 1.5 cm. The images 
were generated with Living Image 3.2 software (Caliper Life Sciences). In order to measure 
the fluorescence signal of the individual sample, a circular region of interest was defined 
manually and applied to all samples in all images in the same size. 
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3.5. Magnetic Resonance Imaging 
 
Magnetic resonance imaging of S. aureus infections occupies a central role in this thesis. 
Since only sparse preliminary studies were published, many imaging experiments had to be 
performed to evaluate the capability of MRI to visualize sites and course of infection. 
In general, magnetic resonance imaging was performed in close collaboration with Volker 
Sturm (AG Jakob, Department of Experimental Physics 5, University of Würzburg). Volker 
Sturm developed and adapted all measurement protocols/sequences for the magnetic 
resonance scanner, operated the MR scanner, generated images and determined values 
from scanner-derived raw data. 
Animal handling procedure 
The animal imaging experiments were performed on a 7 Tesla small animal scanner (Bruker 
Biospec system, Bruker BioSpin, Reinstetten), which is located in a biosafety level 1 area in 
the Department for Experimental Physics 5 (University of Würzburg). Since experiments with 
S. aureus require a biosafety level 2 environment, a special containment device was 
necessary to separate infected animals and S. aureus containing samples from environment. 
This was achieved with the help of a home-made container (Fig. 3.1). The container had the 
shape of a cylinder with a bed located inside, on which mice were placed during the imaging 
experiments. Mice received inhalation anesthesia during the imaging experiment (1.0 to 1.5 
% isoflurane in O2). The inhalation gas was warmed in order to prevent a decrease of body 
temperature during the experiment. Heart bead and breathing was monitored with a 
balloon, placed on the chest of the mice. In the case of a strong decline of breathing or heart 
bead rate, the experiment was stopped, the inhalation anesthesia aborted and the mouse 
removed from the container and allowed to recover.  
Anatomical and iron oxide particle based 1H MR imaging 
All measurements were performed in an adjustable double resonant (19F and 1H) home-built 
birdcage coil in the scanner. In order to image the anatomy or tissue composition at the site 
of infection, a turbo spin echo (TSE) sequence was applied to receive either two-dimensional 
slice images (effective echo time/repetition time [TEeff/TR]: 13.4 ms / 2500 ms; inter-echo 
time: 6.7 ms; turbo factor: 4; FOV: 25 x 25 mm2; matrix: 200 x 200; slice thickness: 1 mm; 16 
slices; NA: 2) or three-dimensional data sets (effective echo time/repetition time [TEeff/TR]: 
20.4 ms / 500 ms; inter-echo time: 5.1 ms; turbo factor: 4; FOV: 25 x 25 x 25 mm3; matrix: 
100 x 96 x 100; NA: 1). In chapter 4, T2 maps were acquired to visualize edema formation in 
the infected thigh muscle or to visualize CLIO particle accumulation, thus a multi slice spin 
echo (MSME) sequence was used (effective echo time/repetition time [TEeff/TR]: 6 ms / 6000 
ms; NE: 40; FOV: 25 x 25 mm2; matrix: 128 x 128; slice thickness: 1 mm; 10 slices interlaced; 
NA: 1). The second MR method to image the accumulation of iron oxide nanoparticles at the 
site of infection was the application of T2
* sequences. Therefore 3D multi gradient echo 
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(MGE) scans were performed (effective echo time/repetition time [TEeff/TR]: 2 ms / 100 ms; 
inter-echo time: 2.7 ms; NE: 16; FOV: 40 x 25 x 25 mm3; matrix: 128 x 80 x 80; NA: 2). The 
signal decay parameters were then fitted pixel per pixel with a T2/T2
* maximum likelihood 
estimation based on Rice distribution (Sijbers J et al. 1999). 
 
Fig. 3.1: Animal imaging container for magnetic resonance imaging of mice with S. aureus thigh 
infection. The container was constructed to comply with biosafety level 2 restrictions. Mice were 
placed on the inner bed and received inhalation anesthesia during the imaging experiment. Heart 
bead and breathing was controlled with the balloon, which was placed on the chest of the mice. 
 
19F MRI with perfluorocarbon emulsions 
The MR active agent applied in this thesis was perfluorocarbon emulsion. These particles are 
detected not by 1H MRI, as iron oxide particles are, but by 19F MRI. In chapter 4, 3D steady 
state free precession chemical shift imaging (SSFP-CSI) sequences were used with the same 
geometry than the anatomical 1H – TSE scans (Pulse shape: hermite; Pulse bandwidth: 5400 
Hz; TACQ / TR: 10.24 ms / 13.6 ms; FOV: 25 x 25 x 16 mm3; spectral points: 512; matrix: 48 x 
48 x 8; - NA: 4). The signal of the 19F peak was integrated and the data afterwards 
interpolated into a matrix of 200 x 200 x 16 pixel by zerofilling. After defining the 19F 
threshold, the image was overlayed onto the 1H TSE scan in order to show perfluorocarbon 
emulsion accumulation in anatomical context. 
In chapters 5 and 6, quantification of perfluorocarbon emulsion accumulation at the site of 
infection became necessary to determine differences between antibiotic treatments. To 
reach this goal, the total 19F signal at a given location in the infected thigh muscle had to be 
determined. In this regard, a problem might be variations in the B1 field. In order to 
circumvent this or minimize this effect, only mice of equal size and weight were chosen for 
experimentation and all of them were placed in the same position in the rather homogenous 
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B1 field of the birdcage coil. Furthermore, the 
19F MR signal intensity was normalized to the 
apparent noise amplitude of the measurement in order to receive an estimate of the 19F 
content in a given voxel. The apparent mean noise amplitude of the 19F measurement was 
determined by fitting the pixel intensity histogram with a Gaussian noise model. 
Furthermore, in order to avoid false – positive results, each voxel was considered as ‘fluorine 
filled’ only if the 19F peak amplitude was at least four times higher than noise amplitude. This 
threshold was applied to all measurements in these chapters. 
The 19F MR sequence in these chapters was composed of two acquisition weighted 3D 
steady state free precession chemical shift imaging (SSFP-CSI) sequences with different pulse 
phase increments but the same geometry than the anatomical 1H TSE scans (θ: 0° / 180°, 
Pulse shape: hermite; pulse bandwidth: 5400 Hz; TACQ/TR: 10.24 ms /13.1 ms; FOV: 25 x 25 
x 16 mm3; spectral points: 512; matrix: 31 x 31 x 20; NA: 4). Both data sets were combined 
by ‘sum-of-square’ (SoS) and the 19F spectral line summed. The data was then zero-filled into 
a matrix of 100 x 100 x 64 pixels. 
MR measurement protocols needed between 1 and 3 hours per mouse. 
 
3.6.  Histology 
 
Histological examination of the abscess area in the thigh infection model was performed to 
address three questions: first, what is the histological appearance of the primary site of 
infection in this model, second, how and where accumulate iron oxide nanoparticles and 
perfluorocarbon emulsions at the site of infection, and third, is the histological appearance 
of infection altered by administration of contrast agents? 
Therefore, three groups of mice received either CLIO (iron oxide particles), perfluorocarbon 
emulsion (Atto647N-fluorescent or non-fluorescent home-made emulsions) or 0.9 % NaCl 
solution as negative control at day 2 p.i.. The infected thigh muscles were recovered either 
at day 3 or day 8 p.i. to cover both acute and chronic phase of inflammation. In addition, the 
liver and the spleen of perfluorocarbon and negative control group mice were recovered to 
compare differences in histologic appearance by the accumulation of the tracer. 
The muscles for general histology and iron staining, as well as liver and spleen of 
perfluorocarbon and negative control group mice were immediately fixed in a 10 times the 
volume of 10 % neutral buffered formalin solution (Sigma-Aldrich) than the organ, while half 
of the infected thigh muscles from perfluorocarbon group mice and of the negative control 
group mice were immediately frozen at – 80°C for cryotome cutting and 
immunohistochemistry. 
The formalin fixed muscles, spleens and livers were brought to Dr. Stefan Kircher (Institute 
of pathology, university of Würzburg), who kindly conducted further steps of sample 
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preparation and analysis. The fixed samples were therefore embedded in paraffin and cut to 
2 µm thick transversal slices. The sections were stained with haematoxylin-eosin according 
to the standard protocol at the Institute of Pathology in order to visualize immune cells at 
the site of infection. Another set of sections from infected thigh muscles of iron oxide group 
and negative control group mice was stained with Berlin blue staining to reveal intracellular 
iron content and thus iron oxide nanoparticles. This staining was achieved with a mixture of 
equal volumes of 20% hydrochloric acid solution (SigmaAldrich) and 10% potassium 
ferrocyanide solution (SigmaAldrich). Counterstaining with eosin led to visualization of cells 
by microscopic analysis. All stained tissue sections were analyzed together with Dr. Stefan 
Kircher (Institute of pathology, university of Würzburg). 
The frozen infected thigh muscles from perfluorocarbon and negative control group mice 
were frozen immediately after recovery at – 80°C. The frozen specimen were then brought 
to Dr. Martin Wartenberg (Institute of pathology, university of Würzburg), who kindly 
conducted cryotome cutting of samples to slices of 10 µm thickness. The slices were either 
fixed in 3.7 % formaldehyde solution at room temperature in the dark for 10 minutes and 
then stored at – 80°C until staining and/or microscopy or not fixed at all and immediately 
stored at – 80 °C. Prior to staining, samples were thawed at room temperature in the dark 
and rinsed once with PBS. 4 drops of Image-iT Fx signal enhancer (Life Technologies, 
Darmstadt) to reduce background fluorescence was added and the slices incubated for 30 
minutes in a humid environment at room temperature in the dark. 
After rinsing with PBS, one third of the samples was incubated with anti-Ly6G biotin-
conjugated antibody (eBioscience or Miltenyi Biotech) overnight in humid environment at 4 
°C in the dark. After incubation, slices were rinsed with PBS and stained with a mixture of 
streptavidin-conjugated Atto550 (5 µg/ml, Atto-Tec, Siegen), phalloidin-Atto425 conjugate 
(0.5 nmol/ml, Atto-Tec) and NucBlue Live Cell Stain (2 drops/ml, Life Technologies, 
Darmstadt) for 60 minutes at room temperature in the dark. 
The second third of samples was incubated for 60 minutes in the dark with a mixture of 
phalloidin-Atto425 conjugate (0.5 nmol/ml, Atto-Tec) and NucBlue Live Cell Stain (2 
drops/ml, Life Technologies), while the last third of samples was stained only with NucBlue 
Live Cell stain for 60 min. 
All samples were rinsed with PBS after staining and covered with ProLong Gold antifade 
reagent (Live Technologies). The mounting medium was allowed to cure overnight before 
samples were investigated with the confocal laser scanning microscope (Leica TCS SP5, 
Mannheim). 
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3.7. Perfluorocarbon particle emulgation 
 
For some experiments in chapter 4, fluorescently labeled perfluorocarbon emulsion was 
mandatory. Since all commercially available emulsions at the beginning of this thesis lacked 
proper fluorescence labels, this emulsion had to be made by our own. To achieve this, 
fluorescently labeled 15 % v/v perfluorocarbon emulsion was generated by a sonication 
approach. In general, 2 ml perfluorocarbon emulsion was produced by mixing 300 µl 
perfluoro-15-crown-5-ether (Chempur Feinchemikalien GmbH, Karlsruhe) with 80 mg of 
surfactant commixture (resulting in 4 % w/v of final emulsion). Two different compositions 
of the surfactant commixture were applied in this thesis: one with fluorescent labeling and 
another one without fluorescent labeling. The exact composition of particles is stated in 
table 3.1. 
 
Table 3.1: Composition of surfactant commixture of home-made perfluorocarbon emulsions. *: Soy 
L-α-phosphatidylcholine (Otto Nordwald GmbH, Hamburg), +: cholesterol  (Sigma-Aldrich), ~: 
Atto550- or Atto647N-1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (Atto550- or Atto647N-DOPE, 
Atto-Tec) 
Perfluorocarbon 
particle 
surfactant 
compounds 
molecular 
weight (g/mol) 
mol% of final 
particle 
m/2ml final 
emulsion 
     non-fluorescent 
control particle 
L-α-phosphatidyl-
choline* 
775.037 75 68.59 mg 
cholesterol+ 386.654 25 11.41 mg 
     fluorescent 
particle 
L-α-phosphatidyl-
choline* 
775.037 74.5 67.78 mg 
cholesterol+ 386.654 25 11.35 mg 
DOPE-Atto647N or 
DOPE-Atto550~ 
1485 0.5 0.87 mg 
 
Following mixing, 1.7 ml sterile 0.9 % NaCl solution was added and the crude emulsion 
sonicated (Sonifier 250, Branson Ultrasonics, Danbury, CT, USA) with following settings: 20 
min non-stop, output control: 7, duty cycle: 22 %. This resulted in perfluorocarbon-filled 
liposomes of various sizes and thus, to receive a homogenous emulsion with small 
liposomes, a filtering approach was chosen to exclude large particles. Serial filtration 
through 1.2 µm, 0.7 µm and 0.45 µm (all filters from msscientific, Berlin) syringe filters 
proved to be the most efficient way to prevent clogging of filters with liposomes by 
simultaneously delivering sufficient amounts of final emulsion consisting only of small 
liposomes. The size distribution of the various perfluorocarbon liposomes was kindly 
determined by Peter Buschmann (AG Krüger, Organic Chemistry, University of Würzburg) via 
laser-scattering microscopy. The 19F signal of three exemplary perfluorocarbon emulsions 
was measured by magnetic resonance. 
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3.8. Flow cytometry 
 
Flow cytometry was used to identify the immune cells that harbor perfluorocarbon emulsion 
at the site of infection. Since perfluorocarbon emulsion do not deliver inherent fluorescence 
signal, fluorescently labeled emulsion had to be applied in order to identify the tracer in 
cells. Therefore Atto647N-fluorescent perfluorocarbon emulsion was produced according to 
previously mentioned protocol (see chapter 3.7) and intravenously administered in mice 
with infection of S. aureus in the left thigh muscle at day 2 p.i.. A control group of infected 
mice received 0.9 % NaCl solution instead of perfluorocarbon emulsion. The infected thigh 
muscles of both groups were recovered 16 hours post administration and homogenized via 
pressing through a cell strainer (BD Biosciences, Heidelberg). The resulting cell suspension 
was diluted with 0.9 % NaCl or PBS and filtered through another cell strainer to exclude cell 
clumps that might have interfered with flow cytometric analysis. In order to prevent 
unspecific binding of fluorescently labeled antibodies to Fc receptors, which are frequent on 
neutrophils, samples were incubated first with FcR Blocking reagent (Miltenyi Biotech, 
Bergisch Gladbach) for 10 minutes at 4 °C in the dark. Afterwards, the cell suspensions were 
incubated with either 0.9 % NaCl or various antibody cocktails for 1 hour at 4 °C in the dark. 
All antibody cocktails consisted of anti-CD11b FITC and anti-Ly6G PE conjugated antibodies 
(both Miltenyi Biotech, Bergisch Gladbach) but differed in their third antibody. The third was 
coupled to a fluorescence marker which excited at 405 nm and emitted at 450 nm and was 
targeted either against CD11c, B220, CD68, CD90.2 or F4/80 (see table 3.2). 
 
Table 3.2: Antibody mixtures applied in the flow cytometry analysis for the identification of 
perfluorocarbon emulsion accumulation in immune cells at the site of infection in the S. aureus 
thigh infection model. *: from Miltenyi Biotech, #: eBioscience 
 
Flow cytometry mix 
Flow cytometer (MACS Quant Analyzer) channel 
V1 channel B1 channel B2 channel 
1 no antibodies, incubation with 0.9 % NaCl as control 
2 anti-CD11c-VioBlue* 
anti-CD11b-FITC* anti-Ly6G-PE* 
3 anti-B220-VioBlue* 
4 anti-CD68-VioBlue* 
5 anti-CD90.2-VioBlue* 
6 anti-F4/80-PacificBlue# 
 
After incubation, samples were washed with 1 ml PBS, centrifuged (400 g, 10 min) and the 
pellet resuspended in 150 – 200 µl FACS buffer. Ten to fifty thousand cells were then 
analyzed on the flow cytometer (MACS Quant Analyzer, Miltenyi Biotech) using the violet 
laser (405 nm) and the blue laser (488 nm) with their corresponding FL channels 1 (V1), 2 
(B1) and 3 (B2) for determination of cell type by expression of specific antigens and the red 
laser (635 nm) with its corresponding FL channel 6 (R1) for measuring the perfluorocarbon 
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emulsion’s fluorescence. Results were analyzed with either MACSQuantify (Version 2.4, 
Miltenyi Biotec) or with Flowing Software (Version 2.5.0 by Perttu Terho, University of Turku, 
Finland). 
 
3.9. Cell sorting 
 
Cell sorting of the immune cell populations at the site of infection was applied as second 
method besides flow cytometry to identify the cell populations that harbor perfluorocarbon 
emulsion. Female Balb/c mice were therefore challenged with S. aureus Xen29 into the left 
thigh muscle. 100 µl of commercially available (VS1000H, Celsense) or home-made 
fluorescent perfluorocarbon emulsion (Atto550 or Atto647N labeled) was administered 
intravenously at day 2 p.i. and the infected thigh muscle were recovered 16 – 20 hours after 
tracer administration. The abscess was excised from the surrounding muscle tissue and 
homogenized by pressing through a 70 µm cell strainer (BD Biosciences, Heidelberg). The 
resulting cell suspension was further diluted with sterile PBS and filtered through another 
cell strainer to receive a single cell suspension and remove cell aggregations which might 
have interfered with cell sorting. Three different cell sorting methods were used in this 
study: density gradient centrifugation, magnetization-activated cell sorting (MACS) and cell 
sieving with pluriBeads (Pluriselect, Leipzig). 
Density gradient centrifugation 
First, Histopaque-1083 solution (Sigma-Aldrich) was added to a conical tube. Histopaque-
1077 (Sigma-Aldrich) was then carefully layered above. The tissue homogenization single cell 
suspension was layered on top of the Histopaque gradient and the tube was then 
centrifuged for 30 minutes at 700 x g at room temperature. Granulocytes should aggregate 
at the Histopaque-1083 / Histopaque-1077 interface, whereas lymphocytes and monocytes 
should be found at the Histopaque-1077 / aqueous sample remnant. 
Magnetization-activated cell sorting 
The muscle homogenization was filtered through a second 70 µm filter (BD Biosciences, 
Heidelberg) to exclude cell clumps. The number of cells was then counted and diluted to gain 
a final concentration of 1 x 107 cells / ml. The following cell separation was then performed 
with either the ‘Anti-Ly-6G MicroBead Kit’, ‘Anti-CD11b MicroBead Kit’ or with anti-F4/80-
FITC antibodies and ‘anti-FITC MicroBeads’ (all Miltenyi Biotech). To note, all following steps 
prior sorting were done without washing the samples in order to prevent loss of 
perfluorocarbon emulsion that is not incorporated or attached to cells. Single cell suspension 
was pre-incubated with ‘FcR Blocking Reagent’ (Miltenyi Biotech) to prevent unspecific 
binding of antibodies to immune cells via Fc receptors according to manufacturer’s 
instructions. For F4/80+ cell sorting, single cell suspension was then incubated for 30 
minutes with anti-F4/80-FITC antibodies (eBioscience, Frankfurt or Miltenyi Biotech) at 4° C 
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in the dark. Next, anti-FITC MicroBeads (Miltenyi Biotech) were added following 
manufacturer’s instructions and suspension was incubated for 30 minutes at 4 °C in the dark. 
Regarding Ly6G+ or CD11b+ cell sorting, single cell suspension was incubated with anti-Ly6G-
biotin or anti-CD11b-biotin antibodies (Miltenyi Biotech) for 30 minutes at 4° C in the dark. 
After incubation, anti-biotin MicroBeads were added and the suspension was incubated for 
30 minutes at 4° C in the dark. In the meantime, either XS or LD columns (Miltenyi Biotech) 
were placed in the separation magnet and rinsed with buffer. Samples were poured after 
incubation onto the selection / depletion columns and the flow through collected. The 
column was removed from the separator and the sorted cells were flushed out of the 
column with an appropriate amount of buffer. Flow-through and sorted cells were then 
investigated for 19F signal in the MR scanner. 
Cell sieving with pluriBeads 
The number of cells / ml of the single cell suspension (derived from tissue homogenization) 
was counted with the help of a ‘Neubauer chamber’ and diluted to achieve a final 
concentration of 1 x 107 cells / ml. The following cell separation was performed with either 
M-bead kits targeting CD11b or Ly6G antigens (CD11b M-pluriBeads Kit anti-ms or Ly6G M-
pluriBeads Kit anti-ms, Pluriselect) or with S-bead kits targeting CD4 or CD19 antigens (CD4 
S-pluriBeads Kit anti-ms or CD19 S-pluriBeads Kit anti-ms, Pluriselect) according to the 
manufacturer’s instructions. To note, all following steps prior sorting were done without 
washing the samples in order to prevent loss of perfluorocarbon emulsion that is not 
incorporated or attached to cells. Prior sorting, single cell suspension was pre-incubated with 
‘FcR Blocking Reagent’ (Miltenyi Biotech, Bergisch Gladbach) to prevent unspecific binding of 
antibodies to immune cells via Fc receptors according to manufacturer’s instructions. For 
CD11b and Ly6G, 1.5 ml of single cell suspension was mixed with 500 µl of anti-CD11b or 
anti-Ly6G-M-beads and for CD4 and CD19, 1 ml of single cell suspension was mixed with 350 
µl anti-CD4 or anti-CD19-S-beads. The samples were then incubated for 30 min at room 
temperature on a roller mixer. The beads are coated with antibodies against the indicated 
surface antigens, which are characteristic for specific immune cell populations. Thus, cell 
with the specific antigens on their surface bind to the beads. In the meantime, Pluriselect 
cell strainers were prepared and after incubation loaded with the bead-sample mixture. The 
suspension of beads and cells were then pipetted into the proper cell strainer (either S-
pluriStrainer or M-pluriStrainer). The beads and thus the bound cells remained in the 
strainer since they were too large to fit through. The flow-through, containing all antigen-
negative cells was collected for analysis. The beads were then taken up into an equally large 
volume than the original sample. To check for cell sorting filter passage of perfluorocarbon 
emulsion, a 1:1000 diluted Atto550-labeled tracer sample was pipetted onto either a Ly6G- 
or a CD4-sorting filter unit. The flow-through was collected and the fluorescence signal 
(measured by the IVIS system) compared to the pre-sorting sample. 
The fluorescent signals of the single cell suspension (prior to sorting), the flow-through and 
the beads with the bound cells were analyzed in the IVIS system (IVIS Lumina II, Caliper Life 
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Sciences) with following parameters: exposure, 30 s; FStop, 2; excitation, 535 nm; emission, 
DsRed; Epi-illumination; lamp level; R, low; field of view (FOV), 12.5; and height, 1.5 cm. The 
signal was measured in a circular region-of-interest of same size for all samples. As controls 
served the S- and M-beads only and the single cell suspension of the infected thigh muscle of 
an infected mouse which had not received fluorescent perfluorocarbon emulsion. 
Cell sorting efficiency was investigated by flow cytometry. Therefore, sorted cells were 
detached from beads by incubation with detachment buffer (supplied with the kit) for 10 
minutes in the cell strainer. After incubation, the luer lock of the cell strainer was opened 
and the released cells collected. Those released cells, the unsorted muscle homogenizate 
and the flow-through cells were first incubated with FcR Blocking reagent (Miltenyi Biotech, 
Bergisch Gladbach) for 10 minutes at 4 °C in the dark and then either with a mixture of anti-
CD90.2-VioBlue and anti-Ly6G-APC (both Miltenyi Biotech) or with anti-B220-VioBlue 
(Miltenyi Biotech) and anti-CD11b-PerCP antibodies (eBioscience) for 1 hour 4 °C in the dark. 
Cells were then washed with 1 ml FACS buffer and the cell pellet resuspended in 200 µl FACS 
buffer. Flow cytometry was performed on the MACS Quant Analyzer (Miltenyi Biotech). Cell 
populations were thereby visualized in APC vs. VioBlue or PerCP vs. VioBlue density blots and 
by histograms of VioBlue, PerCP and APC. The number of CD90.2, B220, Ly6G or CD11b 
positive cells was measured for all samples in histograms and ploted as ‘% of all visible’ with 
MACSQuantify (Version 2.4, Miltenyi Biotec) or with Flowing Software (Version 2.5.0 by 
Perttu Terho, University of Turku, Finland). 
 
3.10. Determination of cytokine/chemokine levels 
 
Flow cytometry based bead assays 
The levels of various cytokines and chemokines at the site of infection in the S. aureus thigh 
infection model were measured with the ‘Mouse Th1/Th2 10plex Ready-to-Use FlowCytomix 
Multiplex’ or ‘Mouse Chemokine 6plex FlowCytomix Multiplex’ (both eBioscience). In 
general, infected thigh muscles were recovered and immediately homogenized with a tissue 
homogenizer (DispoMix, BioLabProducts). The resulting cell suspension was then centrifuged 
(4000 g, 5 min, room temperature) and the resulting supernatant filtered through a 0.22 µm 
syringe filter (Merck Millpore) to exclude all cells. 12.5 µl of the resulting cell-free muscle 
homogenization was then analyzed according to manufacturer’s instructions with the above-
mentioned kits. 
Briefly, the samples, serial dilutions of defined cytokines/chemokines (12.5 µl each) solutions 
or buffer (12.5 µl) as negative control were mixed with the corresponding bead mixture 
(12.5 µl) and detection antibody-biotin mixture (25 µl) in 1.5 ml tubes. The mixture was 
incubated for 2 h RT in the dark. Cytokines/chemokines bind to the specific beads and 
detection antibodies during this incubation period. Following incubation, 1 ml of Assay 
buffer (provided in the kit) was added and all tubes were centrifuged for 5 min at 200 x g at 
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room temperature. The supernatant was discarded, leaving 100 µl in each tube. In the next 
step, Streptavidin-PE solution (25 µl) was added and all tubes were incubated for 1 hour at 
room temperature in the dark. After another washing step with Assay buffer, further 200 µl 
Assay buffer were added to the residual 100 µl liquid in the tubes and all samples analyzed 
on the flow cytometer (FACSCalibur, BD Biosciences, Heidelberg). 
In principle, the cytokine/chemokine bead kits consisted of various antibody-conjugated 
beads to target specific cytokines or chemokines in solution. The beads could be 
distinguished from each other by two parameters: by size and by fluorescence in the FL-3 
channel (far red emission) of the cytometer. The different sizes could be distinguished in the 
FSC vs. SSC plot. The beads bound with their conjugated antibody specifically to cytokines or 
chemokines in solution. This resulted in concentration dependent bead-cytokine/chemokine 
complexes. The detection antibody was conjugated to biotin and bound the 
cytokines/chemokines either in solution or at the surface of the beads. The Streptavidin-PE 
solution finally bound to the biotin part of the detection antibody. The washing steps 
removed all soluble components with exception of the beads due to their sedimentation 
during centrifugation. In the end, this resulted in bead-antibody-cytokine/chemokine-
detection antibody-biotin-streptavidin-PE complexes in the final flow cytometry sample. To 
note, the higher the cytokine/chemokine concentration in serum or homogenate, the more 
was bound to the beads, the more could be bound by detection antibodies on the beads and 
the more PE fluorescence marker accumulated at the bead. In consequence, the more 
cytokine/chemokine was bound to the bead, the higher was the PE fluorescence of the bead. 
This could be measured in a FL-2 vs. FL-3 density or dot plot and was visualized as ‘migrating’ 
bead populations to higher FL-2 fluorescence for higher cytokine/chemokine concentrations.  
The flow cytometry gating strategy aimed therefore at measuring the FL-2 fluorescence of 
each individual bead population in the sample (Fig. 3.2). In order to achieve this goal, the 
beads were first gated in the FSC vs. SSC dot plot to discriminate the two different sized bead 
populations. Two FL-2 vs. FL-3 density plots enabled discrimination of the different antigen-
specific beads by their intrinsic FL-3 fluorescence. The mean fluorescence intensity of bound 
PE fluorescence was measured in this plot by defining rectangular regions around the 
individual beads (same size and geometry for all measurements). A series of samples with 
defined cytokine/chemokine concentration enabled the generation of a calibration curve 
and automatic calculation of cytokine/chemokine concentration in the samples with 
FlowCytomix Pro software (Version 3.0, eBioscience, Frankfurt). 
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Fig. 3.2: Gating strategy of flow cytometry based bead assay to measure cytokine/chemokine 
concentration at the site of infection. Beads consisted of two different sized populations which 
could be differentiated in the FSC vs. SSC dot plot. Two FL-2 vs. FL-3 density plots showed then 
individual antigen-specific bead populations (distinguished by their inherent FL-3 fluorescence) with 
their cytokine/chemokine concentration dependent FL-2 fluorescence. 
 
Enzyme-linked immunosorbent assays (ELISA) 
As second method to confirm the cytokine results from flow cytometry based assays, two 
ELISAs were performed to measure the amounts of MCP-1 and IFNγ at the site of infection. 
Both assays were performed according to manufacturer’s instructions (Mouse CCL2 (MCP-1) 
ELISA Ready-SET-Go and Mouse IFN gamma ELISA Ready-SET-Go, both eBioscience). 
Briefly, 96well plates were coated with capture antibody in coating buffer overnight at 4 °C. 
The next day, wells were washed five times (with 1 minute incubation) with wash buffer. 
Each well was then blocked with assay diluents for 1 h at room temperature. After 5 washing 
steps with wash buffer, the standard curve was defined by serially diluting a defined 
cytokine / chemokine concentration. These standard curve samples and the experimental 
tissue homogenization samples were then added to the 96 well plate and incubated for 2 h 
or overnight at 4 °C. Following 5 washing steps, the detection antibody – biotin conjugate 
was added and the well plates were incubated for 1 h at RT. After washing, avidin – HRP 
(horse radish peroxidase) conjugate was added and incubated for further 30 minutes at RT. 
Plates were then washed and substrate solution added. After 15 minutes at RT, enzyme 
reaction stop solution was added and the plates investigated at 450 nm in the ELISA reader. 
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Standard curve was then generated with software Graph Pad Prism 5 (GraphPad, La Jolla, 
CA, USA), as well as the concentrations of the unknown, experimental samples determined. 
 
3.11. Data analysis and statistics 
 
Statistical analysis of colony-forming unit, bioluminescence signal and 19F volume and signal 
measurements were performed either with GraphPad Prism 5.0 software (GraphPad, San 
Diego, USA) or with Microsoft Office Excel 2007 (Microsoft, Redmond, WA, USA). Either 
Kruskal-Wallis with Dunn’s post-test or one-way ANOVA with Bonferroni’s post test were 
applied to determine statistical significance between different groups of mice. 
Bioluminescence values and images were determined/generated with Living Image 3.2 
(Caliper Life Science).  
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4. Imaging of Staphylococcus aureus infections 
 
Staphylococcus aureus infections are a major threat to health care systems worldwide. This 
opportunistic pathogen is able to provoke a wide array of different diseases including 
critical, life-threatening ones (Lowy FD, 1998). The emergence of antibiotic resistant S. 
aureus strains has increased the urge for new efficient antibiotics even more. And although a 
number of new compounds have entered the clinics in the last decade, most novel promising 
compounds still fail in preclinical or clinical evaluation. Our idea was that in vivo imaging 
technologies like bioluminescent imaging, positron emission tomography or magnetic 
resonance imaging might help to get a much clearer picture about the efficacy of promising 
compounds in preclinical animal models and they might additionally help to identify possible 
toxic side effects, too. Unfortunately, the above-mentioned imaging technologies, maybe 
with the exception of bioluminescent imaging, are not evaluated in detail to visualize 
infections in small animal disease models. Therefore, the first experimental chapter of this 
work deals with the evaluation of two imaging modalities: bioluminescent imaging (BLI) and 
magnetic resonance imaging (MRI). Regarding MRI, the basic idea was on one hand to test 
different native proton-based MR sequences for visualization of tissue changes by the 
infection itself while on the other hand the application of MR active contrast agents or 
tracers might lead to an accumulation at the site of infection and thus might visualize the 
infection indirectly. Two contrast agent/tracer based MR methods should be investigated in 
this study due to their accumulation in immune cells after intravenous administration: 
ultrasmall ironoxide nanoparticles and perfluorocarbon emulsions. The imaging experiments 
were in this context based on one animal model of S. aureus infection: the thigh infection 
model. Thus the following part of this work describes the evaluation of this animal model, 
the infection imaging experiments and the influence of 19F magnetic resonance imaging of 
perfluorocarbon emulsions, a modality applied to investigate these questions for the first 
time, on the outcome of the infection experiments and possible acute toxic side effects 
caused by the application of the tracer substance. 
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4.1. Results 
 
4.1.1. The S. aureus thigh infection model 
Before trying to visualize infections in vivo with bioluminescence and/or magnetic resonance 
imaging, the animal model had to be chosen and evaluated first. The S. aureus thigh 
infection model was selected, because it leads to a localized infection with a bulky abscess 
and therefore predefines the region of interest for imaging experiments. It is of clinical 
importance since this type of infection is commonly associated with meticillin-resistant S. 
aureus strains and might lead in human patients to systemic infections like sepsis (King MD 
et al. 2006, Boucher HW, Corey GR. 2008). 
Female Balb/c mice were therefore infected into the left thigh muscle with 2.2 x 108 CFU S. 
aureus Xen29, a derivative of S. aureus ATCC 12600 with a chromosomally integrated 
luxABCDE operon that confers luciferase expression and activity in metabolic active bacteria 
(Francis KP et al. 2000). The infected thigh muscle, liver, spleen and the kidneys were 
recovered at different time points after start of infection to determine the bacterial burden 
in terms of colony-forming units. The overwhelming number of bacteria (over 99.99 % at all 
time points) could be found at the site of initial infection, the thigh muscle. The CFU 
numbers were rather stable in the infected thigh muscle with small increase between day 1 
p.i. and day 3 p.i. and a small decrease between day 3 p.i. and day 7 p.i., but the differences 
were statistically not significant (Fig. 4.1 A). The strongest variation of bacterial burden could 
be seen between the initial injection of bacteria into the thigh muscle (2.2 x 108 CFU) and 
day 1 p.i. (slightly above 109 CFU), suggesting strong growth in the first 24 h p.i.. Small 
numbers of bacteria could be detected by plate counting regularly in the liver and 
sporadically in the spleen and kidneys with a similar pattern than in the thigh muscle (Fig. 4.1 
B – D): a small increase of median CFU numbers between day 1 p.i. and day 3 p.i. and a slight 
decrease between day 3 p.i. and day 7 p.i., but the only statistical significant difference was 
for CFU in the liver at day 3 p.i. vs. CFU in the liver at day 7 p.i., indicating decrease in this 
organ or decreased systemic spreading from the primary source of infection, the thigh 
muscle. Overall, the highest isolatable bacterial numbers in the investigated organs could be 
seen at day 3 p.i., and a slight or significant decrease was measured for all organs until day 7 
p.i.. It has to be mentioned, that about 30 – 50 % of the spleen and kidney samples showed 
no colonies on the agar plates after homogenization, serial dilution and plating of the organs 
(but due to experimental setup, these samples received values at the detection limit). This 
proves the lack of systemic infection, a disease that can evolve in human patients following 
skin, skin-structure or deep tissue infections with S. aureus (King MD et al. 2006, Boucher 
HW, Corey GR. 2008). 
The injection of the bioluminescent S. aureus strain Xen29 enabled non-invasive 
bioluminescence imaging in parallel to the tissue recovery for CFU determination. Imaging 
was performed in a small animal in vivo imaging device for detection of bioluminescence and 
fluorescence signal (IVIS Lumina 2, Caliper Life Science). The average radiance signal was 
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very strong immediately after infection (5 – 15 min post infection). After the first 24 h of 
infection, a strong drop of photon emission was seen, but signal recovered to a lower level 
than initially until 48 h p.i. (Fig. 4.1 E). The signal then stayed in a slowly increasing plateau 
phase until the end of the experiment at day 7 p.i.. With the exception of the 
bioluminescence development within the first 24 h, the results of CFU determination and 
bioluminescent imaging were congruent in showing a rather stable phase of bacterial burden 
in the infected thigh muscle. 
Histological examination (Fig. 4.1 F) of recovered muscles at day 3 p.i. showed a massive 
infiltrate of neutrophils with interspersed macrophages/monocytes and the intact muscle 
fibers (appearing as rose bundles due to hematoxylin-eosin staining). The immune cells 
surrounded a central necrotic area. Histological slices from muscles recovered at day 7 p.i. 
showed similarly neutrophils as the predominant immune cell population at the site of 
infection, but with a slightly higher macrophage/monocyte content and fibroblast-enriched 
granulation tissue. The immune cells accumulated at this time point around a bulky area of 
necrosis. 
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Fig. 4.1: CFU values and bioluminescence signal over time, as well as histological appearance of 
infection in the S. aureus thigh infection model. Mice (n = 5 – 6 per indicated time point) were 
challenged with ca. 2.2 x 108 CFU S. aureus Xen29 into the left thigh muscle. A – D: Shown are the 
single CFU values and the respective medians determined for the infected thigh muscles (A), livers 
(B), kidneys (C) or spleens (D) at indicated time points after start of infection. Organs were harvested, 
homogenized and serial dilutions plated on B-agar. E: Development of mean bioluminescent signal 
+/- SEM during the course of infection (6 animals). Mice were imaged immediately after infection (+ 
5 min, shown as time point 0), and then every 24 h. The average radiance signal was measured in a 
manually defined region of interest (same size and geometry for all mice). F: Exemplary hematoxylin 
– eosin stained section of a paraffin – embedded, formalin – fixed thigh muscle. Muscle was 
recovered at day 3 p.i.. Statistical significant differences are indicated with asterisk (*: P < 0.05). 
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4.1.2. Native, proton-based magnetic resonance imaging 
After establishing the thigh infection model with S. aureus Xen29 and imaging of bacterial 
burden via bioluminescence imaging in the first part of this chapter, the experiments in the 
following were performed to visualize S. aureus infections in the thigh muscle with magnetic 
resonance imaging. Female Balb/c mice were therefore infected with 2.2 x 108 CFU S. aureus 
Xen29 and magnetic resonance imaging was performed at several time points after start of 
infection. A variety of different MR protocols were tested for visualization of changes in 
signal pattern in the infected thigh muscle (data not shown), but in the end, only T2 weighted 
MR methods proved to visualize clear changes in the infected thigh muscle without 
indicating changes in the control muscle which was inoculated with sterile 0.9 % NaCl 
solution (Fig. 4.2). Imaging at several different days after start of infection showed increased 
T2 values in the infected thigh muscle, but not in the non-infected, 0.9% NaCl solution 
inoculated one. This was congruent with earlier studies that demonstrated increased T2 
relaxation times at sites of inflammation in S. aureus infection models (Marzola P et al. 1999, 
Kaim AH et al. 2002). The area of prolonged T2 relaxation times was in these and other 
studies correlated with an area of massive immune cell immigration, tissue destruction and 
edema formation (Kaim AH et al. 2003). The differences in T2 signal between infected and 
control muscle could at least be seen at day 2 p.i. and lasted until the end of the experiment 
at day 10 p.i.. Interestingly, the area of heightened T2 values became slightly larger between 
day 2 and day 6 p.i., but decreased in size until day 10 p.i.. Nonetheless, the area of 
prolonged T2 relaxation times was of rather diffuse shape in most MR images and, even 
more important, a clear distinction between infected and non-infected thigh muscle tissue 
remained impossible due the high variations in T2 relaxation times and the lack of a clear 
border between heightened and normal T2 values. 
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Fig. 4.2: Consecutive transversal T2 maps of one representative mouse imaged at day 2 (first row), 
day 3 (second row), day 6 (third row) and day 10 p.i. (fourth row). A group of mice (n = 5) was 
challenged with 2.2 x 108 CFU S. aureus Xen29 in the left thigh muscle. MR imaging was performed at 
the indicated time points and three consecutive T2 map slices of one representative mouse are 
shown. Mouse drawing indicates the location and orientation of the MR imaging slice. (co: control 
tube). For illustration, arrows point at the area of elevated T2 relaxation times (only in the first row of 
pictures). 
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4.1.3. Imaging of iron oxide (CLIO) particles at the site of infection 
The lack of clear identification of infected tissue by native proton-based MR method made it 
inevitable to evaluate contrast agent based methods to define and visualize the area of 
infection. Cross-linked ironoxide nanoparticles have been shown to accumulate at sites of 
inflammation and infection, thus enabling visualization of site of infection and the 
quantification of severity of disease (Kaim AH et al. 2002, Kaim AH et al. 2003). The most 
suitable methods to visualize this accumulation are T2 or T2
* weighted methods. The 
administration of CLIO particles at acute phase of inflammation (day 2 p.i.) led to detectable 
susceptibility effects at the abscess area 24 h after injection (Fig. 4.3 two upper rows). The 
‘black’ rim could be visualized by both T2 and T2
* maps and indicates accumulation of CLIO 
particles which induced signal distortion. A similar ‘black’ rim accumulation pattern in the 
abscess area could be seen when CLIO particles were administered at day 6 p.i. and imaging 
was performed at day 7p.i.. To test for specificity of CLIO accumulation at the site of 
infection, 0.9 % NaCl solution was administered into the right thigh muscle of mice. This 
injection did not lead to abscess formation, as expected due to the lack of pathogens, and, 
notably, not to accumulation of contrast agent in the right thigh muscle. But although CLIO 
accumulated specifically at both time points at the rim of the abscess area, its accumulation 
pattern did not always allow distinction of infected and not-infected tissue areas. The 
accumulation was sparse and rather diffuse when visualized by T2 weighted MRI especially at 
acute phase of inflammation (day 3 p.i., Fig. 4.3 upper row). Visualization of CLIO 
accumulation with T2
* weighted MRI delivered a much clearer picture, but the intrinsic 
variation in signal strength complicated the identification of anatomical context. The signal 
distortion effect prevents furthermore the visualization of edema formation (indicated by 
longer T2 relaxation times) in the CLIO accumulation region. 
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Fig. 4.3: T2 maps and T2
* weighted MR images of one representative CLIO treated mouse at day 3 
(upper two rows) and day 7 p.i. (lower two rows) visualize signal distortion effects at the rim of the 
abscess area. A group of mice (n = 4) was challenged with 2.2 x 108 CFU S. aureus Xen29 in the left 
thigh muscle and with 0.9 % NaCl solution in the right thigh muscle. CLIO particles were administered 
intravenously at day 2 p.i.. MR imaging was performed 24 h after administration and at day 7 p.i.. 
Three consecutive slices of one representative mouse are shown for each method at both time 
points. Mouse drawing indicates the location and orientation of the MR imaging slice. (co: control 
tube). For illustration, arrows point at the area of CLIO accumulation and thus signal distortion (only 
in the first row of pictures). 
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4.1.4. Accumulation of perfluorocarbon emulsion at the site of 
infection 
A second MR agent based method to visualize inflammation by magnetic resonance imaging 
is 19F MRI of intravenously administered perfluorocarbon emulsions. It has been shown 
recently that the application of perfluorocarbon emulsions during the course of various 
diseases which are linked to inflammation led to accumulation of 19F signal at the site of 
inflammation. Perfluorocarbon emulsion accumulated, for example, at the rim of brain 
damage in an ischemia model or at the heart muscle in a stroke model (Flögel U et al. 2008). 
Nonetheless, at the beginning of this PhD thesis, no experiments were described in literature 
that utilized and evaluated this method to locate and image sites of infection or 
accompanying inflammation. Consequently, the following experiments were conducted to 
test whether this method is capable to visualize S. aureus thigh infections in the mouse. 
 
4.1.4.1. Administration of perfluorocarbon emulsion led to a ‘hollow sphere’ 
accumulation pattern in the infected thigh muscle 
To test for specific accumulation of perfluorocarbon emulsion at the site of infection, female 
Balb/c mice were injected with S. aureus Xen29 into the left thigh muscle and with the 
carrier substance 0.9 % NaCl solution into the right thigh muscle. In conclusion, the following 
experiments are conducted with the same setting than those described in chapter 4.1.3 with 
the exception of the applied contrast agent/tracer, thus enabling direct comparison of CLIO 
and perfluorocarbon emulsions as contrast delivering substances to visualize sites of 
infection with MRI. In contrast to CLIO particles, perfluorocarbons cannot be visualized with 
1H based MR methods, but only with specific 19F magnetic resonance methods. Since the 
mammalian body does not harbor sufficient amounts of 19F, a second 1H based image is 
necessary to visualize the anatomical context of perfluorocarbon accumulation. Therefore, 
19F-SSFP CSI images were overlayed on 1H-TSE images to visualize the anatomy of the site of 
infection and the accumulation of the PFC tracer (Fig. 4.4). 
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Fig. 4.4: Principle of 19F MR imaging with perfluorocarbon emulsions as MR active tracer. 1H TSE MR 
images served to visualize the anatomy of the infected thigh muscle, while 19F-SSFP CSI images 
visualized the accumulation of perfluorocarbon emulsion at the site of infection. Both images can be 
overlayed, since the investigated animal is quiescent and has not to be moved throughout and 
between the measurements. In this case, female Balb/c mouse was challenged with 2.2 x 108 CFU S. 
aureus Xen29 in the left thigh muscle and with sterile 0.9 % NaCl solution in the right thigh muscle. 
Perfluorocarbon emulsion was administered intravenously at day 7 p.i. and accumulation at the site 
of infection was imaged with MRI at day 10 p.i.. (co: control tube) 
 
Intravenous administration of perfluorocarbon emulsion during acute phase of inflammation 
(at day 2 p.i.) and MR imaging 24 h later showed accumulation of 19F in the infected left 
thigh muscle, but not in the 0.9 % NaCl treated right muscle, indicating specificity of 
perfluorocarbon accumulation at spots of severe inflammation and infection. The tracer 
accumulated at the rim of the area that showed extended T2 relaxation times (compared to 
surrounding muscle tissue), that is, at the rim of the edema area (Fig. 4.4). To note, no 
accumulation of perfluorocarbon could be detected in the center of the edema area. 
Consecutive MRI slices or the 3D reconstruction from the site of infection visualized a 
‘hollow sphere’ pattern of 19F accumulation around the abscess area (Fig.4.5). 
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Fig. 4.5: 19F-SSFP CSI overlays (blue color scale) on 1H TSE images (grayscale) shows accumulation of 
19F at the rim of the abscess area in the shape of a ‘hollow sphere’ in one representative mouse at 
acute phase of inflammation. Female Balb/c mice (n = 5) were challenged with 2.2 x 108 CFU S. 
aureus Xen29 in the left thigh muscle and with sterile 0.9 % NaCl solution in the right thigh muscle. 
Perfluorocarbon emulsion was administered intravenously at day 2 p.i. and accumulation at the site 
of infection was imaged with MRI at day 3 p.i.. The mouse drawing indicates location and orientation 
of the consecutive slices in anatomical context. This whole series of images was generated out of one 
measurement of one representative mouse. (co: control tube) 
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Fig. 4.6: 19F-SSFP CSI overlays (blue color scale) on 1H TSE images (grayscale) shows accumulation of 
19F at the rim of the abscess area in the shape of a ‘hollow sphere’ in one representative mouse at 
chronic phase of inflammation. Female Balb/c mice (n = 5) were challenged with 2.2 x 108 CFU S. 
aureus Xen29 in the left thigh muscle and with sterile 0.9 % NaCl solution in the right thigh muscle. 
Perfluorocarbon emulsion was administered intravenously at day 8 p.i. and accumulation at the site 
of infection was imaged with MRI at day 9 p.i.. The mouse drawing indicates location and orientation 
of the consecutive slices in anatomical context. This whole series of images was generated out of one 
measurement of one representative mouse. (co: control tube) 
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To investigate the accumulation of perfluorocarbon emulsion at the site of infection during 
chronic phase of inflammation, female Balb/c mice received a single intravenous 
administration of emulsion at day 8 p.i. and accumulation was imaged 24 h later with 19F 
MRI. Congruent with the results from acute phase, only the infected thigh muscle showed 
19F signal, but not the non-infected 0.9 % NaCl solution treated muscle. Perfluorocarbon 
emulsion accumulated at the rim of the edema area (with higher T2 values) and formed a 
‘hollow sphere’ pattern, with the lack of 19F signal in the center of the abscess area (Fig. 4.6). 
Importantly, the infection or inflammation itself did not induce higher 19F values, because 
without intravenous administration of perfluorocarbon emulsion, no 19F signal could be 
detected in the field of view at any time point, neither at acute nor at chronic phase of 
inflammation (data not shown). Furthermore, intravenous administration of perfluorocarbon 
emulsion into non-infected mice did not lead to any detectable 19F signal in the thigh muscle 
(data not shown). 
 
4.1.4.2. Variation of perfluorocarbon administration or imaging time points 
resulted in different 19F accumulation patterns 
Administration of perfluorocarbon emulsion led at both, acute and chronic phase of 
inflammation, to a stable and strong 19F ‘hollow sphere’ accumulation pattern in the infected 
thigh muscle. But to date, the imaging was performed only at 24 h post administration and 
the following experiments were therefore designed to learn more about the accumulation 
kinetics of perfluorocarbon emulsion at the site of infection. 
To study the durability of 19F signal and thus perfluorocarbon emulsion accumulation at the 
site of infection, mice (n = 3 per group) with S. aureus Xen29 infection of the thigh muscle 
received a single intravenous administration of perfluorocarbon emulsion at day 2 p.i.. MR 
imaging started 24 h later and the mice were then imaged every 48 h until day 9 or 10 p.i. to 
reveal variations in the 19F accumulation pattern. But beginning with the first measurement 
and ending with the last one, a ‘hollow sphere’ accumulation pattern could be visualized in 
all mice at all time points when infected with a similar amount of bacteria than applied in the 
earlier experiments (1.1 x 108 CFU, see Fig. 4.7 third and fourth row). In addition, the 19F 
signal remained stable in terms of pattern and intensity in all imaged mice of this group, 
indicating enduring perfluorocarbon accumulation at the rim of the edema area. In contrast 
to this showed mice that were infected with smaller numbers of bacteria a different 19F 
signal pattern at late stages of the infection. While 19F MRI at day 3 and day 6 p.i. revealed a 
similar pattern than seen in mice with higher infectious dose, namely the ‘hollow sphere’ 
accumulation of perfluorocarbons at the site of infection, the images generated at days 8 
and 10 p.i. showed only sparse and diffuse accumulation at the rim of the abscess area (Fig. 
4.7 first and second row). This loss of 19F signal was accompanied by a reduction of 
bioluminescence signal at the site of infection (data not shown). The determination of 
colony-forming units at the end of the experiment showed only minor bacterial burden in 
this low-infection dose group mice (between 1.8 x 103 and 3.2 x 106 compared to ca. 109 CFU 
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for the high-infection dose group). In conclusion, the disappearance of 19F signal at the site 
of infection in the low-infection dose group was accompanied by a reduction of bacterial 
burden, suggesting spontaneous healing or the failure of S. aureus to establish chronic 
infection in the thigh muscle at this initial inoculum. 
 
 
Fig. 4.7: Influence of infectious dose on durability of 19F accumulation at the site of infection. 
Female Balb/c mice were challenged with either 2.3 x 107 (two upper rows) or with 1.1 x 108 CFU S. 
aureus Xen 29 in the left thigh muscle. Perfluorocarbon emulsion was intravenously administered at 
day 2 p.i. and mice were then investigated with MRI at the indicated time points. T2 maps of the 
edema formation in one representative mouse of each group are shown in rows 1 and 3, while 19F-
SSFP CSI overlays on 1H-TSE images are shown in rows 2 and 4. (co: control tube) 
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Fig. 4.8: 19F-SSFP CSI overlays (blue color scale) on 1H TSE images (grayscale) of four mice at 
different time points after administration of perfluorocarbon emulsion indicate 19F accumulation 
kinetics at the site of infection. Mice were challenged with 1.9 x 108 CFU S. aureus Xen29 in the left 
thigh muscle and perfluorocarbon emulsion was administered at day 2 p.i.. Mice were then imaged 
at indicated time points after administration of perfluorocarbon emulsion to determine the first time 
point of emergence of visualizable 19F accumulation pattern in the infected thigh muscle. (n.d.: not 
determined) 
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The next aim was to learn more about the accumulation kinetics of perfluorocarbon 
emulsion at the site of infection. Four mice were therefore infected with 1.9 x 108 CFU S. 
aureus Xen29 in the left thigh muscle and perfluorocarbon emulsion was administered 
intravenously at day 2 p.i.. Former experiments in this chapter demonstrated, that this 
application leads to a visualizable accumulation of 19F at the rim of the abscess area, but to 
date, it was unknown, at which time point exactly the accumulation reaches a signal level 
that enables imaging. To investigate this, mice were investigated with 19F MRI at different 
time points immediately after administration of the emulsion, but before 24 h post 
administration. Until 8 h post administration almost no 19F signal could be detected in the 
infected thigh muscle (Fig. 4.8). Two out of four mice showed the ‘hollow sphere’ 
accumulation pattern at 11 h post administration, suggesting that the perfluorocarbon 
accumulation reaches visualization limit at around 10 to 12 h post administration (for this 
combination of infectious dose and perfluorocarbon administration time point). 
Furthermore, by now, only two time points have been tested for administration of 
perfluorocarbon emulsion during course of infection: acute (day 2 p.i.) and chronic (day 8 
p.i.) phase of infection and inflammation. 19F MR imaging revealed for both cases 
accumulation of perfluorocarbons at the rim of the abscess area in the shape of a ‘hollow 
sphere’, but accumulation data to other time points was lacking. Thus, the following 
experiments sought to investigate the dependence of administration time point and 19F 
accumulation pattern. Therefore, the time point of perfluorocarbon emulsion administration 
was systematically varied from 2 hours p.i. to day 8 p.i. and the accumulation was visualized 
at several time points after administration (not earlier than 24 h post administration) to get 
information about the durability of accumulation pattern in the infected thigh muscle (Fig. 
4.9). Interestingly, administration of perfluorocarbon emulsion earlier than 2 days p.i. failed 
to elicit the typical accumulation pattern in the infected thigh muscle. Only very little 
disperse 19F signal could be detected in the field of view. Administration between day 2 p.i. 
and the last evaluated time point day 8 p.i. led, in contrast, to a steady ‘hollow sphere’ 
pattern in the infected thigh muscle. The differences in 19F accumulation pattern size fitted 
to the size of edema area imaged by T2 maps, thus suggesting that the differences in size are 
not connected to the time point of perfluorocarbon administration but to the size of the 
abscess. 
In summary, perfluorocarbon emulsion accumulates in the shape of a ‘hollow sphere’ in the 
murine S. aureus thigh infection model circumscribing the rim of the edema area, which is 
indicated by higher T2 values. To note, administration of the contrast media earlier than 2 
days p.i. failed to cause the ‘hollow sphere’ pattern. The accumulation reaches detection 
limit at around 12 h post administration and accumulation remains detectable until the end 
of the experiment (if the initial inoculum is around 108 CFU and S. aureus is able to establish 
chronic infection). 
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Fig. 4.9: Variation of the time point of perfluorocarbon administration leads to differences in 19F 
accumulation at the site of infection. Mice were challenged with 1.9 x 108 CFU S. aureus Xen29 in 
the left thigh muscle and perfluorocarbon emulsion was administered at indicated time points p.i.. 
19F accumulation was visualized at different time points after start of infection by 19F-SSFP CSI MR 
overlays (blue color scale) on 1H TSE images (grayscale), especially during acute phase of 
inflammation (day 3 p.i.) and chronic phase of inflammation (days 8 and 10 p.i.). (No PFC: mice have 
not received perfluorocarbon emulsion at this time point; n.d.: not determined). 
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4.1.4.3. The accumulation mechanism of perfluorocarbon emulsion in the S. 
aureus thigh infection model 
The experiments of the last chapter identified 19F accumulation in the area of the infected 
thigh muscle only in a defined field of view that covered the thigh muscles and a few 
millimeters to the posterior and anterior ends of the mouse. This was caused by the 
necessary use of a 1H/19F double-resonant birdcage coil with this restricted size to enable 
imaging with sufficient sensitivity in an acceptable time span. In consequence, other possible 
sites of perfluorocarbon accumulation in the mouse could not be visualized by these imaging 
experiments. Thus, in order to identify further spots of accumulation, female Balb/c mice 
were infected with 1.5 x 108 CFU S. aureus Xen29 in the left thigh muscle and 
perfluorocarbon emulsion was administered intravenously at day 2 p.i. (Similar to most of 
the experiments in the last chapter). Mice were sacrificed 24 hours after administration and 
fixed immediately in formalin solution. The fixated mice were then measured in a larger 
birdcage coil. Owing to the worse sensitivity of this coil and the need for good spatial 
resolution and high signal-to-noise ratio, the measurement time had to be extended to 24 
hours to enable enough averaging in order to achieve images with sufficient signal-to-noise 
ratio. The 3D reconstruction of the measurement revealed strong accumulation of 
perfluorocarbon in the liver, spleen and infected thigh muscle. These organs could be clearly 
identified by the shapes drawn with 19F MR imaging (Fig. 4.10 left column). Additional sites 
of accumulation were the spinal cord and other bones respectively bone marrows or joints. 
While the accumulation pattern in the infected thigh muscle forms the well-known ‘hollow 
sphere’, congruent with earlier experiments, the liver and the spleen exhibited a continuous 
accumulation of perfluorocarbon, lacking spots of no signal (Fig. 4.10). 
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Fig. 4.10: Ex vivo whole-animal 19F-SSFP CSI overlays (hot color scale) on 1H TSE images (grayscale) 
of one representative mouse shows accumulation of 19F in the thigh infected mouse in anatomical 
context. Mice (n = 3) were challenged with 1.5 x 108 CFU S. aureus Xen29 in the left thigh muscle and 
perfluorocarbon emulsion was administered at day 2 p.i.. Mice were sacrificed 24 h after tracer 
media administration and fixed in 10 % formalin solution. MR imaging was performed after fixation 
of the mouse and images of the 3D reconstruction from either dorsal (upper row) or side view (lower 
row) without anatomical context (left images) or with anatomical context (right images) are shown. 
 
The visualization of the 19F distribution pattern in the whole animal raised the question 
about the efficacy of perfluorocarbon accumulation at the site of infection and about the 
mechanism by which the emulsion is transported to the site of infection. The idea to address 
these questions was to fluorescently label the perfluorocarbon emulsion in order to track 
their behavior after intravenous administration by in vivo fluorescence imaging. Even more 
important, the fluorescent marker would help to gather information about the distribution 
pattern of perfluorocarbon emulsion in tissue, organs and cells by flow cytometry analysis of 
cell populations at the site of infection, isolation or depletion of specific immune cell 
populations and fluorescence microscopy of tissue sections. The first experiments were 
conducted with a commercially available fluorescent perfluorocarbon emulsion 
(VSdmGreen, Celsense), but the fluorescence label was not sufficient to elicit detectable 
signals in any of the applied methods. Due to the lack of other sources of fluorescent 
perfluorocarbon emulsion, it became necessary to develop and produce the emulsions, 
especially the fluorescent ones, by our own. 
Perfluorocarbon emulsions for magnetic resonance imaging are, in principle, tiny liposomes 
consisting of a core of perfluorocarbons, which are neither soluble in water nor in lipids. In 
the emulsion preparation, they are enclosed in a layer of amphiphilic surfactants. This 
surfactant layer is necessary to enable perfluorocarbons in an aqueous environment. In this 
study, a sonication approach was applied to emulsify perfluorocarbon compounds into this 
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liposomal formulation. The standard protocol and particle composition followed, in 
principle, approaches of other groups and their specifications in literature (Winter PM et al. 
2003, Ahrens ET et al. 2005, Flögel U et al. 2008, Southworth R et al. 2009). Perfluoro-15-
crown-5-ether (15 % w/v) was therefore mixed with a surfactant commixture (4 % w/v) 
consisting of L-α-phosphatidylcholine (synonym for lecithin), cholesterol and a fluorescently 
labeled lipid (Atto647N-DOPE or Atto550-DOPE) in sterile 0.9 % NaCl solution. This mixture 
was then sonicated and the resulting emulsion filtered through a series of syringe filters for 
size exclusion (1.2 µm, 0.7 µm and 0.45 µm). In the resulting emulsion (Fig. 4.11 A), 90 % of 
the liposomes showed after this filtration process a final size of less than 250 nm in diameter 
(size determination with laser scattering was kindly performed by Peter Buschmann (AG 
Krüger, Organic Chemistry, University of Würzburg, Germany)). In vitro 19F MR 
measurements of the liposomal perfluorocarbon emulsion showed a resulting 
perfluorocarbon content of 65 % compared to the original, pre-filtration emulsion, resulting 
in a 10 % v / v perfluorocarbon emulsion (at initially 15 v / v % perfluorocarbon, otherwise 
dependent on the initial perfluorocarbon concentration). 
The home-made emulsion was then tested in vivo in the thigh infection model for 
accumulation at the site of infection. Female Balb/c mice were therefore inoculated with 1.4 
x 108 CFU S. aureus Xen29 in the left thigh muscle and perfluorocarbon emulsion was 
administered intravenously at day 2 p.i.. The accumulation of 19F at the site of infection was 
imaged with 19F-SSFP CSI and overlayed on a 1H-TSE image to visualize tracer accumulation in 
anatomical context. All mice treated with home-made emulsion showed an accumulation 
pattern congruent with those of the commercially available preparations. All 
perfluorocarbon emulsions accumulated in the shape of a hollow sphere at the rim of the 
edema area (which was indicated by extended T2 relaxation times compared to not-infected 
thigh muscle tissue). 
 
 
Fig. 4.11 (facing page): Size characterization of home-made fluorescently labeled perfluorocarbon 
emulsion and in vivo fluorescence signal. A. Exemplary size distribution pattern of home-made 
perfluorocarbon emulsions. Perfluoro-15-crown-5-ether was emulsified with fluorescence marker 
containing surfactant commixture by sonication. The upper picture shows size pattern of the 
emulsion after sonication and prior to filtration. The lower picture shows the size distribution after 
serial filtration through 1.2, 0.7 and 0.45 µm syringe filters. The particle sizes were kindly measured 
via laser-scattering microscopy by Peter Buschmann (AG Krüger, Department of Organic Chemistry, 
University of Würzburg). B. Fluorescence images of representative mice that received either 
fluorescent perfluorocarbon emulsion or 0.9 % NaCl solution at day 2 p.i.. Female Balb/c mice (n = 
10) were challenged with 2.2 x 108 CFU S. aureus Xen29 in the left thigh muscle. At day 2 p.i., animals 
received a single intravenous administration of either homemade perfluorocarbon emulsion (with 
fluorescent Atto647N-DOPE in the surfactant commixture) in 0.9 % NaCl solution or 0.9 % NaCl only. 
Mice were imaged at the indicated time points and the average radiance signal of the manually 
defined regions of interest (blue oval frame) then measured (quantification in Fig. 4.12 A). 
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The fluorescence labeling of the perfluorocarbon emulsion enabled additionally to magnetic 
resonance imaging, fluorescent imaging as second modality to visualize accumulation and 
study the kinetics of the applied agent. Thus, Atto647N-labeled perfluorocarbon emulsion 
was applied intravenously to S. aureus Xen29 thigh infected Balb/c mice at day 2 p.i., and 
fluorescence imaging with the IVIS system (IVIS Lumina II, Caliper Life Science) showed in all 
animals of the perfluorocarbon group (‘PFC group’) a strong fluorescence signal at 30 
minutes post administration in the whole mouse, suggesting instant dissemination of tracer 
throughout the whole body via the blood stream (Fig. 4.11). Two control groups were 
applied in this experiment. The first control group of mice received 0.9 % NaCl solution (‘no 
contrast agent’ group) instead of perfluorocarbon emulsion and the second group received 
perfluorocarbon emulsion with the same composition than the Atto647N-labeled group but 
without the Atto647N fluorescence label. Administration of non-fluorescent perfluorocarbon 
emulsion resulted in the same level of fluorescence signal at the site of infection than the 
‘no contrast agent’ group at time point 30 min p.i. and all later time points. Furthermore, it 
showed in vitro a similar fluorescence signal level in the Cy5.5 channel of the IVIS system 
than 0.9 % NaCl solution (background level). Fluorescence imaging at 12 and 24 hours post 
administration revealed localized elevated signal levels in the infected thigh muscle of 
Atto647N-labeled perfluorocarbon emulsion treated mice, while no further spots of 
fluorescence signal could be detected in this or one of the other groups. The lack of signal in 
liver and spleen area, which is suggested by 19F MRI, might be associated with tissue depths 
of these organs and the presence of the fur between these organs and the CCD camera. The 
signal quantification of the regions of interest, drawn in the images shown in Fig. 4.11, 
demonstrated a strong increase of fluorescence signal at the site of infection at 30 minutes 
post administration and a strong decline in the first 48 hours post administration (Fig. 4.12 
A). The measurements at 30 min, 12 h and 24 h post administration showed significantly 
elevated average radiance levels, while later measurements signal converged to those of the 
‘no contrast agent’ negative control group. The lack of signal in ‘no contrast agent’ group 
mice demonstrated in addition, that luciferase activity of the bioluminescent S. aureus strain 
Xen29 did not lead to detectable photon signal after filtering of fluorescence signal with 
these settings (Cy 5.5 emission filter was applied for filtering in the IVIS Lumina II imaging 
device). 
Parallel to the in vivo imaging experiments, blood samples of all mice were collected in order 
to image the fluorescence signal in whole blood (Fig. 4.12 B). Imaging at 30 minutes post 
administration showed the strongest signal of all blood samples for the group that had 
received perfluorocarbon emulsion (‘PFC group’). Within the first 24 hours most of the 
fluorescence diminishes from the samples and the signal approximates to the signal derived 
from the negative control group, indicating rapid clearance of PFC tracer from the blood. 
Only the measurements at 30 min and 12 h post administration demonstrated significantly 
higher average radiance values than the control group. 
  
 4.1. Results 71 
 
Fig. 4.12: In vivo or ex vivo determination of 19F or fluorescence signal of home-made 
perfluorocarbon emulsion in blood or organs. Mice were challenged with 2.2 x 108 CFU S. aureus 
Xen29 in the left thigh muscle and home-made perfluorocarbon emulsion (with Atto647N-DOPE in 
the surfactant commixture) or 0.9 % NaCl solution as control (‘no contrast agent’ group; to note, non-
fluorescent perfluorocarbon emulsion delivered in vitro and in vivo similar fluorescence signal levels 
than 0.9 % NaCl solution) was administered at day 2 p.i.. A. In vivo fluorescence signal in the 
manually defined region of interest at the site of infection (see images in Fig. 4.9). Statistical 
significant differences between PFC group mice and control group mice (no perfluorocarbon 
emulsion) are indicated by asterisks (*: P < 0.05; ***: P < 0.005). B. Fluorescence signal of blood 
samples of perfluorocarbon treated and control group mice at different time points after 
administration of tracer. Statistical significant differences between PFC group mice and control 
group mice (no perfluorocarbon emulsion) are indicated by asterisks (*: P < 0.05; ***: P < 0.005). C. 
Fluorescence signal of homogenized tissue samples of perfluorocarbon treated and control group 
mice at day 7 p.i.. Statistical significant differences between PFC group mice and control group mice 
(no perfluorocarbon emulsion) are indicated by asterisks (*: P < 0.05; **: P < 0.01). D. Ex vivo 19F 
signal of homogenized tissue samples at different time points after administration. Time point day 
2 represents 30 min post tracer administration. 
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Organs were recovered at several time points after start of infection in order to measure the 
19F content and the fluorescence signal at the end of the experiments, at day 7 p.i.. 
Determination of the fluorescence signal of the homogenized organs at day 7 p.i., namely in 
the infected thigh muscle, the kidneys, lung, spleen and liver, showed significantly elevated 
fluorescence signal for the PFC group compared to the negative control group only in the 
thigh muscle and the liver, but not in the spleen (Fig. 4.12 C). But overall, differences in 
fluorescence of the homogenizations were weak, with the exception of the liver. The 19F 
content of homogenizations of the infected thigh muscle, liver and spleen, the main spots of 
perfluorocarbon accumulation in the whole mouse ex vivo imaging experiment, were 
determined at 30 minutes (day 2 p.i.), 24 hours (day 3 p.i.) and 120 hours (day 7 p.i.) after 
administration of perfluorocarbon emulsion (Fig. 4.12 D). Interestingly, there was no 
detectable 19F signal in the infected thigh muscle at 30 min post administration, which is 
congruent with earlier experiments that demonstrated first in vivo measurable 19F 
accumulation at the site of infection at around 10 – 12 hours after intravenous injection 
(compare Fig. 4.8). In contrast, the liver and the spleen, although less pronounced than at 
later time points, showed accumulation of perfluorocarbon emulsion at this very early time 
point. The 19F signal increased in all three organs until 24 h post administration, revealing 
measurable amounts of perfluorocarbon in the infected thigh muscle. Nonetheless, only 
about 10 % of the detected total signal accounts for accumulation at the site of infection, 
while most of the signal is found in the liver. The signal then decreased until day 7 p.i. in all 
organs, with the strongest reduction seen in the spleen. These results, taken together with 
the results derived by imaging of fluorescence signal of the Atto647N-labeled emulsion in 
whole blood samples, suggest clearance of perfluorocarbon emulsion from the mice body by 
a yet unidentified route and mechanism. 
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After identifying the accumulation in global scale, the next step was to further narrow the 
accumulation mechanism down, and to identify whether and which cells are involved. 
Former studies with this MR tracer imaging modality have shown, that in murine stroke, 
pneumonia and ischemia models, which are linked to massive monocyte/macrophage 
migration to the site of inflammation, perfluorocarbon is transported primarily by 
macrophages/monocytes (Flögel U et al. 2008, Janjic JM et al. 2008, Ebner B et al. 2010), but 
there were no studies published, which investigated the accumulation mechanism and the 
participating immune cells in infectious disease models. This is of special importance as S. 
aureus infections are mainly linked to massive neutrophils activation and influx and only to a 
less severe magnitude to macrophages/monocytes accumulation (Cheng AG et al. 2009). The 
idea was to identify the immune cell population or populations that participate in 
perfluorocarbon trafficking to the site of infection by labeling the perfluorocarbon emulsion 
with a fluorescent dye that can be identified by flow cytometry. In addition, the different 
immune cell populations which are present at the site of infection could be distinguished by 
flow cytometry, too, due to prominent and specific surface antigens. Well-known antigens 
were targeted by antibodies in order to identify crucial and/or important immune cell 
populations. To identify neutrophils, Ly6G, a prominent antigen on the surface of this cell 
type, was targeted (Daley JM et al. 2008). CD11b served as marker for macrophages, 
monocytes and activated neutrophils (Fischer MA et al. 2011). CD11c is a common antigen 
marker for dendritic cells in mice, although it has been shown recently that dendritic cell 
down-regulate this marker after activation (Singh-Jasuja H et al. 2013). CD45R (or synonym: 
B220) is mostly found on B cells (Coffman RL and Weissman IL. 1981), while T cells were 
identified by their expression of CD90.2 (or synonym: Thy1.2) antigen (Buttke TM et al. 
1983). 
In order to identify the different immune cell populations at the site of infection, mice were 
infected with 1.5 x 108 CFU S. aureus Xen29 in the left thigh muscle and homemade 
perfluorocarbon emulsion with Atto647N-DOPE in its surfactant commixture or 0.9 % NaCl 
as control were administered intravenously at day 2 p.i.. The muscles were recovered 16 
hours post administration and homogenized via pressing the muscle tissue through a cell 
strainer. Several samples of the homogenization were incubated with either 0.9 % NaCl 
solution or different cocktails of antibodies and the resulting cell fluorescence was measured 
in a flow cytometer (MACSQuant analyzer, Miltenyi Biotech). The samples without further 
addition of fluorescently labeled antibodies were analyzed first and the analysis of the 
fluorescence signal in channel R1, which visualizes extinction at 638 nm and emission at 655 
– 730 nm (this fits to the extinction/emission spectrum of Atto647N), showed for mice, that 
had not received perfluorocarbon emulsion, only background fluorescence signal. In contrast 
to this, Atto647N-emulsion treated mice contained a further population of cells with 
increased fluorescence signal, resulting in a second peak in the histogram (Fig. 4.13 A). 
The other samples received different cocktails of antibodies, which consisted of anti-Ly6G PE 
conjugated, anti-CD11b FITC conjugated and various VioBlue conjugated antibodies. The 
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last-mentioned antibodies were in this regard used to identify CD11c, B220, CD68, CD90.2 or 
F4/80 positive cell populations in different measurements of the same samples.  
The gating strategy was focused on the prevention of false-positive classification by 
unspecific binding of antibodies to Fc receptors, which are prominent on neutrophils. Cells 
were therefore either classified as Ly6G+ CD11b+ or Ly6G- CD11b+ in the anti-Ly6G PE vs. 
anti-CD11b-FITC dot plot (Fig. 4.13 B, regions 1 and 2) or Ly6G- VioBlue+ in the anti-Ly6G PE 
vs. VioBlue dot plot (Fig. 4.13 B, region 3). Ly6G+ CD11b- cells could not be identified in any 
of the mice tested, suggesting activation of all neutrophils prior or with their arrival at the 
site of infection. This corresponds to former experiments demonstrating activation of 
neutrophils by myeloperoxidase which resulted in enhanced CD11b expression (Lau D et al. 
2005, Schymeinsky J et al. 2007). 
All regions of all samples derived from control group mice, which had not received 
Atto647N-labeled perfluorocarbon emulsions, showed only one peak in the histogram of the 
R1 channel (Fig. 4.13 C – G, upper rows, region 1 (Ly6G+ CD11b+): blue curves, region 2 
(Ly6G- CD11b+): red curves, region 3: (Ly6G- VioBlue+): green curves). The fluorescence 
signal strength of the peaks of different regions had, in this context, similar values. This 
suggests that neither the labels of the antibodies nor auto-fluorescence of the different cell 
populations lead to detectable signals in channel R1. In consequence, signal from samples 
derived from Atto647N labeled perfluorocarbon group mice in this channel has to originate 
from the fluorescence labeling of emulsion. 
 
Fig. 4.13 (facing page): Flow cytometry investigation of fluorescent perfluorocarbon emulsion 
accumulation in immune cells. Mice were challenged with 1.5 x 108 CFU S. aureus Xen29 in the left 
thigh muscle and homemade perfluorocarbon emulsion (with Atto647N-DOPE in surfactant 
commixture) was administered intravenously at day 2 p.i.. The infected thigh muscles were 
recovered 16 h post tracer administration and homogenized by pressing through a cell strainer. Cells 
were then incubated with anti-Ly6G-PE, anti-CD11b-FITC and different VioBlue-conjugated antibodies 
and analyzed with a flow cytometer. A. Overlay histogram of cells from perfluorocarbon treated 
and untreated mice showed a second peak with a cell population with higher fluorescence signal in 
the R1 (Atto647N) channel. B. Gating strategy to identify different immune cell population from 
the infected thigh muscle. Activated neutrophils are considered as Ly6G+CD11b+ and therefore 
locate in R1, monocytes/macrophages at the site of infection should exhibit Ly6G-CD11b+ pattern 
(R2). Other immune cell population were defined by VioBlue+Ly6G- pattern to exclude unspecific 
binding of VioBlue-conjugated antibodies to Fc receptors of neutrophils (R3). C – G. Overlay 
histograms of signal in the Atto647N channel for the different cell populations from the three 
Gates/Regions: R1 (blue curve): Ly6G+CD11b+, R2 (red curve): Ly6G-CD11b+, R3 (green curve): either 
Ly6G-CD11c+ (C), Ly6G-B220+ (D), Ly6G-CD68+ (E), Ly6G-CD90.2+ (F) or Ly6G-F4/80+ (G) and the 
overall fluorescence signal of all cells (black line) for either perfluorocarbon treated (upper row) or 
not treated mice (lower row). H. Atto647N vs. PE dot blot shows a Ly6G+ population with higher 
Att647N fluorescence than the bulk of Ly6G+ cells. 
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And indeed, the R1 channel histograms of samples from Atto647N labeled perfluorocarbon 
mice (Fig. 4.13 C – G, black curve) exhibited two peaks similar to those seen for samples 
without antibody addition to the testing (Fig. 4.13 A). The fluorescence histogram overlays of 
all regions showed a shift of the blue curve (region 1, Ly6G+ CD11b+ cells) to increased 
fluorescence values in channel R1 (where Atto647N exhibits fluorescence signal) of 
perfluorocarbon group mice (Fig. 4.13 C – G, lower rows). This shift could be seen in all 
samples, as both antibodies were applied to all tests, and it was the highest increase of 
fluorescence signal for all regions. The fluorescence of Ly6G- CD11b+ cells in 
perfluorocarbon treated mice, visualized as red curve in all measurements, showed similarly 
an increased signal, although the shift was not as pronounced as with Ly6G+ CD11b+ cells 
(Fig. 4.13 C – G, lower rows). Regarding samples derived from Atto647N-labeled 
perfluorocarbon treated mice, a second population with higher fluorescence levels in the R1 
channel could be measured for Ly6G- CD11c+, Ly6G- CD68+ and Ly6G- F4/80+ cells (Fig. 4.13 
C, E and G; green curves, lower rows), indicating accumulation of fluorescent 
perfluorocarbon emulsions in these populations. Ly6G- B220+ and Ly6G- CD90.2+ cell 
populations exhibited, in contrast, no fluorescence shift in the R1 channel (Fig. 4.13 D and F; 
green curves). 
Most interestingly, in the homogenization samples of the thigh muscles of two out of four 
mice of the perfluorocarbon group, a second population of Ly6G+ cells could be detected, 
that exhibited elevated Atto647N fluorescence compared to the majority of Ly6G+ cells (Fig. 
4.13 H). This suggests a population of neutrophils at the site of infection with increased 
perfluorocarbon emulsion uptake at 16 h post tracer administration. Nonetheless, the 
histogram of Ly6G+ cells did not show a clear second peak with increased fluorescence, but a 
‘thicker right arm’ with higher fluorescence values (data not shown). 
The results of these flow cytometry experiments were quantified with respect to two 
parameters: the amount of different cell populations at the site of infection and the mean 
R1 channel fluorescence signal (Atto647N, labeling of perfluorocarbon emulsions) of single 
cells of the various populations. The quantification of different immune cell populations in 
the homogenized infected thigh muscle showed that about 50 % of all cells in the abscess 
area were Ly6G+ CD11b+ activated neutrophils (Fig. 4.14 A). This was, by far, the largest 
detectable cell population at the site of infection. Ly6G- B220+ B cells and Ly6G- CD90.2+ T 
cells were detected, too, but to a much smaller degree, each population representing about 
3 – 4 % of all cells. The smallest populations were Ly6G- CD11c+ dendritic cells, Ly6G- CD68+ 
macrophages or Ly6G- F4/80+ macrophages, comprising around 1 % of total cells, 
respectively (Fig. 4.14 A). 
Each of these cell populations was then measured for their mean fluorescence signal in the 
R1 channel of the flow cytometer. The mean fluorescence intensity of cells in the samples of 
control group mice, that had not received Att647N-labeled perfluorocarbon emulsion, was 
around 70 – 90 units (data not shown, but indicated in black curve in Fig. 4.13 A). Similar 
values could be measured for the Ly6G- B220+ B cells and Ly6G- CD90.2 + T cells of 
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fluorescently labeled perfluorocarbon treated mice, suggesting no accumulation of 
fluorescence marker and thus of perfluorocarbon emulsion in these cell populations. The 
other cell populations, namely the Ly6G+ CD11b+ neutrophils, Ly6G- CD11b+ phagocytes, 
Ly6G- CD11c+ dendritic cells, Ly6G- CD68+ macrophages and the Ly6G- F4/80+ macrophages 
showed significantly higher mean fluorescence in the R1 channel. Dendritic cells and 
macrophages delivered in this context the highest values, although the variance was 
especially for the Ly6G- F4/80+ macrophages higher than for the neutrophils. Nonetheless, 
to identify the source of perfluorocarbon emulsion accumulation at the site of infection, 
both parameters, the number of cells at the site of infection as well as their inherent 
Att0647N fluorescence, have to be taken into account. This suggests that the gross of 
perfluorocarbon is located in neutrophils, especially due to their huge majority at the site of 
infection. 
 
 
 
Fig. 4.14: Quantification of flow cytometry investigation to reveal immune cell populations with 
increased Atto647N-labeled perfluorocarbon emulsion uptake. Mice were challenged with 1.5 x 108 
CFU S. aureus Xen29 in the left thigh muscle and homemade perfluorocarbon emulsion (with 
Atto647N-DOPE in surfactant commixture) was administered intravenously at day 2 p.i.. The infected 
thigh muscles were recovered 16 h post tracer administration and homogenized by pressing through 
a cell strainer. Cells were then incubated with anti-Ly6G-PE, anti-CD11b-FITC and different VioBlue-
conjugated antibodies and analyzed with a flow cytometer. (Gating strategy shown in Fig. 4.11) A. 
Analysis of immune cell frequency in the infected thigh muscle. B. Mean fluorescence intensity 
(MFI) in arbitrary units of the different immune cell populations at the site of infection. Asterisks 
indicate statistically significant lower MFI values for B220+ and CD90.2+ cell populations compared to 
Ly6G+ CD11b+, Ly6G- CD11b+, CD11c+, CD68+ and F4/80+ cell populations. Compared to each other, 
B220+ and CD90.2+ cell populations showed no significant differences. 
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Flow cytometry of fluorescently labeled perfluorocarbons at the site of infection showed 
perfluorocarbon derived fluorescence in cells, but cannot visualize signal which is not 
associated with cells. Furthermore, flow cytometry can deliver only information about cell 
populations that can be identified by specific antibody binding. To address perfluorocarbon 
accumulation at the site of infection which is not associated with immune cells, cell sorting 
might be a promising approach. This method might deliver information about 
perfluorocarbon emulsion distribution at the site of infection by offering information about 
perfluorocarbon emulsion signal in specific cell populations or in aqueous phase. 
Female Balb/c mice were therefore infected with 1.5 to 2.0 x 108 CFU S. aureus Xen29 in the 
left thigh muscle and received perfluorocarbon emulsion (VS1000H, Celsence, Pittsburg, PA, 
USA) at day 2 p.i.. The muscles were recovered 16 - 18 hours later and homogenized by 
pressing them through a cell strainer. Different cell sorting methods were tested to separate 
specific cells from the crude muscle homogenate, namely magnetization-activated cell 
sorting (MACS), density gradient centrifugation and cell sieving (Pluriselect). Density gradient 
centrifugation of infected muscle homogenizations did not result in distinct layers of 
monocytes and granulocytes in the histopaque gradient. Thus, cell sorting by this 
centrifugation based method was not possible, maybe due to changes in macrophage and 
granulocyte cell densities during anti-infective activity, possibly caused by phagocytosis or 
vesicle release. 
The magnetization activated cell sorting approach on the other hand was characterized by 
the loss of a large and highly variable numbers of cells in the cell separation columns 
independently of their surface marker composition. In consequence, both the sorted cell 
samples (from the column) and the flow through samples (which should include all cells and 
soluble compounds with the exception of the sorted cells) showed much smaller cell 
numbers than the initial tissue homogenization sample. This led either to comparably high 
19F MR signals for Ly6G+ or CD11b+ sorted cells and for the Ly6G- respective CD11b-column 
flow through or to detectable 19F MR signal only in the column flow through samples. But 
importantly, all of them showed comparable or lower signal levels than the initial 
homogenization. Sorting of muscle homogenization for F4/80+ cells resulted in only 
negligible cell numbers and no detectable 19F MR signal. In consequence, the 19F signal in 
flow through samples might indicate perfluorocarbon emulsion accumulation by a cell 
independent mechanism. To address this, the muscle homogenization was filtered through 
0.45 µm syringe filters (msscientific, Berlin) to exclude cells from the analyte and then the 19F 
MR signal was determined. The filtration resulted in a severe to almost complete loss of 19F 
MR signal compared to unfiltered samples, suggesting cell dependent accumulation. 
Importantly, filtration of the perfluorocarbon emulsion itself did only lead to weak or 
negligible loss of 19F signal compared to unfiltered samples. In conclusion, the high variance 
of cell sorting efficiency by this method prohibited quantification of perfluorocarbon 
emulsion accumulation at the site of infection. The 19F signal of muscle homogenization 
could neither be attributed to a specific cell population nor to a cell unspecific accumulation 
mechanism by this method. 
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Finally, the third tested method, the cell sieving approach, delivered in this study feasible cell 
sorting efficiency without interfering with later fluorescence or MR measurements of the 
sorted samples. For this approach, the intravenous administration of homemade 
perfluorocarbon emulsion with Atto647N- or Atto550-DOPE in its surfactant commixture or 
not-fluorescently labeled, but otherwise identical, perfluorocarbon emulsion as control, 
enabled detection of perfluorocarbon emulsion by fluorescence imaging. The animal 
experiment was apart from that performed exactly like the other experiments of above-
mentioned cell sorting experiments. After muscle recovery, the muscle homogenizations 
were incubated with antibody-conjugated beads in order to select specific immune cell 
populations to separate them from the muscle homogenate. The samples were filtered 
through size exclusion filters, which let all cells pass with the exception of bead-bound 
antigen-specific immune cells. After this sorting step, the unsorted muscle homogenate, the 
separated bead-bound cells and the filter-flow-through were investigated for efficiency of 
sorting and perfluorocarbon derived fluorescence signal. 
Four different antigen-specific sorting beads were used to separate immune cell populations 
from muscle homogenate. First, anti-Ly6G-beads were applied to sort neutrophils out of 
crude muscle homogenate. Second, anti-CD11b-beads to target activated neutrophils, 
monocytes and macrophages. The third bead population aimed at the CD4 antigen, which is 
commonly expressed by T helper cells and finally, anti-CD19-beads to separate B cells from 
the homogenate. 
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Fig. 4.15 (facing page): Efficiency of cell sorting for the identification of perfluorocarbon loaded 
cells at the site of infection. Mice were challenged with 2.0 x 108 CFU S. aureus Xen29 in the left 
thigh muscle and homemade perfluorocarbon emulsion (with Atto550-DOPE in surfactant 
commixture) was administered intravenously at day 2 p.i.. The infected thigh muscles were 
recovered 18 h post tracer administration and homogenized by pressing through a cell strainer. Cells 
were then incubated with anti-Ly6G-, anti-CD11b-, anti-CD4- and anti-CD19-beads to separate 
specific immune cell populations out of the muscle homogenate by size exclusion. A. Flow cytometry 
analysis of muscle homogenate, separated cells and flow through (homogenate without separated 
cells). Samples were incubated with either anti-Ly6G-APC and anti-CD90.2-VioBlue or with anti-
CD11B-PerCP and anti-B220-VioBlue and analyzed on the flow cytometer. B. Sorting lead to an 
enrichment of antigen-specific immune cell populations in the ‘cell’ samples and a decrease in the 
‘flow-through’ samples, indicated by higher or lower frequency. Shown are the means +/- SEM of all 
events as measured in the flow cytometer. Statistically significant differences are indicated by 
asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005). (n.d.: not determined) 
 
 
After sorting, the unsorted muscle homogenate, the filter-flow-through and the sorted cell 
population were investigated by flow cytometry in order to evaluate the efficiency of 
sorting. A similar degree of Ly6G+ and CD11b+ cells (about 50 % of all detected events) than 
in earlier experiments (for comparison: Fig. 4.14) could be seen in the crude muscle 
homogenate (Fig. 4.15). Cell sorting resulted in a decrease of the ratio of Ly6G+ respectively 
CD11b+ cells compared to total cells in ‘flow-through’ samples, while the ‘sorted cell’ 
samples showed increased abundance of these cell types. Likewise, an enrichment of CD4+ 
respectively CD19+ cells could be seen for sorted cells with the proper antigen-specific 
beads, although these antigens remained underrepresented in the sample. Overall, cell 
sorting did not deliver pure samples of Ly6G+, CD11b+, CD4+ or CD19+ cells or, vice versa, 
muscle homogenates depleted from these cell populations, but nonetheless, the frequency 
of the cell populations was strongly enriched or reduced after sorting. In consequence, 
determination of perfluorocarbon emulsion signal in these samples gives a strong hind about 
the distribution pattern of the tracer at the site of infection. 
The perfluorocarbon emulsions could be, in principle, detected by two independent 
methods. First, by their inherent 19F signal, which can be measured by 19F MRI, and secondly, 
by fluorescence imaging of the Atto550 label, which is part of the lipid envelope around the 
perfluorocarbon core. 19F MRI of the sorted and crude samples delivered unfortunately only 
very low signal for all samples, thus it was impossible to compare the different sorted and 
unsorted samples. One explanation for this might be the rather strong dilution of samples, 
which is necessitated by the sorting protocol. 
Fluorescence imaging of the Atto550-label, in contrast, showed detectable signal for all 
samples with the exception of non-fluorescent perfluorocarbon control sample, as expected 
(Fig. 4.16). This resulted in close-to-background fluorescence signal for the control, non-
82 Chapter 4. Imaging of Staphylococcus aureus infections 
fluorescent perfluorocarbon emulsion and significantly higher values for the crude muscle 
homogenate samples. Importantly, one further control sample consisting only of diluted 
perfluorocarbon emulsion demonstrated, that particles were small enough to fit through the 
pores of the cell sorting filter and thus fluorescence signal was similarly strong for the ‘flow-
through’ sample compared to the pre-sorting sample. This means, that all perfluorocarbon 
emulsion signal in the ‘sorted cell’ samples must originate from cell-associated 
perfluorocarbon emulsion. In this context, sorting of muscle homogenate for Ly6G+ cells 
resulted in increased average radiance signal for the bead-bound cells compared to the 
crude unsorted muscle homogenate and flow-through fraction, which included all cells and 
supernatant with the exception of Ly6G+ cells. The ‘flow-through’ sample showed 
furthermore significantly lower signal than the Ly6G+ ‘sorted cell’ fraction and the crude 
homogenate. A similar, but less pronounced, picture could be seen for CD11b sorting. The 
cells that bound to the antigen-specific beads showed higher fluorescence values than the 
crude muscle homogenate and the flow-through fraction, which, again, had lower 
fluorescence than the unsorted homogenate. 
Sorting for CD4+ and CD19+ cells resulted in opposite results. The sorted cell population, 
either predominantly T helper cells for CD4 sorting or B cells in the case of CD19 sorting, 
showed lower fluorescence signal than the ‘flow-through’ fraction. This indicates lower 
perfluorocarbon emulsion content in the T helper and B cell populations than in the crude 
homogenate, while Ly6G+ neutrophil and CD11b+ activated neutrophils, monocytes and 
macrophage cell fractions show stronger perfluorocarbon emulsion derived fluorescence 
signal than the muscle homogenate itself. And furthermore, a reduction of Ly6G+ or CD11b+ 
cells in the muscle homogenate reduced the fluorescence signal strongly, suggesting that 
most of the perfluorocarbon emulsion is associated with these cell populations. 
 
 
Fig. 4.16 (facing page): Fluorescence signal of muscle homogenate, sorted cells and flow-through. 
Mice were challenged with 2.0 x 108 CFU S. aureus Xen29 in the left thigh muscle and homemade 
perfluorocarbon emulsion (with Atto550-DOPE in surfactant commixture) was administered 
intravenously at day 2 p.i.. The infected thigh muscles were recovered 18 h post tracer 
administration and homogenized by pressing through a cell strainer. Cells were then incubated with 
anti-Ly6G-, anti-CD11b-, anti-CD4- and anti-CD19-beads to separate specific immune cell populations 
out of the muscle homogenate by size exclusion. A. Fluorescence signal of 500 µl sample prior 
(‘homogenate’) and after cell sorting (‘cells’) as imaged in the IVIS. Note, the dilution factors of the 
individual samples were slightly different, thus the samples cannot be compared directly in this 
picture. Nonetheless, this image shows that all samples had signals above background levels. B. 
Mean fluorescence intensity of homogenates, flow-throughs and cells. Signal was measured in the 
IVIS (Caliper Life Science, Hopkinton, MA, USA) and calibrated according to the dilution factor of the 
sample. Shown are the means +/- SEM of all groups. Statistically significant differences are indicated 
by asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005). 
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Most importantly, cell sorting delivered in contrast to flow cytometry information about 
perfluorocarbon signal distribution over entire cell populations, not individual cells. 
Therefore, it gives better insights into the global distribution and localization of the tracer at 
the site of infection. With respect to the cell sorting results, it seems most likely that the 
majority of perfluorocarbon emulsion is located in Ly6G+ and/or CD11b+ cells. It has to be 
noted in this context, that flow cytometry of cell populations at the site of infection earlier in 
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this chapter showed that Ly6G+ neutrophils express the CD11b antigen at the site of 
infection, too. Therefore, it is reasonable that both antigens targeted overlapping or 
congruent cell populations in this experiment. In conclusion, results from cell sorting fit to 
the flow cytometry results showing accumulation of perfluorocarbon emulsion in 
neutrophils, monocytes and macrophages. Beyond that, cell sorting showed that the 
majority of perfluorocarbon emulsion signal is associated with these cell populations and 
that perfluorocarbon emulsion appears only at low amounts extracellularly at the site of 
infection. 
 
4.1.4.4. Histology and fluorescence microscopy 
Flow cytometry analysis of perfluorocarbon accumulation at the site of infection made the 
homogenization of the tissue sample necessary. This might have led to damaging or 
destructing of the perfluorocarbon carrying cells and thus to loss of signal or information. 
Therefore histology was applied as second method to visualize spots of fluorescently labeled 
perfluorocarbon emulsions. Mice were infected with 1.9 – 2.2 x 108 CFU S. aureus Xen29 in 
the left thigh muscle and either CLIO particles (cross linked ironoxide particles), 
commercially available non-fluorescent or Atto647N labeled homemade perfluorocarbon 
emulsion or 0.9 % NaCl solution as control was administered intravenously at day 2 p.i. CLIO 
particles were included in this experiment since it was described in literature, that they have 
a similar accumulation mechanism than perfluorocarbon emulsions (Kaim AH et al. 2002, 
Kaim AH et al. 2003). 
 
 
 
 
Fig. 4.17 (facing page): Histological appearance of abscesses in CLIO and PFC treated mice. Female 
Balb/c mice were challenged with 2.2 x 108 CFU S. aureus Xen29 in the left thigh muscle and either 
CLIO (A – D) or perfluorocarbon emulsion (E and F) was administered intravenously at day 2 p.i.. 
Muscles were recovered at acute phase of inflammation (A, B, E) or at chronic phase of inflammation 
(C, D, F), fixed in formalin, paraffin-embedded and cut to 2 µm thick slices. A. Hematoxylin – eosin 
staining of one representative CLIO treated mouse at acute phase of inflammation (d3 p.i.). B. Berlin 
blue staining of one representative CLIO treated mouse at acute phase of inflammation (d3 p.i.). C. 
Hematoxylin – eosin staining of one representative CLIO treated mouse at chronic phase of 
inflammation (d8 p.i.). D. Berlin blue staining of one representative CLIO treated mouse at chronic 
phase of inflammation (d8 p.i.). E. Hematoxylin – eosin staining of one representative PFC treated 
mouse at acute phase of inflammation (d3 p.i.). Hematoxylin – eosin staining of one representative 
PFC treated mouse at chronic phase of inflammation (d8 p.i.). Arrows point at spots of iron oxide 
accumulation (They appear as blue spots in the Berlin blue stained tissue sections). (Images adapted 
from Hertlein T et al. 2011). 
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Thigh muscle/abscess samples were in the first approach recovered at days 3 and 8 p.i., fixed 
in formalin, embedded in paraffin and cut to 2 µm thick slices. Samples of all mice were then 
stained with hematoxylin and eosin (HE) to visualize different immune cell populations. CLIO 
treated mouse samples were additionally stained with Berlin blue iron staining to reveal 
accumulation of ironoxides. All following samples were analyzed together with an 
experienced pathologist (Dr. Stefan Kircher, Institute for Pathology, University of Würzburg). 
The HE staining at acute phase of inflammation (day 3 p.i.) showed for all mice a massive 
infiltration of neutrophils at the rim of the abscess area as well as some interspersed 
macrophages (Fig. 4.15 A/E). They surrounded a central area of necrosis. There could be 
seen no difference in immune cell content or density between perfluorocarbon, CLIO and 0.9 
% NaCl treated mice. Furthermore, no accumulation of lipid or perfluorocarbon bubbles 
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could be observed in perfluorocarbon treated mice, which would have indicated growth or 
fusion of perfluorocarbon emulsions in vivo. The samples of chronic phase of inflammation 
(day 8 p.i.) showed a bulky central necrotic area encircled by a dense accumulation of 
granulocytes, macrophages and fibroblasts (Fig. 4.15 C/F). Similar to the results from acute 
phase of inflammation, no difference in immune cell composition or density could be 
delineated between perfluorocarbon emulsion, CLIO and 0.9 % NaCl treated mice. Berlin 
blue iron staining offered the visualization of CLIO particles in the histological samples, they 
appear as blue spots. Investigation of the acute phase of inflammation (day 3 p.i.) samples 
showed some blue spots of iron accumulation in granulocytes and macrophages of CLIO 
treated mice samples. Perfluorocarbon emulsion or 0.9 % NaCl treated mice had, as 
expected, no blue spots at the site of infection. A slightly stronger accumulation of CLIO 
particles, especially in macrophages, could be seen for samples from CLIO treated mice at 
chronic phase of inflammation (day 7 p.i.). The samples from 0.9 % NaCl or perfluorocarbon 
treated mice were, again, free of blue signal. 
Perfluorocarbon emulsion remained undetectable by these methods and there was no 
further histological method available to stain or visualize fluorine or perfluorocarbon in 
tissue sections. Therefore, fluorescence labeling of the perfluorocarbon emulsions became 
necessary to track the emulsion after in vivo application. For this purpose, female Balb/c 
mice were infected with 1.9 x 108 CFU S. aureus Xen29 in the left thigh muscle and either 
homemade perfluorocarbon emulsions with Atto647N-DOPE in its surfactant commixture or 
non-fluorescent but otherwise equal emulsions were administered intravenously at day 2 
p.i.. The infected thigh muscles were recovered 16 h after administration and immediately 
frozen. The frozen tissue was then sectioned to 10 µm thick slices and either investigated 
directly with a confocal laser scanning microscope (Leica TCS SP 5, Mannheim, Germany), 
stained with Hoechst 33425, with Hoechst 33425 and Atto520-phalloidin or with Hoechst 
33425, Atto520-phalloidin and different immune cell specific antibodies and afterwards 
analyzed by fluorescence microscopy. 
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Fig. 4.18: Fluorescence microscopy of frozen tissue sections of Atto647N-labeled perfluorocarbon 
emulsion treated mice. Mice were challenged with 1.9 x 108 CFU S. aureus Xen29 and 
perfluorocarbon emulsion was administered intravenously at day 2 p.i.. Muscles were recovered 16 h 
later and immediately frozen. The tissue samples were then cut with a cryotome into 10 µm thick 
sections and stained with Hoechst 33425 and Atto425-Phalloidin. A-C: Tissue sections of mice from 
Atto647N-labeled perfluorocarbon emulsion group with varying magnification showed spots of 
Atto647N fluorescence in close proximity to cell nuclei. Arrows point at spots of Atto647N 
fluorescence. D: Tissue section of control group which had received perfluorocarbon emulsion 
without fluorescence label showed no fluorescence in the Atto647N channel. 
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The native unstained slices showed some spots of Atto647N fluorescence, with a pattern 
ranging from single, intensively fluorescent points to larger areas of weaker signal (data not 
shown). The Hoechst 33425/Atto520-Phalloidin double stained slices visualized similar 
accumulation of Atto647N fluorescence in the infected thigh muscle, although the amount 
seemed to be reduced compared to unstained samples. Nonetheless, the double staining 
offered a nice anatomic view of muscle bundles and accumulation of immune cells (Fig. 4.16 
A - C). The Atto520-phalloidin staining visualized, in this context, muscle tissue by binding to 
F-actin, while Hoechst 33425 stain visualized DNA and thus, enabled visualization of cell 
nuclei. The Atto647N fluorescence was in all tested samples in the proximity of the cell 
nuclei. The pattern was similar to those seen in unstained samples, meaning either single 
spots of intense signal or larger areas with less pronounced Atto647N fluorescence. The 
signal sometimes accumulated in a pattern that resembled the shape of cellular plasma. 
Most importantly, none of the samples exhibited Atto647N fluorescence in muscle bundles, 
meaning all detectable signal was close to immigrated immune cells. Moreover, no Atto647N 
fluorescence could be seen with the same microscope settings in samples of mice that had 
received non-fluorescent perfluorocarbon emulsions (Fig. 4.16 D). 
Furthermore, no Atto647N fluorescence could be detected in any of the antibody stained 
tissue sections. This staining protocol to target specifically immune cell populations required 
long phases of incubation. During these steps, the slices were covered with buffer. 
Perfluorocarbon emulsion might be washed out of the sections during the incubation steps, 
what in turn might be an explanation for the loss of perfluorocarbon derived fluorescence 
compared to Hoechst 33425/Atto520-Phalloidin stained samples. The loss of 
perfluorocarbon emulsion derived fluorescence was in this context observed by other 
investigators, too (Flögel U et al. 2008). 
 
  
 4.1. Results 89 
4.1.5. Perfluorocarbon administration does not change the 
fundamental parameters of infection 
After investigating the accumulation mechanism at the site of infection, the question arose, 
whether or not, administration of perfluorocarbon emulsion or the following magnetic 
resonance imaging has any influence on the infection itself. To address this question, two 
groups of female Balb/c mice were infected with 2.2 x 108 CFU S. aureus Xen29 and received 
either 0.9 % NaCl solution at day 2 p.i. or perfluorocarbon emulsion. 
The infected thigh muscle, the liver and the spleen were recovered either prior 
administration, 24 hours (day 3 p.i.) or 5 days (day 7 p.i.) post administration, homogenized 
and the colony forming units determined. The CFU results were similar to those described in 
chapter 4.1.1, and showed highest bacterial numbers in the infected thigh muscle and only 
low numbers or no bacteria at all in the spleen and liver at all examined time points (Fig. 
4.19 B – D). There could be seen no significant difference in bacterial burden in the infected 
thigh muscle, only slightly higher numbers at day 3 and day 7 p.i. for the perfluorocarbon 
group (PFC), but differences were small and statistically not significant (Fig. 4.19 B). A similar 
picture could be seen in the liver. The CFU counts were similar between perfluorocarbon 
treated and not-treated mice at all time points (Fig. 4.19 C). In the spleen, almost no bacteria 
could be detected at day 2 and day 7 p.i. (Fig. 4.19 D). At day 3 p.i. there might be some 
difference in bacterial counts between perfluorocarbon and mock treated mice, with higher 
values for the perfluorocarbon group, but differences were not statistically significant and 
the results overlapping. 
Since the bioluminescent S. aureus strain Xen29 was administered to the mice, 
accompanying non invasive bioluminescence imaging was possible. The time course of 
bioluminescence signal at the site of infection, measured in a manually defined region of 
interest with same size and geometry for all mice, showed congruent development of 
photon emission for both groups (Fig. 4.19 A). Perfluorocarbon treated as well as not-treated 
mice had a strong decrease of bioluminescent signal within the first 24 hours and a recovery 
to a stationary phase with slight variations between day 4 and day 7 p.i.. The values of both 
groups were comparable in signal and differences were very small and statistically not 
significant. 
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Fig. 4.19 (facing page): Comparison of CFU values, bioluminescent signal and immune cell 
frequency in the abscess between perfluorocarbon treated and not-treated mice in the S. aureus 
thigh infection model. Mice were challenged with ca. 2.2 x 108 CFU S. aureus Xen 29 into the left 
thigh muscle. All mice of ‘PFC’ groups received a single intravenous administration of 
perfluorocarbon emulsion at day 2 p.i., while the ‘no contrast agent’ group mice received a single 
bolus of 0.9 % NaCl solution. A: Development of bioluminescent signal in ‘PFC’ (5 animals) and ‘no 
contrast agent’ (8 animals) groups during infection. Means +/- SEM are displayed. B – D: CFU counts 
in infected thigh muscles, livers and spleens of either perfluorocarbon emulsion treated or control 
mice. Single CFU counts per mouse and the respective medians per groups for the indicated time 
points are shown. Time point day 2 p.i. is prior to administration of tracer, day 3 p.i. is 24 hours after 
administration and day 8 p.i. is 5 days post perfluorocarbon emulsion administration. E: Flow 
cytometry analysis of immune cell populations in the infected thigh muscle. Infected thigh muscles 
of perfluorocarbon emulsion and control treated mice were recovered 24 hours post tracer 
administration and homogenized. Single cell suspensions were then incubated with various 
fluorescently labeled antibodies and analyzed with the flow cytometry protocol described in Fig. 4.13 
(only difference to previous experiments: no anti-CD11b antibody). There are no statistically 
significant differences between both groups (both groups: n = 4). 
 
 
The establishment of a flow cytometry protocol to analyze the occurrence of 
perfluorocarbon emulsion derived fluorescence in different immune cell populations at the 
site of infection in previous experiments (Chapter 4.1.4.3, especially Fig. 4.13) enabled the 
comparison of incidence of different immune cell populations at the site of infection. The 
idea was, that the migration behavior of phagocytic immune cells might be altered after 
uptake of perfluorocarbon emulsion in the blood stream. The frequency of T (CD90.2+) and B 
(B220+) cells seemed to be, in this context, slightly increased in the perfluorocarbon 
emulsion treated group, while the incidence of neutrophils (Ly6G+) seemed to be decreased 
to the same extent (Fig. 4.19 E). Nonetheless, the elevated levels of B and T cells are due to 
very high numbers in only one out of four mice of the perfluorocarbon group. The other 
mice of this group showed similar levels than the control group. Most importantly, there are 
no statistical significant differences between both groups for any of the investigated immune 
cell populations, indicating unaltered cellular immune response, at least regarding the 
frequency of cells. The frequency of dendritic cells (CD11c+) and macrophages (CD68+ and 
F4/80+) were very low and congruent to earlier experiments (compare Fig. 4.14). 
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At last, cytokine and chemokine levels in the infected thigh muscles were measured and 
compared between perfluorocarbon treated and not-treated mice. The infected thigh 
muscles were therefore recovered before (day 2 p.i.), 24 hours after (day 3 p.i.) and 5 days 
(day 7 p.i.) after intravenous administration of the emulsion. The muscles were then 
homogenized and the levels of various cytokines and chemokines determined with flow 
cytometry bead assays (eBioscience). High levels of cytokines IL-1α, IL-2 and IL-6 as well as of 
chemokines MCP-1, MIP-1α and RANTES could be seen at day 2 p.i. in both groups, with no 
significant differences between them (Fig. 4.20). Lower levels of cytokines IL-4, IL-5, IL-10, IL-
17, IFNγ and TNFα, as well as of chemokine MCP-3 could be measured, with no differences 
between perfluorocarbon and control group mice. Almost no detectable levels of GM-CSF 
and MIP-1β were seen in the infected thigh muscle at all three time points. The level of IL-2 
and IL-6 decreased, similar regarding trend and gravity in both groups, between day 2 p.i. 
and day 7 p.i.. The amounts of IL-1α, IL-4, IL-10, IL-17, MCP-3 and MIP-1α remained 
invariably at their initial level, while the levels of IL-5, IFNγ and RANTES ascended between 
day 2 and day 7 p.i.. But nonetheless, despite some differences in the levels of cytokines or 
chemokines between perfluorocarbon treated and not-treated mice, for example, in MCP-1 
amounts at day 3 p.i. or MIP-1α at day 7 p.i., the differences were small, statistically not 
significant and results overlapping. Moreover, the pattern of cytokines and chemokines was 
similar in both groups and therefore, it has to be stated that perfluorocarbon administration 
resulted in unaltered cytokine or chemokine release compared to the administration of 0.9 
% NaCl solution. 
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Fig. 4.20: Cytokine and chemokine pattern in the infected thigh muscle of PFC treated and 
untreated mice. Mice were challenged with 2.2 x 108 CFU S. aureus Xen29 in the left thigh muscle. 
Muscles were recovered at indicated time points, homogenized and stored at -80°C until 
determination of cytokine or chemokine levels. A. the mean cytokine levels +/- SEM for PFC treated 
(5 animals each time point) and untreated groups (5 animals each time point) are shown. Cytokine 
levels were measured via flow cytometry with ‘Mouse Th1/Th2 10plex FlowCytomix Multiplex Kit’ 
(eBioscience). B. Shown are the mean chemokine levels +/- SEM for PFC treated (5 animals each 
time point) and untreated groups (5 animals each time point). Chemokine levels were measured via 
flow cytometry with ‘Mouse Chemokine 6plex FlowCytomix Multiplex Kit’ (eBioscience). 
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4.2. Discussion 
 
Infectious diseases are a constant threat to public health worldwide. Although the 
identification of antibacterial compounds and its introduction into clinics has led to a strong 
decrease of deaths caused by infectious diseases, especially in developed countries 
(Yoshikawa TT 2002), the WHO estimated, nonetheless, that in 2002 about 25.9 % of all 
deaths worldwide were caused by infectious diseases (The World Health report 2004. Annex 
Table 2). Moreover, the emergence of new, formerly unknown pathogens, the development 
and spreading of antibiotic-resistance and the aging of human population exerts a constant, 
maybe even increasing, pressure on public health systems. In consequence, there is a 
sustained need for new and more efficient vaccines and antibiotics. Of special interest in this 
context is the opportunistic pathogen Staphylococcus aureus. This pathogen is able to cause 
a wide variety of diseases, ranging from superficial skin infections to invasive diseases like 
pneumonia, sepsis or endocarditis (Lowy FD. 1998). S. aureus is furthermore notorious in 
developing or acquiring resistance against antibiotics, thus limiting treatment options to 
fight life-threatening S. aureus infections. For illustration, MRSA infections alone affect more 
than 170.000 patients per year in the EU, causing more than EUR 380 million extra in-
hospital costs (Köck R et al. 2010). In consequence, it is of paramount importance to develop 
new therapeutics and strategies against this pathogen. 
In addition to the mere generation of new antibiotics or vaccines, the identification of sites 
of infection and the disease-inducing pathogen are of highest importance to enable targeted 
and efficient therapy. In vivo imaging technologies like positron emission tomography, 
magnetic resonance or bioluminescence imaging offer in this context non-invasive platforms 
to visualize and estimate the severity of disease in real-time. Moreover, these platforms 
might help to elevate the preclinical testing of promising compounds and strategies to fight 
infections in animal models. Simultaneously, they might help to reduce the number of 
animals necessary for preclinical evaluation of new compounds by delivering information 
about the gravity of disease of more than one time point per animal. 
The goal of this chapter was therefore to test whether bioluminescence imaging and 
magnetic resonance imaging are capable to visualize the effects of S. aureus infection non-
invasively and whether they can be included in a preclinical testing strategy of new 
compounds, or not. The main focus of the project in this context was the evaluation of 
magnetic resonance imaging as infection imaging modality, since earlier studies 
demonstrated the usefulness of bioluminescence imaging with genetically engineered 
luciferase-expressing S. aureus strains in several animal models (Contag CH et al. 1995, 
Francis KP et al. 2000, Kadurugamuwa JL et al. 2003b, Xiong YQ et al. 2005, Steinhuber A et 
al. 2008). The benefit of magnetic resonance imaging to visualize sites of S. aureus 
infections, in contrast, was only rarely investigated at the beginning of this study. 
Interestingly, former investigations concentrated either on the utility of native 1H MRI to 
evaluate the efficacy of antibiotics or on the usefulness of iron oxide particles as contrast 
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agents to identify the site of infection. It was, for example, depicted that T2 weighted MRI 
visualizes sites of edema and inflammation with high resolution and enable identification of 
sites of infection especially in soft tissue or close to bones (Tang JS et al. 1988, Beltran J 
1995). Consequently, MRI was used to assess the efficacy of vancomycin and 
imipenem/cilastatin in a S. aureus thigh infection model (Marzola P et al. 1999). But this 
study showed, that, although T2 weighted MRI proved very useful to identify the site of 
infection, the clear definition of the area of infection as well as the quantification of the 
severity of disease remained challenging or not feasible with these methods. The variance of 
the MR results was rather high and the values of vancomycin and mock group overlapping, 
thus preventing statistically significant differences, although histology proved the efficacy of 
vancomycin treatment in this experiment. The second approach to apply MRI as infection 
imaging technology was the evaluation of iron-based contrast agents as infection or 
inflammation specific imaging probes. It was shown, that ultrasmall superparamagnetic iron 
oxide (USPIO) particles accumulate after intravenous administration in activated 
macrophages (Kaim AH et al. 2002). The labeled macrophages migrated in the S. aureus 
thigh infection model to the site of infection, leading to accumulation of USPIOs at the 
abscess (Gelissen J et al. 1999, Lutz AM et al. 2005). 
But these last-mentioned, contrast agent-focused studies did not investigate whether 
antibiotic therapy has an effect upon accumulation of contrast agent at the site of infection 
and therefore, the question whether contrast agent based MRI might deliver clearer results 
about efficacy of antibacterial therapy than native 1H MRI alone remained unanswered. The 
main goal of this chapter was in consequence to test different MR methods, especially 
contrast agent based ones, to visualize sites of infection to enable in the following chapters 
the application of MRI as an preclinical in vivo antibiotic testing platform. 
The first step was to establish and characterize an animal model. The S. aureus thigh abscess 
model was chosen, because it leads to bulky and localized abscesses in the infected thigh 
muscle. It was furthermore used in the former MR studies of antibiotic efficacy testing 
(Marzola P et al. 1999) and USPIO evaluation (Kaim AH et al. 2002, Lutz AM et al. 2005). The 
intramuscular injection of 2.2 x 108 CFU S. aureus Xen29 led to a stable bacterial community 
of ca. 109 CFU after an initial phase (first 24 hours) of bacterial growth (Fig. 4.1). The 
bacterial burden in the liver, kidneys and spleen were very low or not detectable during the 
experiment, proving a localized infection in the thigh muscle. The histological examination of 
the infected thigh muscles showed a dense infiltration of granulocytes at the rim of an 
emerging abscess area at acute phase of inflammation (day 3 p.i.), surrounding a central 
area of necrosis. These results were congruent with the MR based imaging studies based on 
this animal model (Marzola P et al. 1999, Kaim AH et al. 2002, Lutz AM et al. 2005). 
Since S. aureus Xen29 harbors the luxABCDE operon and is thus able to express bacterial 
luciferase, accompanying bioluminescence imaging was possible. The photon emission of 
this strain dropped strongly within the first 24 hours of infection from a very strong signal to 
almost background values (Fig. 4.1 E). Reason for this behavior might be a phase of adaption 
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from high nutrient medium conditions to nutrient limitation in the murine host. The signal 
increased from day 1 p.i. until day 4 p.i., but did not reach the initial levels again. From day 4 
to day 7 p.i., the signal remained at a stable level, suggesting a constant bacterial 
community. In summary, the bioluminescence signal between days 4 and 7 p.i. fitted nicely 
to CFU counts of these time points, both of them indicating constant numbers of bacteria in 
the infected thigh muscle. The initial phase of infection is in contrast characterized by a large 
discrepancy in the results derived from CFU counting and bioluminescence imaging. This has 
to be taken into account when trying to measure the bacterial burden with bioluminescence 
imaging in the early phase of infection. 
The first MR experiments were facilitated to explore the effects of infection in the thigh 
muscle on native 1H MR parameters. As expected from earlier publications (Marzola P et al. 
1999), T1 weighted MRI did not visualize changes in the infected thigh muscle, while T2 
weighted MRI indicated edema formation at least from day 2 p.i. until the end of the 
experiment. But a clear distinction of infected and not-infected tissue remained impossible 
since elevated T2 relaxation times in the center of the edema formation did not form a clear 
border but a continuous decrease to values of normal, healthy tissue (as measured for 
example in the right, control muscle). The values showed furthermore high variance 
between different mice, thus reducing the chance to visualize quantitative differences 
between antibiotic treatments even more. In conclusion, the MR results were congruent 
with the study published by Marzola P et al. in 1999, demonstrating the usefulness of T2 
weighted MRI to visualize sites of infection, but lacking on the other hand a sufficient 
quantification of severity of infection. 
One idea to cope with this problem was the application of iron oxide particles (USPIOs) as 
contrast agents to image the border between abscess and healthy tissue by MRI. These 
particles accumulate in activated macrophages after intravenous application (Gelissen J et al. 
1999). The subsequent migration of the immune cells to the site of infection then leads to 
accumulation of USPIOs at the rim of the abscess area (Kaim AH et al. 2002). In our 
experiments, the intravenous administration of cross-linked iron oxide particles (CLIO), 
which are very similar to USPIOs, at day 6 p.i. led to accumulation of iron particles at the rim 
of the edema area (which is indicated by increased T2 relaxation times) at chronic phase of 
inflammation and enabled thereby a distinction of infected and not-infected tissue (Fig. 4.3). 
This fits nicely to the above-mentioned former studies, but the application of CLIOs at acute 
phase of inflammation (day 2 p.i.) caused only sparse and rather diffuse signal distortion 
effects at the rim of the abscess area, suggesting less pronounced accumulation and 
avoiding clear distinction of abscess and healthy tissue. But this hampered the quantification 
of abscess volume and thus the estimation of the disease severity. Another reason against 
iron oxide particles is the fact, that they are usually detected by their signal distortion effects 
at the site of accumulation, inducing ‘black spots’ in the images. Their accumulation can be 
imaged quite nicely in the thigh muscle, since this tissue delivers sufficient and continuous 
inherent MR signal, but an application in, for example, systemic infection models, where one 
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encounters tissues with less inherent signal, an identification of spots of accumulation and 
their quantification might be very challenging. 
Another, recently developed MR tracer based method to identify sites of inflammation, is 19F 
MRI with perfluorocarbons. Perfluorocarbons, the imaging ‘agent’ of this method, are 
therefore in most studies formulated as emulsion, since this compound class is neither 
soluble in water nor in lipids. The intravenous application of the perfluorocarbon emulsion in 
murine models of ischemia, stroke, pulmonary inflammation or arthritis led to accumulation 
of perfluorocarbons at the site of inflammation (Flögel U et al. 2008, Ebner B et al. 2010, 
Balducci A et al. 2012). This accumulation can be visualized background-free by 19F MRI since 
the mouse does not harbor intrinsically sufficient amounts of 19F. Nevertheless, the 19F 
image can then be overlayed on a 1H MR image to visualize the accumulation in anatomical 
context (Janjic JM, Ahrens ET 2009). 
The intravenous administration of perfluorocarbon emulsion in the S. aureus thigh muscle 
infection model at acute phase of inflammation (day 2 p.i.) led to accumulation of 19F signal 
at the rim of the edema or abscess area on the MR images 24 hours later (Fig. 4.5). The 
accumulation formed a ‘hollow sphere’ circumscribing a central volume with no detectable 
perfluorocarbon. A similar picture could be seen, when perfluorocarbon emulsion was 
injected at chronic phase of inflammation (day 8 p.i.). In conclusion, the 19F signal 
accumulated at both time points in the shape of a ‘hollow sphere’ at the rim of the abscess 
area, thus defining the area of infection in an easy to identify manner. 19F MRI with 
perfluorocarbons as tracer substance seems after this first experiments much better suited 
to investigate the effect of antibiotic therapy than native 1H based MRI or MRI with iron 
oxide nanoparticles. To test for durability of 19F accumulation at the site of infection, a 
further group of mice was imaged at various time points after administration of 
perfluorocarbon emulsion at day 2 p.i.. The imaging at days 3, 5, 7 and 9 showed consistent 
accumulation of tracer at the site of infection (Fig. 4.7), suggesting stable signal after one 
single administration of perfluorocarbon emulsion and thus enabling time course imaging of 
the abscess area. Interestingly, a weaker infectious dose did not only lead to a smaller 
number of bacteria in the infected thigh muscle after 10 days of infection than initially 
injected, but also to a reduction or partial loss of 19F accumulation around the abscess area. 
This means, that CFU determination as well as 19F MRI suggests some kind of healing 
process. But nonetheless, the initial accumulation of perfluorocarbon emulsion at the site of 
infection led to the well-known ‘hollow sphere’ pattern around the edema area, which is 
indicated in the T2 maps. Taken together, these results suggest a correlation of 
perfluorocarbon emulsion accumulation or stability at the site of infection and the bacterial 
burden or severity of disease. 
The following experiments sought to investigate the kinetics of accumulation in greater 
detail. It was unknown till these experiments, whether perfluorocarbon accumulates 
immediately after intravenous administration at the site of infection, or not. It was 
furthermore not clear, whether administration of tracer at other time points than day 2 and 
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day 8 p.i. leads to detectable amounts of 19F at the site of infection. Thus, in the first 
experiments, MR imaging was started immediately after administration of perfluorocarbon 
emulsion to define the first time point of visualizable 19F ‘hollow sphere’ accumulation at the 
site of infection. Although, the time points were not congruent in the four investigated mice, 
a first visualization of prefluorocarbon in the infected thigh muscle was possible at least in 
two of them at around 11 hours post administration (Fig. 4.8). The results derived from 
variation of administration time point experiments showed a lack of perfluorocarbon 
accumulation at the site of infection when the tracer was applied at 2 or 24 hours post 
infection, while administration at later time points led in all other mice to ‘hollow sphere’ 19F 
pattern around the abscess area (Fig. 4.9). Taken together, these experiments suggest a 
specific accumulation that depends on the status of the infection or immune response. It 
seems to be more probable that the status of the immune response is responsible for 
accumulation or the lack of accumulation at the site of infection, since it was shown in 
former studies of ischemia, stroke and pulmonary inflammation that perfluorocarbon 
emulsions accumulate in macrophages and monocytes, whose subsequent migration to the 
site of inflammation led to fluorine MR signal (Flögel U et al. 2008, Ebner B et al. 2010). 
Recently, it was shown in addition that macrophages and monocytes, but also neutrophils 
are able to take up perfluorocarbon emulsion and their migration behavior leads to 
accumulation of 19F signal at sites of inflammation (Temme S et al. 2013). Therefore, it seems 
likely that phagocytes are not attracted in sufficient amounts to the site of infection to 
induce visualizable MR signal at early phase of infection (until day 2 p.i.), while the activation 
of phagocytes, especially neutrophils and macrophages/monocytes, becomes strong enough 
at later stages. 
The former MR imaging experiments visualized the accumulation of perfluorocarbon 
emulsion at the site of infection in a small field of view (approximately 3 cm of the length of 
the mouse), but gave no hinds about further sites of accumulation. To investigate this, whole 
mice were fixed in formalin solution (24 hours after perfluorocarbon administration), after 
being challenged with S. aureus and having received a single emulsion application at day 2 
p.i., and were imaged by 19F MRI in different, larger 1H / 19F double-resonant MR coil, which 
enabled whole animal imaging. The 3D reconstruction of these ex vivo measurements 
showed strong accumulation of perfluorocarbon in the liver, spleen and infected thigh 
muscle, as well as low amounts in spinal cord and bones (Fig. 4.10). This highly selective 
pattern, seen in all investigated mice, suggests a specific mechanism causing the 
accumulation of tracer. It seems probable that perfluorocarbon emulsions are filtered from 
the blood by cellular uptake in liver cells and phagocytes in the blood, bone marrow or 
spleen. 
In order to address this question, methods to measure the perfluorocarbon emulsion 
content of organs and cells became necessary. In a first approach the 19F amounts in organ 
homogenizations were determined with ex vivo MRI. The distribution in the perfluorocarbon 
signal in the liver, spleen and thigh muscle proved that most of the signal could be detected 
in the liver (Fig. 4.12), covering about 80 % of the total signal, while only about 10 % of the 
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total signal counted for the infected thigh muscle. 19F signal was in this context very early (30 
min after injection) measurable in liver and spleen, but not in the infected thigh muscle. This 
suggested a filtration-like mechanism for the accumulation in liver and spleen, while the 
accumulation at the site of infection seems to depend on a more time-consuming 
mechanism, maybe cellular uptake in the blood and their subsequent migration to the 
abscess area. In consequence, most of the applied perfluorocarbon emulsion did not reach 
the area of interest. Therefore, future developments of perfluorocarbon emulsions should 
aim for targeted approaches to increase the specificity of accumulation. Maybe even an 
approach to hide the emulsion for phagocytes or liver filtration might become necessary or 
beneficial. Most importantly, due to low amounts of blood that could be recovered during 
course of infection, an ex vivo 19F measuring approach with MR failed. An idea to circumvent 
this problem was the application of fluorescently labeled perfluorocarbon emulsions. 
Unfortunately, the commercially available formulations exhibited too weak fluorescence 
labeling to identify them in vivo or in blood samples. This made the home production of 
emulsion with higher amounts of fluorescence labels necessary. 
A sonication approach was used to emulsify perfluorocarbons in a lipid surfactant 
commixture to receive liposomal formulations for intravenous application. The composition 
of the particles followed in principle former descriptions in literature (Partlow KC et al. 2007, 
Southworth R et al. 2009). The core of the particles consisted in this context of perfluoro-15-
crown-5-ether, a compound with 20 magnetically equivalent 19F atoms, which was 
surrounded by a layer of lecithin stabilized with cholesterol. The sonication led to particle 
populations with different sizes in each preparation, but after serial filtration through 
different sized syringe filters, a single particle population with a size of less than 0.45 µm 
remained in the preparation. The intravenous administration in the S. aureus thigh infection 
model led to the well-known ‘hollow sphere’ accumulation pattern around the abscess area 
in the infected thigh muscle and to further spots of accumulation in the liver and spleen. No 
differences between homemade and commercially available emulsions could be determined, 
suggesting comparability of the results derived from both preparations. The addition of 
Atto647N-DOPE to the surfactant commixture enabled strong fluorescent labeling of the 
emulsion and thus fluorescence imaging of perfluorocarbon emulsions in ex vivo and in vivo 
samples. 
The intravenous application at day 2 p.i. led to a very strong fluorescence signal in the whole 
mouse at 30 min post administration, indicating global distribution via the blood stream and 
availability of emulsion in the whole animal. At 12 hours p.i., this extensive fluorescence 
signal was gone, but a specific accumulation at the site of infection could be imaged. 
Surprisingly, the fluorescence signal at the site of infection decreased steadily between 12 
hours and 48 hours post administration and reached almost the background level of control 
mice, which had not received fluorescent perfluorocarbon emulsion at 72 hours post 
administration. No fluorescence signal could be detected in liver or spleen areas of the mice. 
The fur of the mouse, which was not removed at these spots, but at the infected thigh 
muscle, might have decreased the signal as well as the depths of both organs in the body of 
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the mouse. This seemed to be a reasonable explanation for the surprising lack of in vivo 
fluorescence signal from these organs, although the ex vivo 19F MR experiments indicated 
perfluorocarbon accumulation in both of them. This hypothesis was furthermore 
corroborated by measuring the fluorescence signal of the homogenizations of organs, which 
were collected at day 7 p.i.. The fluorescence signal of liver and infected thigh muscle 
homogenizates were significantly higher in mice treated with fluorescently labeled 
perfluorocarbon emulsion than in mice treated with non-fluorescent control emulsions (Fig. 
4.12). Nonetheless, the spleen, one major source of 19F MR signal in ex vivo measurements, 
delivered only slightly but not significantly higher values for fluorescent emulsion vs. control. 
Since less sample volume was needed for fluorescence imaging than for 19F MRI, measuring 
the content of fluorescence signal of perfluorocarbon emulsions in the blood became 
feasible. The fluorescence signal in the blood of mice treated with fluorescently labeled 
preparations showed a very robust signal immediately after injection, that strongly 
decreased in the first 24 hours to reach the signal level of control treated mice at least at 72 
hours post infection. This suggests a rapid clearance or uptake of the perfluorocarbon 
emulsion. One has to take into account for all these experiments that it is highly likely that 
the fluorescence label, which is exposed at the surface of the emulsions, gets bleached or 
inactivated in the mouse’s body under in vivo conditions, although Atto647N was chosen 
because of its high pH stability. This might lead to lower values or stronger reduction of 
signal than indicated by 19F MRI. The perfluorocarbon in the core of the emulsion is in 
contrast to this biologically and chemically inert and in addition shielded from the 
surrounding environment, thus 19F signal reduction or loss is less probable. 
Taken together, the fluorescence imaging results suggest in principle the same distribution 
pattern of perfluorocarbon emulsion than 19F MRI, with some technical advantages like 
faster gathering of images or values and smaller sample sizes for ex vivo measurements, but 
could not, as initially expected, deliver higher sensitivity. The fluorescence labels are 
furthermore prone to bleaching or inactivation in the in vivo environment. But on the other 
hand they inaugurated a whole new choice of methods to investigate the accumulation of 
perfluorocarbon emulsions like flow cytometry or fluorescence microscopy. 
In order to characterize those immune cells who take up perfluorocarbon emulsion in vivo, 
the infected thigh muscles were recovered early after administration of perfluorocarbon 
emulsion, namely 16 hours, since the in vivo 19F MR imaging results suggested a detectable 
accumulation at around 11 to 12 hours post administration. To recover as much viable 
immune cells as possible, a gentle and fast approach for homogenization via pressing 
through a cell strainer was chosen. The resulting homogenizate was then incubated with 
different fluorescently labeled antibodies to identify those immune cell populations who 
exhibit perfluorocarbon associated Atto647N fluorescence. Former studies have 
demonstrated the accumulation of perfluorocarbon emulsions in macrophages/monocytes 
(Flögel U et al. 2008, Ebner B et al. 2010) and a very recent study, which was not available 
during the experimental part of this thesis, additionally in neutrophils (Temme S et al. 2013). 
Therefore the flow cytometry analysis was primary focused on neutrophils and macrophages 
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and secondary on other immune cells like dendritic cells, T cells and B cells. The binding of 
antibodies to immune cell population specific surface-exposed antigens should serve to 
identify them. Ly6G was applied to identify neutrophils since it was described that this 
antigen is primarily expressed on neutrophilic granulocytes and expression increases during 
maturation (Fleming TJ et al. 1993). Macrophages were identified by their expression of the 
antigens F4/80 or CD68 (Zhang X et al. 2008). CD11b is mainly expressed on 
macrophages/monocytes and microglia in mice, but upon activation neutrophils start to 
express this antigen in larger amounts, too (Anderson DC et al. 1986). Mouse CD11c is 
present on dendritic cells in lymphoid organs and blood and serves as predominant marker 
to identify or deplete this immune cell population (Rahman S et al. 2010). The CD45R (B220) 
antigen served as marker for B cells due to its expression on this set of immune cells until 
they differentiate to plasma cells (Kroese FG et al. 1985). T cells were identified by 
antibodies against the antigen CD90 (Thy1.2), which is highly expressed on thymocytes and 
peripheral T cells in blood and lymphoid tissue (Ledbetter JA et al. 1979). 
The gating strategy of the flow cytometry analysis was based on the exclusion of unspecific 
binding of antibodies to neutrophils via their binding to Fc receptors, which are highly 
expressed on activated neutrophils (Huizinga TW et al. 1990). Therefore, the B1 and B2 
channels of the MACSQuant flow cytometer were occupied by detecting anti-CD11b FITC 
and anti-Ly6G PE conjugated antibodies. Neutrophils were expected to show either CD11b+ 
Ly6G+ (activated neutrophils) or CD11b- Ly6G+ (not activated) pattern. The other antibodies 
were used in conjugation with VioBlue or PacificBlue, both of them were detected in the V1 
channel. Cells were only regarded as dendritic cells, T cells, B cells or macrophages, if they 
lacked binding of anti-Ly6G antibody. This means, they were gated and quantified in a B2 
(anti-Ly6G PE) vs. V1 (anti-CD11c, anti-CD68, anti-CD90.2, anti-B220 or anti-F4/80 VioBlue) 
dot plot as PE signal negative but VioBlue positive cells. The majority of the isolated cells at 
the site of infection were Ly6G+ CD11b+ activated neutrophils, representing about 50 % of 
total cells. Minor amounts (about 2 - 4 % of total cells) of Ly6G- B220+ B cells and Ly6G- 
CD90.2+ T cells could be identified, as well as the same amount of Ly6G- CD11b+ cells. The 
macrophage specific antigens CD68 and F4/80 could be identified in only about 1 % of total 
cells, and dendritic cells (Ly6G- CD11c+) accounted for further 1 % of total cells. In summary, 
the results are congruent with former studies proving that neutrophils constituted the main 
part of the immune cells at the site of infection, and their action is essential for the immune 
response against S. aureus. (Cheng AD et al. 2009, Cho JS et al. 2012). 
The fluorescence of the perfluorocarbon emulsion label (Atto647N) could be visualized in 
the R1 channel of the flow cytometer. Hence, Atto647N was the only fluorescence label in 
this experiment that was excited by the red laser at 638 nm, thus preventing signal spillover 
from other fluorescence labels and preventing the need for compensation. When measuring 
the Atto647N fluorescence of cells, two peaks could be seen in the histograms of Atto647N-
labeled perfluorocarbon emulsion treated mice, while control emulsion treated mice 
showed only one peak. In conclusion, perfluorocarbon emulsion conjugated signal could be 
detected in cells, indicating intracellular or cell-bound perfluorocarbon emulsion 
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accumulation. The identification of different cell types with specific antibodies showed, that 
a shift to increased R1 channel signal could be detected for Ly6G+ cells, but only in the 
samples of fluorescently labeled perfluorocarbon emulsion treated mice. Interestingly, some 
samples showed in the Atto647N vs. anti-Ly6G PE dot plot a second Ly6G+ neutrophil 
population with higher Atto647N fluorescence signal than the main population. Source for 
this second neutrophil population with stronger perfluorocarbon emulsion uptake might be 
the portion of neutrophils that circulated in the blood stream, when the tracer was 
administered. They might have incorporated the fluorescent perfluorocarbon emulsion in 
the blood stream prior to their migration to the site of infection. It seems reasonable that 
this population vanishes rather fast from flow cytometry analysis due to the short life span 
of neutrophils. And when dying, they might release the perfluorocarbon emulsion, which 
might be subsequently taken up by other neutrophils at the site of infection. Overall, the 
elevated levels of Atto647N fluorescence prove the accumulation of perfluorocarbon 
emulsion in or with Ly6G+ neutrophils. 
However, Ly6G+ neutrophils were not the only cell population at the site of infection with 
elevated Atto647N fluorescence, Ly6G- CD11c+ dendritic cells as well as macrophages (Ly6G- 
CD11b+, Ly6G- CD68+ as well as Ly6G- F4/80+ cell populations) showed increased Atto647N 
fluorescence, too, while Ly6G- CD90.2 T cells and Ly6G- B220+ B cells lacked elevated R1 
channel signal levels. In summary, fluorescently labeled perfluorocarbon emulsion 
accumulated in neutrophils, macrophages and dendritic cells at the site of infection, all of 
them phagocytotic active cell types. Thus, the flow cytometry analysis of perfluorocarbon 
emulsion accumulation showed in principle results similar to those of former studies (Flögel 
U et al. 2008, Ebner B et al. 2010). These studies demonstrated accumulation in phagocytes, 
too, although, in contrast to our results, the main portion of perfluorocarbon emulsion was 
taken up by macrophages and monocytes. Explanation for this might be the different disease 
models used to study perfluorocarbon emulsion. These former studies investigated the 
accumulation in models of stroke, ischemia and pulmonary inflammation, while this study 
focused on the accumulation at sites of S. aureus infection. A further study, which was 
published after the experimental part of this PhD thesis, showed interestingly 19F 
accumulation in neutrophils and macrophages in a subcutaneous model of inflammation 
(Temme S et al. 2013). This fits very nicely to the results of this study. 
Altogether, fluorescent perfluorocarbon emulsion could be detected in neutrophils, 
macrophages and dendritic cells at the site of infection in the S. aureus thigh infection 
model. The main part of identified immune cells at the site of infection was assigned as 
neutrophils, accounting for about 50 % of total cells. Since macrophages, dendritic cells and 
neutrophils displayed similar Atto647N fluorescence, the lion’s share of fluorescently labeled 
perfluorocarbon emulsion should be assigned to neutrophils at the site of S. aureus 
abscesses in the thigh infection model due to their predominant number. 
Flow cytometry of fluorescently labeled perfluorocarbons at the site of infection showed 
nicely perfluorocarbon derived fluorescence in cells, but could not visualize emulsion which 
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is not associated with cells. Furthermore, flow cytometry can deliver only information about 
cell populations that can be identified by specific antibody binding and moreover, it 
visualizes the perfluorocarbon emulsion content of individual cells but not of the global 
accumulation strength in cell populations. To address the question whether perfluorocarbon 
emulsion accumulates at the site of infection outside of immune cells and moreover, which 
immune cell population carries the biggest load of emulsion, cell sorting experiments were 
conducted. 
The hypothesis, that perfluorocarbon emulsion is transported to the site of infection by the 
action of immune cells, suggested and shown by former models of inflammatory diseases, 
but not infection models (Flögel U et al. 2008, Ebner B et al. 2010), can be addressed in two 
ways by this method: first by sorting of individual immune cell populations in order to 
measure their perfluorocarbon emulsion signal and second, by depletion of individual cell 
populations in order to measure the residual perfluorocarbon emulsion signal in the 
homogenate. The second approach might provide information not only about the emulsion 
content of the depleted immune cell population, but also about perfluorocarbon emulsion 
that accumulates outside of cells at the site of infection. This in turn might indicate an 
unspecific, not necessarily infection-associated accumulation mechanism. 
A variety of different cell sorting methods were applied to answer these questions: density 
gradient centrifugation, magnetization-activated cell sorting (MACS) and cell sieving 
(Pluriselect). Density gradient centrifugation did not result in clearly separated cell 
populations, maybe due to changes in density of immune cells after entering the 
inflammatory environment at the site of infection. Magnetization activated cell sorting was 
characterized by the loss of many cells in the separation columns, independently of the 
expression of specific surface antigens. In consequence, the sorted Ly6G+ and CD11b+ cell 
samples exhibited only small 19F MR signal, while F4/80+ cells showed no detectable signal. 
But the flow through samples (all cells and soluble components with the exception of sorted 
cells and cells that were lost in the column) displayed similar strong signal than the sorted 
cell samples. Nonetheless, the exclusion of cells from these samples by filtration led to a 
strong decrease of 19F MR signal. These results indicate cellular accumulation of 
perfluorocarbons, although the majority of 19F MR signal was lost in the sorting columns and 
could not be addressed to any source. 
The cell sieving approach, finally, enabled sorting of immune cells without losing too much 
cells and perfluorocarbon signal. This method is based on the binding of immune cells via 
specific antigens to antibody-conjugated beads. In the following filtering step remained the 
bead-bound cells in the filter since the beads are too large to fit through the pores. Hence, 
the depletion of specific immune cell populations from crude muscle homogenate was 
possible, but the bead-bound cells could be recovered from the filter, too, by simple 
reuptake in buffer. Four bead populations were applied to cell sorting to target different 
surface antigens and thus different immune cell populations. Ly6G- and CD11b- targeted 
beads were used to identify the perfluorocarbon emulsion signal in neutrophils (Ly6G, Daley 
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JM et al. 2008) and neutrophils, monocytes and macrophages (CD11b, Fischer MA et al. 
2011). CD4-targeted beads to aim at T helper cells (Zhu J et al. 2010) and CD19-targeted 
beads for B cells (Kehrl JH et al. 1994). Unfortunately, flow cytometry of sorted cells, filter-
flow-through and crude muscle homogenate showed that pure immune cell populations or 
complete depletion from crude muscle homogenate failed for all four beads. But strong 
enrichment of the specific immune cell populations in the ‘sorted cell’ samples or reduction 
of abundance in the ‘flow-through’ samples (Fig. 4.15) resulted nonetheless in samples with 
variations in their immune cell content and thus comparison of the perfluorocarbon 
emulsion signal might give insights into the tracer distribution pattern at the site of 
infection. 
Determination of perfluorocarbon content of the samples by 19F magnetic resonance 
imaging delivered only signals close to background, maybe due to the strong dilution of 
samples during sorting process, which was necessitated by the sorting protocol. And 
furthermore, only around 1.0 to 1.5 x 107 cells could be applied in the sorting approach, 
which might not be sufficient for 19F MR determination of perfluorocarbon content. But the 
emulsion could, in principle, be detected moreover by fluorescence imaging since 
fluorescently labeled emulsion was administered. And indeed, fluorescence imaging showed 
detectable signals for all samples with exception of negative control samples. 
Sorting of crude muscle homogenate resulted in variations of fluorescence signal. Sorting of 
Ly6G+ and CD11b+ cells led to increased fluorescence in the ‘sorted cell’ sample while the 
‘flow-through’ samples showed decreased signal. It has to be noted in this context, that flow 
cytometry of immune cell populations at the site of infection earlier in this chapter 
demonstrated that Ly6G+ cells express additionally CD11b in the infected thigh muscle. 
Therefore it is reasonable that both beads targeted similar or overlapping cell populations. 
Overall, the sorted cells had an even stronger fluorescence signal than the crude emulsion, 
suggesting higher concentration of fluorescence marker and thus perfluorocarbon emulsion 
in the sorted cells than in other cell populations at the site of infection. The fluorescence 
signal in the ‘flow-through’ sample was much lower, but still above the signal of non-
fluorescent perfluorocarbon treated mice samples (control). This might suggest further 
sources of perfluorocarbon emulsion at the site of infection than Ly6G+ and/or CD11b+ cells, 
but it is equally possible, that the residual fluorescence signal originates from Ly6G+ and/or 
CD11b+ cells that remained in the flow-through since sorting did not deplete these cell 
populations completely. In summary, enrichment of Ly6G+ or CD11b+ cells resulted in 
elevated fluorescence levels while the reduction of Ly6G+ or CD11b+ cell numbers (in the 
flow-through samples) decreased the fluorescence signal. Thus, Ly6G+ and CD11b+ cells are 
carriers of perfluorocarbon emulsion at the site of infection. 
CD4 and CD19 sorting led to lower fluorescence signal in the ‘sorted cell’ samples than in the 
crude muscle homogenate and in the ‘flow-through’ samples. Moreover, reduction of CD4+ 
or CD19+ cell concentration in the homogenate (flow-through) had no effect upon 
fluorescence signal. This suggests low or no amounts of perfluorocarbon emulsion in T and B 
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cells at the site of infection, although sorting led only to enrichment in the ‘sorted cell’ 
samples. In conclusion, cell sorting indicates perfluorocarbon emulsion accumulation in 
Ly6G+ and CD11b+ cells at the site of infection, but not in CD4+ or CD19+ cells. A reduction 
of fluorescence signal in samples with reduced Ly6G+ and CD11b+ cell concentration 
suggested furthermore, that the majority of perfluorocarbon emulsion signal arises from 
these cell populations. Importantly, a control filtration of diluted perfluorocarbon emulsion 
through cell sorting filters demonstrated, that these particle fit through the pores, thus all 
signal from ‘sorted cell’ samples must originate from cell-associated emulsion. 
Consequently, an unspecific, cell independent accumulation mechanism of perfluorocarbon 
emulsion at the site of infection seems unlikely in the light of these results. 
Flow cytometry and cell sorting delivered a nice analysis of fluorescently labeled 
perfluorocarbon emulsion accumulation in immune cells at the site of infection, but the 
homogenization of the infected thigh muscle was inevitable to analyze the samples. 
Histology, in contrast, might give a hind about the spatial distribution of perfluorocarbon 
emulsion and might help to identify further spots of accumulation that could not be 
addressed by flow cytometry. The first approach to identify immune cell populations and 
contrast agents/tracer (CLIO particles and perfluorocarbon emulsion) at the site of infection 
was to perform standard fixation (formalin fixation with following paraffin embedding) and 
hematoxylin-eosin (HE) staining of the slices. Samples of two different time points after 
administration of the agents were of interest: day 3 p.i. (24 hours after administration of 
agents) to visualize immune response and contrast agent accumulation at acute phase of 
inflammation and day 8 p.i. (6 days after administration of contrast agents) to cover the 
chronic phase of inflammation. Histological examination of acute phase samples from CLIO 
and perfluorocarbon groups revealed a strong neutrophil community in the infected thigh 
muscle with some macrophages, both of them surrounding a central area of necrosis. The 
samples from chronic phase of inflammation showed strong aggregation of neutrophils, but 
in addition macrophages, lymphocytes and eosinophiles. In the center of the immune cell 
accumulation, a large necrotic area could be seen. The HE staining of tissue slices from CLIO, 
perfluorocarbon emulsion or control (0.9 % NaCl) group mice showed comparable results, 
indicating no impact on immune cell activation and migration pattern by perfluorocarbon or 
CLIO. But neither perfluorocarbon emulsion nor CLIO accumulation could be visualized by 
this staining. This means in consequence, that either perfluorocarbon emulsion does not 
lead to a different staining pattern than cytoplasm or it is not incorporated in cells and 
therefore maybe washed away during staining procedure or the emulsion liposomes are too 
small to be visualized by standard light microscopy. Since the fluorescence label of emulsion 
could be detected in immune cells by flow cytometry, one would expect at least in some of 
the neutrophils or macrophages at the site of infection some emulsion accumulation. In 
conclusion, it seems reasonable that the emulsion cannot be visualized by this method and it 
might furthermore give a hind that the liposomes did not fusion and grow in vivo, which 
seemed to be possible due to their hydrophobic nature and amphiphilic surface. 
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CLIO particles cannot be visualized by HE staining, but by Berlin’s blue staining in fixed, 
embedded tissue sections. This iron-specific staining showed iron accumulation in some 
macrophages and granulocytes during acute phase of inflammation and in macrophages, 
lymphocytes and granulocytes during chronic phase of inflammation in CLIO group mice. 
Therefore, this experimental data is congruent with former studies investigating the 
accumulation of USPIO particles at S. aureus induced thigh abscesses (Kaim AH et al. 2002, 
Kaim AH et al. 2003). 
Unfortunately, there was no method available to stain and visualize perfluorocarbons in a 
similar way in fixed tissue section. In order to solve this problem, Atto647N-fluorescently 
labeled perfluorocarbon emulsion was administered intravenously to enable fluorescence 
microscopy of emulsion accumulation in tissue sections from the site of infection. The 
infected thigh muscles were not fixed in formalin, but immediately frozen after recovery and 
cut to 10 µm thick slices in a crytome to offer as native samples as possible. A former study 
has shown that washing and staining of samples from perfluorocarbon treated mice led to 
severe or complete loss of perfluorocarbon fluorescence in tissue sections, and furthermore 
all tested fixation methods led to loss of fluorescence signal in this study (Flögel U et al. 
2008). Thus, the first analysis was performed with native, unstained and untreated slices. 
Several spots of high Atto647N fluorescence or areas with lower fluorescence, that followed 
in principle the shape of cytoplasm of cells, could be visualized in samples of fluorescently 
labeled perfluorocarbon group mice, but not in control perfluorocarbon group mice. The 
fluorescence signal seemed to accumulate in an area close to the border between muscle 
tissue and immune cell aggregation in the immune cell section, but a clear view upon 
anatomical context of Atto647N accumulation was not possible due to the lack of anatomical 
staining. 
In the second approach, a short staining protocol was applied to reveal the tissue at the site 
of perfluorocarbon accumulation. Tissue sections were stained with Hoechst 33425, which 
stains DNA, and with Atto520-Phalloidin, a fluorescently labeled bicyclic heptapeptide that 
binds strongly to actin. The advantage of this staining protocol was the short incubation time 
of the dyes and only one necessary washing step. In result, the staining revealed immune cell 
nuclei and muscle fibers by fluorescence microscopy (Fig. 4.16). An extensive aggregation of 
immune cells could be visualized via cell nucleus staining surrounding a central core with less 
Hoechst 33425 signal (cell nuclei) and absent muscle fibers (imaged by phalloidin dependent 
actin staining). Atto647N fluorescence could be detected in close proximity to Hoechst 
33425 stained cell nuclei, but never overlapping with this signal. The fluorescence signal was 
similar to the signal of unstained samples, although there seemed to be less many spots or 
areas of signal. This might be an indication for loss of Atto647N fluorescence or loss of 
perfluorocarbon emulsion by staining/washing steps. Nonetheless, the detectable signal 
could be visualized either as small, bright spots or larger areas (in a cytoplasm likewise 
shape). This and the lack of signal in phalloidin-stained muscle fibers, suggested 
accumulation of perfluorocarbon emulsion either in the cytoplasm or at the surface of the 
immune cells at the site of infection. Further approaches to stain the immune cells at the site 
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of infection with specific antibodies necessitated further staining, washing and incubation 
steps, but this resulted in complete loss of Atto647N fluorescence and thus failed to identify 
the immune cell population(s) that carried perfluorocarbon emulsion at the site of infection. 
In summary, flow cytometry, cell sorting and microscopy analysis of samples from Atto647N 
(or Atto550)-fluorescent perfluorocarbon group mice demonstrated accumulation of tracer 
emulsion in immune cells at the site of infection. All perfluorocarbon related fluorescence 
signal was in close proximity to nuclei of immune cells at the site of infection and flow 
cytometry indicated most of the signal in neutrophils, lower amounts in macrophages and 
dendritic cells, respectively. Cell sorting demonstrated furthermore, that Ly6G+ and/or 
CD11b+ cell depletion (or reduction) led to considerably reduced perfluorocarbon emulsion 
derived fluorescence, thus suggesting that these cells serve as main source of 
perfluorocarbon emulsion signal. Consequently, it seems to be very likely that 
perfluorocarbon emulsion accumulates at the site of infection mainly in Ly6G+ and CD11b+ 
cells. An unspecific, cell-independent accumulation is unlikely since the majority of emulsion 
derived fluorescence signal is associated with these cells. Nonetheless, two questions could 
not be answered in this regard: First, what happens to the perfluorocarbon emulsion when 
the transporter immune cell dies? And second, inasmuch as perfluorocarbon emulsion 
accumulated in phagocytic immune cells, it raised the question whether perfluorocarbon 
emulsion might have an impact on immune cell function, or not? 
To elucidate the impact of perfluorocarbon emulsion administration on infection and 
immune response in the S. aureus thigh infection model, a series of experiments was 
performed to measure differences in the outcome between perfluorocarbon treated and 
untreated mice. The parameters which were necessary to evaluate the efficacy of antibiotics 
in future experiments were of particular interest. Hence the CFU and bioluminescence 
signal, but also the cytokine/chemokine pattern and the frequency of immune cell 
populations at the site of infection were determined. The bioluminescent signal during 
course of infection showed no difference between perfluorocarbon treated and control 
mice, both of them exhibited a strong signal reduction in the first 24 hours after initially very 
strong photon emission. Both groups showed an increase in bioluminescent signal until they 
reached a plateau phase at around day 4 to day 7 p.i., suggesting comparable development 
of bacterial burden in the infected thigh muscle. The CFU determination in the liver, spleen 
and thigh muscle at days 2 (prior administration), 3 (24 hours post administration) and day 7 
p.i. showed no statistically significant differences between perfluorocarbon and control 
group. Almost no bacteria could be detected in both groups at other sites than the initial 
location of infection, the thigh muscle. In conclusion, perfluorocarbon administration for MR 
imaging purpose did not affect the overall survival of bacteria at the site of infection or the 
efficacy of the immune system to combat the bacterial challenge. 
Similar results were gathered in the flow cytometry analysis of immune cell populations at 
the site of infection. Both groups, perfluorocarbon emulsion and control treated animals, 
had similar frequencies of neutrophils, T cells, B cells, dendritic cells and macrophages in the 
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infected thigh muscle. This suggests, that uptake of perfluorocarbon emulsion in the blood 
stream did not affect or alter the migration behavior of phagocytic immune cells. 
In order to evaluate whether their activity at the site of infection was inhibited by the 
perfluorocarbon loading, or not, the levels of various cytokines and chemokines in the 
infected thigh muscle prior, 24 hours and 5 days post administration were measured via an 
antibody based bead kit with flow cytometry. No differences could be seen in the pattern or 
quantity of cytokine/chemokine response. Both groups showed strong induction of IL-1α, IL-
6, MCP-1 and MIP-1α, and lower levels of IL-10, RANTES and MCP-3. The overall state of 
inflammation was thus unaffected by the uptake of perfluorocarbon emulsion. Furthermore, 
the tracer accumulation in the phagocytic immune cells at the site of infection did not 
interfere with their expression and release of pro-inflammatory cytokine and chemokine 
since perfluorocarbon treated and not-treated mice did not show differences in their 
patterns. 
In conclusion, these experiments demonstrated that intravenous administration of 
perfluorocarbon emulsion and its accumulation at the site of infection, liver and kidneys did 
not alter the general parameters of infection and antibiotic efficacy evaluation in the S. 
aureus thigh infection model. In consequence, 19F MRI with perfluorocarbons is a suitable 
method to evaluate the efficacy of antibiotics without distorting the results. 
In summary, the experiments shown in this chapter were facilitated to investigate the 
capability of MRI to visualize the site of infection in a S. aureus thigh infection model. Among 
the tested native 1H MR methods, which did not rely on MR agents, mainly T2 weighted MRI 
visualized sufficient contrast in the infected thigh muscle. However, as former studies 
encountered, too, the differences in T2 relaxation times between infected and not-infected 
tissue were rather fluctuating and did not offer clear distinction of both areas (Marzola P et 
al. 1999, Kaim AH et al. 2003). The application of small iron oxide particles (in this case 
CLIOs) partially solved this problem by their accumulation at the rim of the abscess area, 
thus defining an area of infection and differentiating between infected and not-infected 
tissue. However, CLIOs lead to signal distortion effects and are therefore typically visualized 
as ‘black spots’. But since several tissues (like bones, lung or liver) do not deliver much signal 
in T2 or T2
* weighted MRI (which is used to image CLIO accumulation), it is not feasible to 
apply this system to other interesting models of S. aureus infection like pneumonia, sepsis or 
catheter-associated infections. A second, recently developed MR agent based modality to 
visualize sites of inflammation is 19F MRI with perfluorocarbon emulsions. However, at the 
beginning of this thesis, it was only shown that perfluorocarbon emulsions accumulate at 
sites of stroke and ischemia (Flögel U et al. 2008). Hence the first experiments evaluated the 
qualification of 19F MR imaging of perfluorocarbon emulsion accumulation to image the site 
of infection. Administration of perfluorocarbon emulsion at acute and chronic phase of 
inflammation led to accumulation at the rim of the abscess area. A big advantage of 
perfluorocarbon emulsion vs. CLIO particles, which served as comparison, was in this regard 
the background-free visualization, since mice do not harbor sufficient inherent amounts of 
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19F. Further experiments elucidated the accumulation in more detail, showing that 
intravenous administration of perfluorocarbon emulsion later than 48 hours post infection 
caused a ‘hollow sphere’ like accumulation pattern within 12 hours after administration 
around the edema area in the infected thigh muscle. This ‘hollow sphere’ like pattern and 
the background-free visualization are promising for the quantification of antibiotic efficacy 
or severity of disease in this model. A global approach to elucidate the accumulation of 
perfluorocarbon emulsion in the mouse showed accumulation of perfluorocarbon primarily 
in the liver, spleen and the infected thigh muscle. Generation of fluorescently labeled 
perfluorocarbon emulsions enabled the investigation of accumulation mechanism. Flow 
cytometry and fluorescence microscopy proved accumulation in immune cells at the site of 
infection. The main part of perfluorocarbon emulsion was in this context detected in 
neutrophils, lower amounts in macrophages and dendritic cells. Therefore, 19F MRI with 
perfluorocarbon emulsions can be regarded as an imaging modality to visualize the immune 
response to infection, but it cannot visualize the pathogen itself. Nonetheless, this opens 
completely new opportunities to investigate host-pathogen interaction in vivo. This modality 
might be an interesting approach to visualize and measure differences in phagocytic immune 
cell migration during vaccination or during treatment with immunomodulatory compounds. 
Moreover, combining 19F MRI with bioluminescence imaging would offer the visualization of 
bacterial burden and immune response non-invasively in the same animal during course of 
infection. 
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5. Imaging of antibiotic therapy with bioluminescence and 19F 
magnetic resonance imaging with perfluorocarbon 
emulsions 
 
Several MR methods were evaluated in the previous chapter for their capacity to visualize 
sites of S. aureus infection in the murine thigh abscess model. And although contrast media 
–independent T2 weighted MRI and CLIO particle imaging with T2 or T2* weighted MRI 
indicated inflammation and abscess formation in the infected thigh muscle, 19F MRI with 
perfluorocarbon emulsions was chosen to investigate the effects of antibacterial therapy 
upon imaging results. This decision was based on the general aim of this study, which was to 
establish a multimodal imaging platform to evaluate the efficacy of antibiotics, and 19F MRI 
with PFCs delivered, in this context, best results to differentiate infected and not-infected 
tissue with easy quantifiable parameters. 
This chapter describes the establishment and evaluation of a two-modality imaging platform 
consisting of Bioluminescence and 19F Magnetic Resonance Imaging to visualize and quantify 
the efficacy of two clinically highly relevant antibiotics to treat S. aureus infections: 
vancomycin and linezolid. The course of the experiment is schematically shown in Fig. 5.1. 
 
 
Fig. 5.1: Schematic representation of the study. The injection of S. aureus Xen29 into the left thigh 
muscle of female Balb/c mice defined the starting point (day 0) of the experiment. Perfluorocarbon 
emulsion was administered intravenously at day 2 p.i., while antibiotic or 0.9 % NaCl solutions were 
applied intraperitoneally at 2 hours p.i. and then every 12 hours. Bioluminescence imaging was 
performed once every 24 hours and magnetic resonance imaging was conducted at days 3 and 7 p.i. 
At day 7 p.i., mice were sacrificed and the infected thigh muscles recovered. 
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5.1.1. Bioluminescence imaging of antibacterial therapy 
To enable bioluminescence imaging during the course of infection, the luciferase-expressing 
S. aureus Xen 29 was chosen. This MSSA strain harbors a stable chromosomal copy of the 
Photorhabdus luminescens luxABCDE operon, which encodes for all necessary genes which 
enable S. aureus to produce luciferase and accompanying compounds to emit photons 
(Francis KP et al. 2000). All BL measurements were standardized by applying an oval area of 
interest at the site of infection to all images and by gathering of average radiance values 
solely in this region. The injection of 3.2 x 108 CFU into the left thigh muscle led to a robust 
bioluminescence signal of similar value for 0.9% NaCl, vancomycin (30 mg/kg/d) and linezolid 
(15 mg/kg/d) treated mice at 15 min p.i. (first data point in Fig. 5.2 A). A strong decrease of 
light emission could be measured for all groups at 24 h after start of infection. The average 
radiance then increased in the following days in the 0.9% NaCl and the vancomycin group 
until it reached a plateau phase between day 3/4 and day 7 p.i. (Fig. 5.2 A). Photon emission 
of the linezolid group remained at the level measured at day 1 p.i. or dropped even further. 
Treatment with either Vancomycin or linezolid led to reduced average radiance values 
compared to the vehicle treated group at all time points after the initial signal drop at day 1 
p.i. with linezolid showing heavier reduction (Tab. 5.1). 
 
Fig 5.2: Bioluminescence signal and colony-forming units in response to antibiotic treatment in the 
thigh infection model with S. aureus Xen29. A. Development of bioluminescence signal during 
course of infection. Female Balb/c mice were challenged with 3.2 x 108 CFU S. aureus Xen29 in the 
left thigh muscle. Antibiotic treatment started 2 hours p.i. and was then continued every 12 hours. 
The first data point (day 0 p.i.) represents the signal from BL measurement at 15 min after injection 
of 3.2 x 108 CFU S. aureus Xen29 into the left thigh muscle. Mice were then imaged every 24 h until 
the end of experiment at day 7 p.i.. Means +/- SEM per group (5 – 6 mice each) are shown. B. Colony-
forming units in the infected thigh muscles at day 7 p.i.. Muscles were recovered after BL and MR 
imaging at day 7 p.i., homogenized and serial dilutions plated on agar plates in order to determine 
the bacterial burden. The results per single mouse and medians of each group are shown. Statistically 
significant differences between the groups are marked by asterisks (**: P < 0.01). (Adapted from 
Hertlein T et al. 2013). 
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Tab. 5.1: Average radiance values at day 3 and day 7 p.i. determined by bioluminescence imaging 
in the region of interest. Bioluminescence signal was measured in an oval region of interest, 
standardized for all mice of all groups. Shown are the mean values +/- SEM for days 3 and 7 p.i.. 
Statistically significant differences between groups are marked by symbols (*: P < 0.05 vs. 0.9 % NaCl 
group, **: P < 0.01 vs. 0.9 % NaCl group, †: P < 0.05 vs. Vancomycin group) 
 
Treatment 
group 
d3 p.i.  d7 p.i.  
Avg radiance 
(p/s/cm2/sr) 
reduction to  
0.9% NaCl group 
Avg radiance 
(p/s/cm2/sr) 
reduction to  
0.9% NaCl group 
0.9 % NaCl 2.8 ± 0.76 × 104  4.79 ± 2.76 × 104  
Vancomycin  
(30 mg/kg/d) 
1.4 ± 0.36 × 104  
 
49 % 7.40 ± 2.02 × 103  
(*) 
85 % 
Linezolid  
(15 mg/kg/d) 
2.19 ± 0.48 × 103 
(**,†) 
92 % 1.85 ± 0.15 × 103 
(**,†) 
96 % 
 
 
5.1.2. Reduction of bacterial burden by vancomycin or linezolid 
The infected thigh muscles were recovered and homogenized at day 7 p.i. after 
bioluminescence and 19F magnetic resonance imaging. The homogenization was diluted 
serially and plated on B-Agar plates to determine the colony-forming units following 
overnight incubation. The injection of 3.2 x 108 CFU S. aureus Xen29 resulted in a mean CFU 
value of 6.55 ± 3.74 x 109 CFU in the thigh muscles of vehicle treated mice at day 7 p.i.. 
Treatment with vancomycin resulted in 2.5 ± 1.97 × 107, linezolid in 3.8 ± 2.58 × 103 CFU at 
the site of infection. Both antibiotics reduced the bacterial burden significantly compared to 
the 0.9% NaCl group with linezolid having a significantly stronger therapeutic effect than 
vancomycin (Fig. 5.2 B). 
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5.1.3. 19F MRI of perfluorocarbon emulsion accumulation at the site of 
infection during antibiotic therapy 
Perfluorocarbon emulsion was administered intravenously 48 h after start of infection and 
the accumulation of 19F in the thigh muscle area was measured and visualized by 19F MRI at 
day 3 and day 7 p.i.. It was shown in chapter 4 and earlier studies that PFC emulsions are 
incorporated by phagocytes in the bloodstream and their subsequent migration to sites of 
inflammation leads to accumulation of tracer (Flögel U et al. 2008, Ebner B et al. 2010). It 
was furthermore shown in chapter 4 that intravenous PFC administration in the thigh 
infection model leads to a ‘hollow sphere’ like pattern of 19F signal at the rim of the abscess 
area in the infected thigh muscle. 
19F MR imaging of the vehicle group mice of this study showed congruent with the results 
from chapter 4 accumulation of 19F tracer at the rim of a sphere-like shape in the infected 
thigh muscle (Fig. 5.3). Vancomycin treatment resulted in similar but smaller ‘hollow 
spheres’ in the infected thigh muscle at both time points, while linezolid led to a very small 
accumulation pattern in the infected thigh muscle. 
 
 
Fig. 5.3: MR imaging of 19F accumulation at the site of infection during antibiotic therapy. Mice 
were challenged with 3.2 x 108 CFU S. aureus Xen29 in the left thigh muscle and received either 0.9% 
NaCl, vancomycin or linezolid solution twice a day. Perfluorocarbon emulsion was administered 
intravenously 48h p.i. and MR imaging was performed at day 3 and day 7 p.i.. 19F chemical shift 
imaging steady-state free precession overlays (hot colors) on 1H turbo spin echo scans (grayscale) of 
one representative mouse of each treatment group are shown. (Adapted from Hertlein T et al. 2013). 
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5.1.4. Quantification of 19F accumulation volume and signal at the site 
of infection 
The idea was to use the ‘hollow sphere’ 19F accumulation pattern at the rim of the abscess 
area to measure the abscess volume as a function of the applied therapy. But the three-
dimensional reconstruction of the 19F accumulation in the infected thigh muscle showed 
gaps and holes in the surface of the sphere. This made the quantification of total abscess or 
19F circumscribed volume impossible. 
The 19F accumulation itself was nonetheless quantifiable in terms of 19F filled volume and in 
terms of total 19F signal in the infected thigh muscle (Fig. 5.4). In this context, the 19F filled 
volume was calculated by adding the overall amount of ‘fluorine filled’ voxels in the infected 
thigh muscle. A voxel was in this regard considered as ‘fluorine filled’ if its 19F signal intensity 
was at least four times higher than the mean background signal. The highest fluorine filled 
volume could be calculated for the 0.9% NaCl group at both MR imaging time points, day 3 
and day 7 p.i.. Mice of this group delivered 3.43 ± 0.34 × 104 and 4.06 ± 0.58 × 104 voxels, 
respectively. Vancomycin treatment led to 83 % reduced 19F filled volume at day 3 p.i. (5.94 
± 1.48 × 103 voxels) and 80 % reduction at day 7 p.i. (8.25 ± 2.40 × 103 voxels). Linezolid 
showed stronger reduction than vancomycin and resulted in 92 % reduction at day 3 p.i. 
compared to the vehicle group (2.73 ± 1.17 × 103 voxels) and 93 % at day 7 p.i. (2.66 ± 0.93 × 
103 voxels). 
Total 19F signal was then calculated by adding the 19F signal of the individual 19F filled voxels 
in the infected thigh muscle. In line with the results from volume calculation, the strongest 
total signal was measured in the 0.9 % NaCl group at both time points. Vancomycin 
treatment induced 84 % reduction at day 3 p.i. (2.03 ± 0.67 × 104 nsif (19F MR signal intensity 
normalized to the apparent noise amplitude of the measurement) for vancomycin vs. 1.29 ± 
0.22 × 105 nsif for the vehicle treated group) and 83 % reduction at day 7 p.i. (3.41 ± 1.37 × 
104 nsif vs. 1.97 ± 0.41 × 105 nsif). Linezolid had an even stronger effect and reduced the 
total signal by 94 % at day 3 p.i. (7.31 ± 3.64 × 103 nsif) and by 96 % at day 7 p.i. (1.21 ± 0.46 
× 104 nsif). 
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Fig 5.4: Quantification of 19F accumulation volume and signal in the infected thigh muscle. Mice 
were challenged with 3.2 x 108 CFU S. aureus Xen29 in the left thigh muscle and received either 0.9% 
NaCl, vancomycin or linezolid solution via intra-peritoneal injection twice a day. PFC emulsion was 
administered at day 2 p.i. intravenously. A/C: Amount of 19F filled voxel in the infected thigh 
muscles at day 3 (A) or day 7 (C) p.i.. B/D: Amount of overall 19F signal in the infected thigh muscles 
at day 3 (C) or day 7 (D) p.i.. Single data points per mouse and the medians of the groups are shown. 
Statistically significant differences are marked by asterisks (*: P<0.05, **: P < 0.01). (Adapted from 
Hertlein T et al. 2013). 
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5.2. Discussion 
 
Preclinical testing of new promising drug candidates is a rather challenging task. And 
although great improvements in the development of in vitro and cell culture based 
evaluation methods were achieved in the past decades, animal experiments are still 
regarded as essential in the evaluation of therapies to treat many diseases (Editorial of 
Nature Medicine 19(10):1191, Winston R 2013). Nonetheless, the principle of the 3 R’s is 
adopted to animal experimentation today, meaning reduction, refinement and replacement 
of animal experiments.  
In vivo imaging technologies such as Positron Emission Tomography, Bioluminescence or 
Magnetic Resonance Imaging have proven their capability to deliver information about the 
state and course of disease in different models and their benefit in preclinical evaluation of 
drug candidates (Wang J et al. 2005, Beckmann N et al. 2007, Sandanaraj BS et al. 2010). 
Their implementation into the preclinical evaluation process seems to be very interesting 
because they are fitting nicely to the idea of the 3 R’s. Refinement of animal experiments or 
even models can be achieved through application of in vivo imaging technologies by offering 
completely new insights into disease development and therapeutic response. 
Bioluminescence imaging, for example, offers non-invasive determination of bacterial 
burden in vivo by detection of luciferase-expressing bacteria in infectious disease models 
(Francis KP et al. 2000). This permits the reduction of animal numbers in the evaluation of 
antibacterial compounds since organs must not be recovered to determine the gravity of 
disease or infection at every time point during course of infection. Furthermore, this imaging 
modality can be extended by photon based imaging methods to visualize and measure the 
immune response to infection. It is possible, for example, to visualize the migration and 
accumulation of immune cells like neutrophils (Niska JA et al. 2012) or to visualize the 
activity of immune cells by imaging myeloperoxidase or elastase activity (Gross S et al. 2009, 
Kossodo S et al. 2011). 
The idea of this study was consequently the implementation of imaging technologies to 
evaluate the efficacy of antibiotics in vivo and to compare the results with the current state-
of-the-art method colony-forming unit determination. The investigations described in 
chapter 4 allowed the application of 19F MRI with perfluorocarbon emulsions to visualize the 
effect of therapy for the first time by this method. Bioluminescence imaging was added as 
second method due its capability to visualize the efficacy of antibiotic therapy, which was 
shown by several former studies (Rocchetta HL et al. 2001, Kadurugamuwa JL et al. 2003, 
Jawhara S et al. 2004, Xiong YQ et al. 2005). 
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Animals were therefore infected intramuscularly (left thigh muscle) with S. aureus Xen29, a 
MSSA strain derived from strain ATCC 12600 by the insertion of the luxABCDE operon from 
Photorhabdus luminescens at a single chromosomal site (Francis KP et al. 2000). This led, 
similar to results from chapter 4, to a strong bioluminescence signal at 15 min p.i., which 
then dropped to almost background noise strength at day 1 post infection (Fig. 5.1 A). 
Treatment with either vancomycin (30 mg/kg/d q12h), linezolid (15 mg/kg/d q12h) or 
vehicle (0.9% NaCl solution) started 2 h p.i. and was continued until the end point of the 
experiment at day 7 p.i.. The bioluminescence signal of the vehicle treated group recovered 
after d1 p.i. to reach a plateau phase between day 3 and day 6 p.i., congruent with results 
shown in chapter 4.1.1.1.. Vancomycin treatment led to lower, but still detectable average 
radiance signals from day 2 to day 7 p.i., while linezolid treated mice had levels of photon 
emission that were close to background signal throughout the whole experiment (Fig. 5.2 A). 
Muscles were recovered at day 7 p.i and the colony-forming units were determined. The 
highest values were gathered for the 0.9 % NaCl group, vancomycin led to a reduction of 
approximately 3 log 10 units and linezolid to 6 log 10 units (Fig. 5.2 B). In principle, the 
efficacy pattern of the three treatment regimens was therefore indicated similarly by BLI and 
CFU counting in terms of quality, but not in quantity, because differences shown with CFU 
determination were much more pronounced than with bioluminescence imaging. Of note, 
the relatively low antibacterial efficacy of vancomycin measured in this study is in line with 
former studies (Marzola P et al. 1999, LaPlante KL et al. 2008). 
The second imaging method applied to investigate the effect and efficacy of antibiotic 
therapy in this study, namely 19F MRI with perfluorocarbon emulsions, measures a 
completely different parameter than bioluminescence imaging or CFU counting. While both 
later-quoted methods determine the bacterial burden either directly (CFU) or indirectly (BLI), 
19F MRI is based on the accumulation of 19F tracer at the site of infection. This accumulation 
is facilitated by inflammation, which accompanies the infection and provokes the 
immigration of phagocytes like monocytes or neutrophils. In consequence, 19F MRI with 
perfluorocarbons images the immune response to infection and not the infection itself. The 
accumulation of 19F in the 0.9 % NaCl group in this study, which received no antibiotic 
therapy and therefore developed an infection similar to the mice described in chapter 4, 
resembled in terms of pattern and volume the accumulation of the 19F MR imaging group in 
chapter 4. This leads, as shown in chapter 4, to a ‘hollow sphere’ 19F pattern around the area 
of inflammation and infection (Fig. 5.3). Vancomycin treatment led to a slightly smaller 19F 
circumscribed volume, while linezolid treatment reduced the volume even stronger (Fig 5.3). 
In conclusion, it can be stated that antibacterial treatment, at least with either vancomycin 
or Linezolid, does not prevent accumulation and visualization of perfluorocarbons at the site 
of infection. Furthermore, 19F MRI with perfluorocarbon emulsions is capable to visualize the 
therapeutic effect caused by vancomycin or linezolid treatment in vivo in a non-invasive 
manner. But the accumulation of 19F was not only visualized, but also measured in terms of 
accumulation volume and overall 19F signal in the infected thigh muscle. The results 
demonstrated, as expected from visualization, the highest accumulation volume and total 
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signal in the vehicle treated mice, the weakest in linezolid treated mice and an intermediate 
value for vancomycin treated ones (Fig. 5.4). A small increase of 19F signal could be observed 
between the 19F MR imaging 12 h post administration of PFC (day 3 p.i.) and day 7 p.i., which 
implies transport of 19F tracer later than 12 h post administration to the site of infection. The 
total abscess or 19F tracer surrounded volume could not be measured by MRI because of 
gaps and holes in the accumulation pattern.  
In general, 19F accumulation volume and total signal in the infected thigh muscle correlated 
very well with bioluminescence imaging results. The signal reduction to the 0.9 % NaCl group 
between bioluminescence signals vs. 19F volumes/signals were 49 % vs 83/84 % at day 3 p.i. 
and 85 % vs. 80/83 % at day 7 p.i. for Vancomycin and 92 % vs. 92/94 % at day 3 p.i. and 96 
% vs. 93/96 % at day 7 p.i. for Linezolid treatment. This means that BLI and 19F MRI indicated 
the same efficacy pattern and overall efficacy of the applied antibiotics in this model. 
Colony-forming unit determination at day 7 p.i. showed in principle the same efficacy 
pattern, but different magnitudes of signal reduction for both antibiotics. Vancomycin led to 
ca. 2 log 10 unit reduction and linezolid to ca. 6 log 10 unit reduction of bacterial burden, 
both of them being much stronger than the signal reduction achieved with bioluminescence 
imaging or 19F magnetic resonance imaging. 
Overall, 19F MRI is capable to visualize and quantify the efficacy of antibiotics to treat S. 
aureus infections in murine models. Based on the results from experiments in chapter 4 and 
former studies, which showed the accumulation of perfluorocarbon emulsions in 
phagocytes, which then migrate to sites of inflammation (Flögel U et al. 2008, Ebner B et al. 
2010), these results suggest that the number of viable S. aureus cells within the abscess 
depends or influences the number of immigrating phagocytic cells. On the other hand, this 
imaging method is therefore independent of the infecting pathogen, but dependent on the 
inflammatory immune response. This, of course, enables the evaluation of clinically relevant, 
not with genetic markers or reporters equipped strains in relevant animal models and 
moreover the testing of new inflammation-modulating compounds. 19F MRI delivers a more 
detailed picture of the state and course of disease than state-of-the-art CFU determination 
by delivering additionally information about anatomy and tissue destruction at the site of 
infection. 
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The technique might furthermore be clinically interesting to detect infection foci of unknown 
origin. Several severe and complicated types of infection, such as S.aureus induced 
osteomyelitis, are difficult to recognize and are associated with high rates of treatment 
failure. The exact localization of infection loci might help to define the most appropriate 
therapeutic measures and to track and control the efficacy of the applied therapy. 
In conclusion, the imaging platform established in this chapter, consisting of 
bioluminescence and 19F magnetic resonance imaging, offers the visualization and 
quantification of antibacterial therapy in vivo in a non-invasive manner. It delivers 
information about the bacterial burden as well as about the inflammatory response during 
the course of infection. The results delivered by both imaging modalities indicated the same 
efficacy pattern of vancomycin and linezolid compared to state-of-the-art CFU determination 
while proffering additional information like time-course development of bacterial burden 
and intensity of inflammation. 
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6. Evaluation of lysostaphin efficacy in murine thigh and 
catheter-related infection models by bioluminescence and 
19F magnetic resonance imaging 
 
19F MRI with perfluorocarbon emulsions has proven, as described in chapter 4, its capacity to 
visualize the abscess formation in a murine thigh infection model of S. aureus. It visualized 
the accumulation of 19F tracer in vivo in a non-invasive manner, thus enabling serially 
imaging of the course of infection in the same animal. Chapter 5 then described the 
combination of this imaging modality with bioluminescence imaging, thereby offering 
information about the bacterial burden and the effects of infection and therapy upon the 
host’s inflammation at the same time. Nonetheless, up to this point, only clinically applied 
antibiotics were administered and investigated by this two-modal platform. Consequently, 
the next step was the evaluation of a new promising compound to treat S. aureus infections: 
lysostaphin. This extracellular zinc metalloprotease glycyl-glycine endopeptidase was 
selected, because it represents a completely new class of antibacterial compounds. In this 
regard, a new, recombinant formulation of lysostaphin was tested in murine thigh and 
catheter-related infection models and efficacy visualized by either 19F MRI with 
perfluorocarbon emulsions and bioluminescence imaging or by bioluminescence only. 
 
6.1. Results 
 
6.1.1. In vitro activity of lysostaphin against S. aureus 
Lysostaphin was first described in 1964 (Schindler CA et al. 1964), but a new recombinant 
formulation of this endopeptidase (Khatri GS et al. 2005), which was supplied by Bharat 
Biotech (Hyderabad, India) was applied in this study. Therefore, the minimal inhibitory 
concentrations (MIC) of the antibacterial substances were measured by broth microdilution 
prior to animal experiments. Vancomycin showed a MIC value of 0.78 µg/ml against S. 
aureus Xen29, the strain used to infect the animals, while oxacillin had a MIC value of 1.56 
µg/ml and the recombinant formulation of lysostaphin a value of 0.004 µg/ml. 
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6.1.2. Lysostaphin reduced the bacterial burden in the thigh infection 
model 
 
 
Fig. 6.1: Schematic representation of the lysostaphin evaluation study in the murine thigh infection 
model. The injection of S. aureus Xen29 into the left thigh muscle of female Balb/c mice defined the 
starting point (day 0) of the experiment. Perfluorocarbon emulsion was administered intravenously 
at day 2 p.i., while antibiotic or 0.9 % NaCl solutions were applied either intraperitoneally 
(vancomycin and oxacillin) or intravenously (lysostaphin) at 2 hours p.i. and then every 12 hours. 
Bioluminescence imaging was performed once every 24 hours and magnetic resonance imaging was 
conducted at days 3 and 7 p.i. At day 7 p.i., mice were sacrificed and the infected thigh muscles 
recovered. 
 
To test for in vivo efficacy of lysostaphin against S. aureus infections, mice were infected 
intramuscularly with 2.4 x 108 CFU S. aureus Xen29, a luciferase-expressing strain (Francis KP 
et al. 2000). The treatment started 2 h after infection and lysostaphin was administered 
either alone at concentrations of 2 mg/kg/d or 5 mg/kg/d or in combination with oxacillin 
(200 mg/kg/d) intravenously at two doses the day. It was shown by previous investigations 
that lysostaphin might exhibit synergistic behavior when combined with β-lactam antibiotics 
like oxacillin (Climo MW et al. 2001, Kiri N et al. 2002). Three groups were defined as 
controls and treated either with vehicle (0.9 % NaCl solution), with vancomycin (30 mg/kg/d) 
or with oxacillin only (200 mg/kg/d), each of them via intraperitoneal application two times a 
day with the first application at 2 h p.i.. Muscles were recovered after 7 days of infection and 
treatment and the colony-forming units in the infected thigh muscle after homogenization 
and serial dilution were determined. The highest CFU values could be detected in the vehicle 
treated group with approximately 1 x 109 CFU (Fig. 6.2 A). Treatment with vancomycin 
reduced the bacterial burden by ca. 1 log 10 unit, oxacillin-only or low-dose lysostaphin by 
1.5 log 10 units. Strongest decrease in bacterial numbers were measured for the high-dose 
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lysostaphin or the low-dose lysostaphin plus oxacillin group with approximately 4 log 10 
units reduction in median.  
 
Fig. 6.2: Bacterial burden in the infected thigh muscles. Mice were infected with 2.4 x 108 CFU S. 
aureus Xen29 in the left thigh muscle. Different treatments, as indicated in the graph, were applied 
first at 2 h p.i., then every 12 h until day 7 p.i.. A: Colony-forming units in the infected thigh muscle 
at day 7 p.i.. Single data points per animal and the median of the corresponding group are shown. 
Statistically significant differences compared to the 0.9 % NaCl group are indicated by asterisks (*: 
P<0.05, **: P < 0.01). The reduction of CFU by 5 mg/kg/d lysostaphin or 2 mg/kg/d lysostaphin plus 
oxacillin was additionally significantly lower than the values of the other antibiotic treatment groups. 
B: Development of bioluminescent signal during the course of infection and therapy. Mice were 
imaged at 1 - 5 min p.i. (time point: day 0 p.i.) and then every 24 h. The means +/- SEM of the 
average radiance in a standardized oval region of interest are shown. (Adapted from Hertlein T et al. 
2014) 
 
6.1.3. Lysostaphin reduced the bioluminescence signal in the thigh 
infection model 
The genomically encoded luciferase of S. aureus Xen29 enabled non-invasive 
bioluminescence tracking of the bacterial burden in this model. The average radiance signal 
detected 1 – 5 min after start of infection was very strong in all groups (time point: day 0 p.i. 
in Fig. 6.2 B). All groups showed a significantly lower signal at 24 h p.i.. A gradual increase in 
photon emission of the 0.9 % NaCl group occurred then from day 2 p.i. until it reached a 
plateau phase between days 5 and 7 p.i.. The lysostaphin + oxacillin group had the lowest 
signal of all groups after day 2 p.i., with values close to background signal, which is around 
103 photons/s/cm2/sr. Vancomycin, oxacillin or lysostaphin (2 mg/kg/d) treatment reduced 
the photon emission significantly compared to the vehicle group from day 1 p.i. to day 7 p.i., 
but the reduction was not as pronounced as for the lysostaphin (5 mg/kg/d) or the 
lysostaphin + oxacillin groups. High-dose lysostaphin treatment led to average radiance 
values similar to those of the vancomycin, lysostaphin (2 mg/kg/d) or oxacillin-only groups at 
days 2 to 4 p.i., but the signal decreased until day 7 p.i. to reach a level close to the 
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lysostaphin + oxacillin group. The reduction of bioluminescent signal was significantly lower 
for all groups compared to the vehicle group from day 2 p.i. to day 7 p.i., but the differences 
between the groups remained statistically non significant. Apart from the infected thigh 
muscle, no further sources of bioluminescent signal could be detected in the infected mice, 
indicating a localized infection.  
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6.1.4. 19F MR imaging of perfluorocarbon accumulation in the infected 
thigh muscle 
After establishing 19F MRI with perfluorocarbons as infection imaging modality in chapter 4 
and demonstrating its capability to visualize the efficacy of antibacterial therapy in chapter 
5, this method was now applied to investigate the anti-infective capacity of a new, promising 
compound: lysostaphin. All animals received therefore a single intravenous administration of 
perfluorocarbon emulsion at day 2 p.i.. The accumulation of 19F tracer at the site of infection 
was then imaged 24 h after administration and at day 7 p.i.. 
Congruent with former experiments, described in chapters 4 and 5, a ‘hollow sphere’-like 19F 
accumulation pattern could be visualized in almost all mice of the vehicle, vancomycin, 
oxacillin-only and low-dose lysostaphin treated groups. The high-dose lysostaphin and the 
lysostaphin + oxacillin groups showed very small accumulation patterns that comprised not 
in all mice a 19F-free inner volume. Nonetheless, all mice showed accumulation of 19F tracer 
only at the rim of the abscess area, no 19F signal could be visualized outside of the abscess 
area (Fig. 6.3). The largest 19F ring structure was visualized in the 0.9 % NaCl group, the 
smallest ones for the 5 mg lysostaphin group and the lysostaphin + oxacillin group. 
Vancomycin, oxacillin or 2 mg lysostaphin treatment led to intermediate structures (Fig. 6.3). 
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The accumulation pattern was not completely closed in many animals, showing gaps and 
holes. Thus, quantification of the overall abscess volume was not possible. However, the 
quantification of 19F-filled volume and overall signal in the infected thigh muscle, as shown 
earlier in chapter 5, remained feasible and was done to compare the results with 
bioluminescence imaging and CFU counting. The highest fluorine-filled volume in terms of 
19F-filled voxels was measured for the vehicle treated group (Fig. 6.4 A/C). Antibacterial 
treatment led, independently from the administered compound, to statistically significant 
reduced accumulation volumes at both time points. The smallest volume was measured for 
the high-dose lysostaphin treatment group, while vancomycin, oxacillin-only, low-dose 
lysostaphin and lysostaphin + oxacillin treatment led at both time points to intermediate 19F-
filled volumes, which were in numbers close to each other. But the differences between the 
treatment groups were only significant for lysostaphin 5 mg vs. oxacillin at day 3 p.i. (Fig. 6.4 
A). 
The overall 19F signal in the infected thigh muscle was measured in addition to the 19F-filled 
volume. Similarly to the fluorine-filled volume results, the highest values were determined 
for the 0.9 % NaCl group, while high-dose lysostapin resulted in the weakest signal (Fig. 6.4 
B/D). The low-dose lysostaphin, vancomycin, oxacillin-only and lysostaphin + oxacillin groups 
showed intermediate values. All antibiotic treatment groups had significantly lower values 
compared to the vehicle group, but the differences between the treatments were not 
significant. 
In summary, both 19F filled volume and overall 19F signal determination led to similar signal 
reduction patterns of antibacterial compounds, indicating similar efficacy patterns. 
Importantly, the signal was reduced in both parameters significantly for all treatment groups 
compared to the vehicle group, demonstrating the anti-infective effect and proving the 
capability of 19F MRI with perfluorocarbons as infection- and therapy-imaging modality. 
 
 
 
Fig. 6.3 (facing page): Two-dimensional 19F CSI magnetic resonance overlays on anatomical 1H TSE 
images of representative mice from the different treatment groups. Mice were infected in the left 
thigh muscle with 2.4 x 108 CFU S. aureus Xen29 and treated with different antibiotics or vehicle 
solution. At day 2 p.i. a single bolus of perfluorocarbon emulsion was administered intravenously into 
each mouse. MR imaging was performed 24 h later (upper row) and at day 7 p.i. (lower row). 19F 
signal is shown in hot colors (red to yellow) upon 1H anatomical images in grayscale. (Adapted from 
Hertlein T et al. 2014) 
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Fig. 6.4 (facing page): 19F accumulation volume and signal strength in the infected thigh muscle at 
days 3 and 7 p.i. measured by 19F MRI. Mice were infected with 2.4 x 108 CFU S. aureus Xen29 into 
the left thigh muscle. Antibiotic treatment started 2 h after infection and was continued two times a 
day until d7 p.i.. At day 2 p.i., all mice received a single intravenous administration of 
perfluorocarbon emulsion and MR imaging was performed 24 h later and at day 7 p.i.. A/C: The 19F-
filled volume of perfluorocarbon emulsion accumulation in the infected thigh muscles of the 
different treatment groups. The volume was measured by adding up all voxel from 19F MR 
measurements with a signal-to-noise ration of above 4. Only voxel in the infected thigh muscle were 
included in the calculation. A. The 19F-filled volume 24 h after perfluorocarbon administration. C: The 
19F-filled volume at day 7 p.i.. B/D: The overall 19F signal of perfluorocarbon emulsion accumulation 
in the infected thigh muscles of the different treatment groups. The overall signal was calculated as 
19F MR signal intensity in the infected thigh muscle normalized to the apparent noise amplitude of 
the measurement. B: The total 19F signal in the infected thigh muscle 24 h after perfluorocarbon 
administration. D: The total 19F signal in the infected thigh muscle at day 7 p.i.. Single data points per 
animal and the median of the corresponding groups are shown. Statistical significance between the 
different treatment groups are indicated by asterisks (*: P < 0.05, **: P < 0.01). (Adapted from 
Hertlein T et al. 2014) 
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6.1.5. Reduction of bacterial burden in the catheter-associated 
infection model by antibiotic treatment 
 
 
Fig. 6.5: Schematic representation of the lysostaphin evaluation study in the murine catheter 
related infection model. A central venous catheter was placed in female NMRI mice 24 hours prior 
the experiment start. The injection of S. aureus Xen29 into the catheter lumen mice defined the 
starting point (day 0) of the experiment. Antibiotic or 0.9 % NaCl solutions were applied either 
intraperitoneally (vancomycin and oxacillin) or intravenously (lysostaphin) at 2 hours p.i. and then 
every 12 hours. Bioluminescence imaging was performed once every 24 hours. At day 4 p.i., mice 
were sacrificed and the catheter, heart, lung, kidneys and spleen recovered. 
 
Catheter-related infections account for a significant number of nosocomial infections 
(Richards MJ et al. 2000). Most of them are associated with a central venous catheter and 
therefore a murine model with central venous catheter-associated S. aureus infection 
(Lorenz U et al. 2008) was chosen to assess the efficacy of lysostaphin alone or in 
combination with oxacillin. Thus, NMRI mice were challenged with 3.7 x 107 CFU of 
bioluminescent S. aureus Xen29 in the lumen of the catheter, which was placed surgically in 
the jugular vein. After 4 days of infection and therapy, the kidneys, heart, lung and catheter 
were recovered and the CFU determined. Five out of eight mice of the vehicle group showed 
bacteria in the heart, and one out of eight in the vancomycin or lysostaphin (2 mg/kg) 
groups. Additionally, bacteria were identified in the lungs of four out of eight vehicle treated 
mice and one out of eight mice of the vancomycin and lysostaphin (2 mg/kg) groups. Mice of 
other treatment groups had no detectable CFU counts in these two organs. 
The highest CFU counts in this model could be measured in the kidneys of the vehicle group, 
proofing invasive disease (Fig. 6.6 A). Antibacterial treatment with each of the applied 
therapeutics led to significantly reduced bacterial burden. The strongest effect was exhibited 
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by the lysostaphin (5 mg/kg) and the lysostaphin + oxacillin groups. Both of them led to 
complete bacterial clearance in the kidneys of five out of eight mice, which is shown in Fig 
6.4 A by plotting them on the detection limit of 102 CFU. Vancomycin, oxacillin-only or 
lysostaphin (2 mg/kg) led to a less pronounced reduction of bacterial burden, but reduction 
was still significant compared to the 0.9 % NaCl group, although vancomycin and lysostaphin 
(2 mg/kg) were considerably less effective than lysostaphin + oxacillin or lysostaphin (5 
mg/kg). 
The CFU counts in the catheter showed a similar picture. The highest CFU counts were 
determined for the vehicle group while treatment with each of the antibiotics or 
combinations led to significant lower values (Fig. 6.6 B). At this site of infection, the 
strongest reduction was achieved by either oxacillin alone or in combination with 
lysostaphin (2 mg/kg). However, a complete eradication of S. aureus Xen 29 could not be 
achieved by any of the therapeutics tested. 
 
Fig. 6.6: Bacterial burden at day 4 p.i. in the catheter-associated infection model. A central venous 
catheter was placed in the jugular vein of NMRI mice (n = 8 per group) and the lumen was filled with 
3.7 x 107 CFU S. aureus Xen29. The catheter was flushed 15 min after start of infection to remove 
non-adherent bacteria. Inner organs and the catheter were removed at day 4 p.i., either 
homogenized or sonicated and dilutions plated to determine CFU counts. A: CFU counts in the 
kidneys at day 4 p.i.. All treatment groups had significantly lower CFU values than the 0.9 % NaCl 
group (vancomycin, oxacillin, lysostaphin 2 mg/kg: P < 0.01; lysostaphin 5 mg/kg and 
lysostaphin+oxacillin: P < 0.005). Vancomycin and lysostaphin 2 mg/kg had significantly higher CFU 
values than lysostaphin 5 mg/kg or lysostaphin+oxacillin (P < 0.05). B: CFU counts in the catheter at 
day 4 p.i.. Single data points per mouse and the medians of the respective group are shown. 
Statistically significant differences are indicated by asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005, 
n.s.: not significant). (Adapted from Hertlein T et al. 2014) 
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6.1.6. Bioluminescent signal development in the catheter-associated 
infection model 
The bioluminescent S. aureus strain Xen29 was applied in this model to enable visualization 
of colonization and spreading of bacteria following infection via the central venous catheter 
by BLI. Mice were therefore imaged immediately after infection (1 – 5 min p.i.) and then 
every 24 h from dorsal and ventral view to visualize sites of emerging photon signal. In 
principle, bioluminescence signal could be detected at four spots: the catheter area from 
dorsal and ventral view, the kidney area from dorsal and the heart/lung area from ventral 
view (Fig. 6.7 A). The signal detected in the catheter area was present from the first 
measurement immediately after start of infection until the end of the experiment, while the 
signals in the kidney area and the heart/lung area emerged at later time points. But not all 
mice of all groups developed bioluminescence signal above background level at all spots. 
Whereas all mice showed photon emission in the catheter area from ventral view (Fig. 6.7 B, 
with lysostaphin + oxacillin group being close to background noise), only four out of eight 
vehicle group and one out of eight vancomycin group mice developed signal in the 
heart/lung area. Most of the mice, with the exception of the lysostaphin + oxacillin group, 
showed additionally elevated photon emission in the kidney area from dorsal view. Oval 
areas of interest were defined at the locations with elevated photon emission and applied to 
all mice at all time points to guarantee comparable results for all treatment groups. 
The quantification of the bioluminescence signal in these areas of interest showed, in 
general, at the catheter area from ventral view and the kidney area from dorsal view, 
increasing photon emission levels for the vehicle group and values close to background for 
the lysostaphin (2 mg/kg) + oxacillin group (Fig. 6.7 B). This led to significantly reduced 
values from day 3 p.i. until the end of the experiment. Oxacillin treatment led in the catheter 
area after day 1 p.i. to a signal reduction, which was similar in magnitude than those of the 
combinatorial group, while the other treatment groups showed intermediate values 
throughout the whole experiment. Interestingly, the photon emission in the catheter area 
from ventral view of vehicle, vancomycin, and lysostaphin (2 and 5 mg/kg) treated mice 
increased until day 2 p.i. and then remained at this level until the end of the experiment. In 
the kidney area, signal levels increased steadily until the end of the experiment for the 
vehicle group and slightly for the treatment groups. Lysostaphin + oxacillin and, less 
pronounced, oxacillin-only group showed a bioluminescence signal close to background 
levels.  
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Fig 6.7: Emergence and development of bioluminescence signal in the catheter-associated infection 
model. Mice (Female NMRI, n = 8 per group) were challenged with 3.7 x 107 CFU of bioluminescent S. 
aureus Xen29 in the lumen of a central venous catheter. All mice were imaged once every 24 h after 
start of infection and average radiance signal was determined in manually defined regions of 
interest. A: Exemplary mouse demonstrating areas of bioluminescence signal emergence during the 
course of infection. The regions of interest, defined from ventral or dorsal view and named catheter, 
heart/lung or kidney area, were applied to all measurements in same orientation and size to 
standardize the measurements. B: Bioluminescence signal development in the catheter area from 
ventral view (upper graph) or in the kidney area from dorsal view (lower graph). Shown are the mean 
values +/- SEM of each group. (Adapted from Hertlein T et al. 2014) 
  
132 Chapter 6. Evaluation of lysostaphin efficacy 
6.2. Discussion 
 
Although a number of new antibiotics has been introduced in the last years, Staphylococcus 
aureus remains a major challenge for public health systems all over the world (Seybold U et 
al. 2006, Chambers HF and Deleo FR. 2009). The emergence of hospital-acquired Meticillin-
resistant S. aureus strains (ha-MRSA), community-acquired MRSA (ca-MRSA) and even 
livestock-associated MRSA strains has increased the pressure to identify and combat 
spreading of S. aureus (Kennedy AD et al. 2008, Schaumburg F et al. 2012). Most of the 
newly introduced antibiotics are members of long- and well-known substance classes with 
improved activity especially against MRSA strains (Ohlsen K, Lorenz U. 2010, Theuretzbacher 
U. 2012). But despite that, there are completely new approaches and compounds to treat S. 
aureus infections in preclinical development like monoclonal antibodies, immunomodulators 
or enzymes (Scott MG et al. 2007, Ohlsen K, Lorenz U. 2010). Among these, one promising 
compound in preclinical development is the endopeptidase lysostaphin. The goal of this 
chapter was therefore to investigate the efficacy of a new, recombinant formulation of 
lysostaphin in relevant animal models. 
In this context, murine thigh and catheter-associated infection models were chosen because 
of their high clinical relevance. Both models mirror types of human infection, which are 
characterized by significant morbidity and mortality in the clinical situation and are 
recognized as difficult-to-treat infections (Lowy FD. 1998). The efficacy of lysostaphin was 
evaluated in this experiments either directly by measuring the bacterial burden in terms of 
CFU counts or by reducing the signals measured by the imaging platform established in 
chapters 4 and 5. Based on the experiments described in these chapters, bioluminescence 
and 19F magnetic resonance imaging with perfluorocarbons were applied to investigate the 
efficacy of lysostaphin: bioluminescence imaging, because it visualizes the development of 
bacterial burden in vivo during the course of infection, what is, in consequence, similar in 
target than CFU counting, which measures the number of viable bacteria at the end of the 
experiment in the infected thigh muscle, while 19F MRI, in contrast, images the accumulation 
of perfluorocarbon emulsion at the site of infection dependent on the immigration of 
phagocytic immune cells and thus the gravity of the innate immune response to infection. 
The endopeptidase lysostaphin is member of a new class of antibacterial compounds with 
high in vitro activity against S. aureus, including MRSA (Huber MM et al. 1989, Polak J et al. 
1993). Notably, MIC values for the lysostaphin formulation used in this study were 100-fold 
lower than those of vancomycin. It cleaves the pentaglycine cross-bridge in the S. aureus cell 
wall (Schindler CA et al. 1964, Sloan GL et al. 1977) and has shown in vivo activity in various 
animal models (Climo MW et al. 1998, Patron RL et al. 1999, Kokai-Kun JF et al. 2007, Kokai-
Kun JF et al. 2009). The in vivo efficacy could for example been demonstrated in 
intraperitoneal infection and kidney abscess models in mice, endocarditis in rabbits or 
mastitis in cows (Harrison EF et al. 1967, Schaffner W et al. 1967, Goldberg LM et al. 1967, 
Oldham ER et al. 1991, Climo MW et al. 1998). One study was furthermore published 
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describing administration of lysostaphin to a neutropenic patient (Stark FR et al. 1974). To 
sum up, all these studies suggested that lysostaphin has the potential to be applied as a drug 
of last resort against drug-resistant S. aureus. 
Lysostaphin was administered at two doses, 2 mg/kg or 5 mg/kg, consistent with the 
concentrations used in former studies with different, recombinant formulations of 
lysostaphin (Kiri N et al. 2002, Kokai-Kun JF et al. 2007). The higher dose, 5 mg/kg, reduced 
significantly CFU values in both murine models and was non-inferior or even superior to the 
control agents oxacillin and vancomycin, which are commonly used to treat S. aureus 
infections. Only in the catheter lumen oxacillin had a similar or slightly stronger activity than 
lysostaphin (5 mg/kg). The higher dose was furthermore superior to the lower dose (2 
mg/kg) in both models. The values derived by bioluminescence imaging verified the results 
from CFU determination showing superiority to vancomycin, low-dose lysostaphin and 
oxacillin with the exception of catheter lumen. Finally, the smallest accumulation of 
perfluorocarbon emulsion at the site of infection for all groups could be visualized by 19F MR 
imaging for lysostaphin (5 mg/kg) treated mice, indicating weak immigration of phagocytic 
immune cells. 
A further group received a combination of low-dose lysostaphin (2 mg/kg) and oxacillin to 
test for in vivo synergy. Former studies demonstrated synergy between β-lactam antibiotics 
and lysostaphin by in vitro and in vivo experiments (Polak J et al. 1993, Kiri N et al. 2002). 
The combination demonstrated efficacies in the reduction of CFU similar to those seen for 
lysostaphin (5 mg/kg) being superior to oxacillin or lysostaphin (2 mg/kg) alone. In the 
catheter lumen, the combination of lysostaphin + oxacillin was even better in reducing CFU 
and bioluminescence values than lysostaphin (5 mg/kg), but only marginally better than 
oxacillin alone. Regarding the 19F accumulation at the site of infection, lysostaphin + oxacillin 
exhibited higher values than lysostaphin (5 mg/kg) and similar ones than vancomycin or 
lysostaphin (2 mg/kg) suggesting higher influx of phagocytes than the high-dose lysostaphin 
group. This results suggest not necessarily synergy in both models, because the reduction of 
CFU, bioluminescence and 19F accumulation signals compared between lysostaphin (2 
mg/kg) and oxacillin-only on the one hand and the simultaneous combination of both on the 
other hand seemed to be closer to being additive than synergistic. Nonetheless, the 
combination of the narrow-spectrum lysostaphin with a broad band β-lactam antibiotic 
might facilitate the application in the clinical situation. 
In conclusion, lysostaphin proved to be very efficient either alone or in combination with 
oxacillin to fight S. aureus infection in both thigh and catheter-associated infections. 
However, concerns have been raised regarding the immunogenicity of and resistance 
development against lysostaphin. For example, lysostaphin-resistant S. aureus clones could 
be identified after low dose lysostaphin treatment (1 mg/kg) in a rabbit endocarditis model, 
while high dose treatment (5 – 15 mg/kg) prevented resistance development (Climo MW et 
al. 2011). The resistance development was connected to mutations in femA, resulting in an 
altered muropeptide structure in which the normal pentaglycine bridge was replaced by a 
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single glycine. Resistance development has also been described following the incorporation 
of other amino acids besides glycine into the peptidoglycan cross bridge (Thumm G et al. 
1997, Tschierske M et al. 1997, Strauss A et al. 1998). Interestingly, this kind of resistance 
development could be prevented by the concomitant application of nafcillin, a β-lactam 
antibiotic. It was furthermore observed, that MRSA or ORSE strains, which developed 
lysostaphin resistance after in vivo treatment with low dose lysostaphin, became sensitive to 
β-lactam antibiotics (Climo MW et al. 2011, Kiri N et al. 2002). A further lysostaphin 
resistance mechanism was recently identified by using a Bursa aurealis insertion approach. 
This mechanism was independent from alterations in cell wall cross bridges, but the in vivo 
importance has not yet been determined (Gründling A et al. 2006). 
Lysostaphin-resistant clones could, in the experiments of this chapter and congruent with 
afore mentioned studies, only be identified in the lysostaphin (2 mg/kg) group, but not in 
lysostaphin (5 mg/kg) or lysostaphin + oxacillin treated mice. This suggests that in vivo 
resistance development can be prevented by short term treatment with high doses of 
lysostaphin or by combining lower doses with β-lactam antibiotics. Furthermore, it seems to 
be recommended to apply lysostaphin only in cases of severe infections with highly-resistant 
S. aureus strains in order to prevent resistance development in the clinical situation. 
A further concern regularly mentioned against application of the polypeptide lysostaphin as 
anti – S. aureus drug is the possible occurrence of adverse immunological effects. 
Nevertheless, studies investigating the topical application of lysostaphin to eradicate nasal S. 
aureus carriage did not induce antibody formation or sensitization (Harris RL et al. 1967, 
Quickel KE et al. 1971). Additionally, multiple intramammary infusions of recombinant 
lysostaphin formulations in cows failed to provoke significant serum antibody titers against 
lysostaphin and did furthermore not show any detrimental effects on the animals (Daley MJ 
et al. 1992). But nonetheless, additional studies are necessary to assess potential adverse 
immune reactions to systemic application of lysostaphin during treatment. 
The second topic of this study was to evaluate the ability of the imaging platform, which is 
described in chapter 5, to visualize and quantify non-invasively differences in efficacy 
pattern of antibiotics, especially new developed ones, in vivo. Challenging the mice with 
bioluminescent S. aureus Xen29 led in both models to bioluminescence signals at the 
primary sites of infection immediately after infection (Fig. 6.2 B and Fig. 6.7 B). No other 
sources of photon emission could be detected before or immediately after infection. During 
course of infection, the vehicle group delivered in both models the strongest 
bioluminescence signal of all groups and lysostaphin + oxacillin the weakest one. In the 
catheter-associated infection model, bioluminescence imaging proved useful to identify 
secondary sites of infection, visualizing emerging signal in the kidney and the heart/lung area 
of some mice. These results could be confirmed by CFU counting at day 7 p.i.. Moreover, 
bioluminescence imaging indicated in both infection models the same antibiotic efficacy 
pattern than CFU counting with the exception of lysostaphin (5 mg/kg) efficacy in the 
kidneys of the catheter infection model. In this case, one might get from the graph in Fig. 6.5 
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B the impression, that the kidneys delivered higher mean bioluminescence signal than 
expected from corresponding CFU counts. Reason for this discrepancy between 
bioluminescence and CFU results might be the considerable loss of bioluminescence signal 
due to tissue depths of inner organs. Variations in the localization and orientation of the 
kidneys (especially if the spinal cord, which strongly absorbs bioluminescence signal of the 
emitted wavelength, is located between one or both kidneys and the detection-CCD camera) 
might have led in this rather small animal number approach to these non-distinctive, highly 
overlapping results. After all, it has to be stated, that the differences in bioluminescence 
signal of the kidney area between the different treatment groups were statistically not 
significant and small in value, while the variance of the single values were rather high. In 
conclusion, bioluminescence imaging has proven its usefulness in preclinical evaluation of 
antibacterial substances in the catheter-associated infection model by visualizing secondary 
sites of infection like kidneys, heart or lungs, but the sensitivity, in terms of quantifying the 
bacterial burden at sites of infection and measuring differences between different treatment 
regimens, was less sensitive than classical CFU determination. 
Regarding the thigh infection model, bioluminescence imaging delivered much more stable 
and continuous signals than in the catheter-associated infection model (with the exception 
of the strong bioluminescence signal drop within the first 24 hours after start of infection). 
Bioluminescence signal was detectable in all groups, with the exception of the lysostaphin + 
oxacillin group, where signal remained close to background levels. The efficacy pattern fitted 
in this model nicely between CFU counting and bioluminescence imaging. The discrepancy 
between the reliability of bioluminescence results of thigh and catheter-associated infection 
model might be caused by differences in the tissue depths of the respective sites of 
infection. The signal derived from abscesses of the thigh infection model are more or less 
standardized by the injection of bacteria at the start of the experiment, while the kidneys 
and the exact location of the catheter depends on the individual mouse and the emergence 
of infection loci. It is consequently of high importance to reconsider bioluminescence 
imaging to quantify bacterial burden in deeper located tissue. Nonetheless, our study is 
conform with published studies demonstrating the benefits of bioluminescence imaging, to 
give additional and precious information about the infection process in real time that might, 
in consequence, help to reduce the number of animals necessary to assess the efficacy of 
novel antibiotics in preclinical studies (Rocchetta HL et al. 2001, Kuklin NA et al. 2003, 
Jawhara S et al. 2004). 
In addition to bioluminescence imaging, 19F magnetic resonance imaging was applied as 
second imaging modality to investigate the efficacy of lysostaphin in the thigh infection 
model. As shown in chapter 5, the accumulation of perfluorocarbon emulsion, which is 
visualized by 19F MRI, at the site of infection is influenced by antibiotic therapy. This modality 
is in contrast to CFU determination or bioluminescence imaging not directly connected to 
the bacterial burden, but to the incorporation of perfluorocarbon emulsion by phagocytic 
immune cells in the bloodstream and their subsequent migration to the site of infection. In 
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consequence, 19F MRI with perfluorocarbon emulsions indicates inflammation in distinct 
areas (Flögel U et al. 2008, Ebner B et al. 2010). 
Therefore, all mice received a single application of perfluorocarbon emulsion at day 2 p.i. 
and were imaged at days 3 and 7 p.i.. The accumulation of 19F at the site of infection was 
visualized by MRI and the anatomical context facilitated by underlaying with a 1H MR image. 
In principle, two parameters became measurable by this method: the 19F-filled volume (in 
terms of voxels) and the overall 19F signal in the infected thigh muscle. Both parameters 
delivered a similar picture regarding the efficacy pattern of the applied antibiotics and 
dosing regimens. The strongest accumulation in volume and signal could be measured for 
the vehicle treated group at both time points, while the weakest ones were measured for 
the lysostaphin (5 mg/kg) group. All treatment groups reached significantly reduced 19F 
accumulation volumes and signals at day 3 and 7 p.i., but the differences between the 
treatment regimens were not significant with the exception of a significantly lower 19F filled 
volume in lysostaphin (5 mg/kg) treated mice compared to oxacillin treated ones at day 3 
p.i.. Nonetheless, a striking discontinuity between the 19F MRI results and the 
CFU/bioluminescence results could be seen regarding the pattern of signal reduction. 
Oxacillin treatment, both alone or in combination with lysostaphin (2 mg/kg), resulted in 
higher 19F values than expected if compared to the efficacy patterns indicated by CFUs or 
photon emission. This suggests a boost in perfluorocarbon uptake by phagocytes or 
enhanced migration to the site of infection, indicating immune-modulation by oxacillin 
treatment. But, to note, the strengthened activation or migration of phagocytes did not lead 
to better clearance of S. aureus in the infected thigh muscle. 
In general, it has been shown by former studies that β-lactam antibiotics enhance pro-
inflammatory cytokine production by inducing the release of bacterial cell-wall components 
(Tauber SC et al. 2008). The incubation of S. aureus cultures led, for example, to greatly 
increased concentrations of lipoteichoic acid and peptidoglycan compared to peptide-
synthesis inhibitor antibiotic treated cultures. These cultures showed additionally an 
induction in release of tumor necrose factor alpha and interleukin-10 in human whole blood, 
which was directly proportional to the concentrations of lipoteichoic acid and peptidoglycan 
(van Langevelde P et al. 1998). Furthermore, the supernatant of these cultures enhanced the 
adhesiveness of endothelial cells for granulocytes and induced release of interleukin-8 and 
monocyte chemotactic protein 1 (van Langevelde P et al. 1999). The induction of pro-
inflammatory immune response to β-lactam treated bacterial cultures could be observed for 
other bacterial pathogens than S. aureus, too. Exposure of Streptococcus pneumoniae 
cultures with β-lactam antibiotics led, for example, to activation of TLR2 and elevated levels 
of IL-8 in HeLa cell cultures (Moore LJ et al. 2007). A systematic testing of several different 
classes of antibiotics demonstrated differential release of lipoteichoic and teichoic acid from 
S. pneumoniae dependent on class and concentration, with β-lactams delivering the highest 
levels of all tested antibiotics when applied at concentrations close to their MIC values 
(Stuertz K et al. 1998, Heer C et al. 2000). 
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Interestingly, treatment with vancomycin did in this context not provoke TLR2 activation and 
IL-8 induction (Moore LJ et al. 2004). Since S. aureus might lead to similar TLR2 activation 
after β-lactam treatment, this in vitro experiment might give an explanation for the 
increased 19F accumulation for the oxacillin group while vancomycin treatment resulted in 
lower perfluorocarbon emulsion accumulation at the site of infection, as shown in this 
chapter. In addition to in vitro studies, several experimental animal models of Escherichia 
coli, Pseudomonas aeruginosa, Streptococcus pneumoniae and Staphylococcus aureus 
infections have shown that β-lactam treatment induced release of pro-inflammatory 
bacterial components, fortified inflammation and was associated with impaired survival or 
elevated bacterial burden (reviewed by Nau R et al. 2005). Therefore, an interesting 
approach to improve the outcome of antibacterial therapy might be to modulate the 
immune response that accompanies infection and therapy. Combining β-lactam therapy with 
either pre-treatment with rifampicin in a S. pneumoniae model (Gerber J et al. 2003) or with 
artenusate in a S. aureus model (Jiang W et al. 2011) improved the outcome compared to β-
lactam treatment only, suggesting a beneficial effect by anti-inflammatory activity of both 
compounds. But further studies are necessary to evaluate the efficacy of such combinations 
in different experimental models in much higher detail. Nonetheless, these studies shift the 
attention to the problem that measuring the bacterial burden at the site of infection might 
not be sufficient to determine the real consequences of infection and therapy. Tissue and 
organ destruction caused by infection and inflammation are of similar importance to the 
patient and, therefore, those effects should attract more attention in preclinical evaluation 
of new, promising compounds. Of importance, magnetic resonance imaging, especially 19F 
MRI with perfluorocarbons, might give such insights by revealing abscess formation, tissue 
destruction and phagocyte immigration in vivo. 
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Tab. 6.1: Inter-experiment variation of CFU, bioluminescence and 19F magnetic resonance results 
for the 0.9 % NaCl and the vancomycin groups. Shown are the median values (CFU, 19F volume and 
19F signal) or the mean values (BL signal) for both groups in the experiments described in chapters 5 
and 6. 
 0.9 % NaCl group vancomycin group 
chapter 5 chapter 6 chapter 5 chapter 6 
infectious dose in CFU counts 3.2 x 108  2.4 x 108  3.2 x 108  2.4 x 108  
CFU (d7 p.i.) in counts 2.39 x 109  8.84 x 108  2.5 × 107 1.25 x 108  
BL signal (d3 p.i.) in p/s/cm2/sr 2.8 × 104 5.75 × 104 1.4 × 104  1.13 × 104 
BL signal (d7 p.i.) in p/s/cm2/sr 4.79 × 104 7.81 × 104 7.40 × 103  7.2 × 103 
19F volume (d3 p.i.) in voxels 3.71 × 104  3.06 × 104  6.89 × 103 7.12 × 103 
19F volume (d7 p.i.) in voxels 4.57 × 104  4.58 × 104  7.93 × 103  8.24 × 103  
19F signal (d3 p.i.) in nsif 1.38 × 105  1.04 × 105  1.81 × 104  1.98 × 104  
19F signal (d7 p.i.) in nsif 2.14 × 105  2.31 × 105  2.35 × 104  2.56 × 104  
 
 
The experiments in this chapter were based on the same animal model and the same 
imaging technologies than those described in chapter 5. Two treatment groups were applied 
in both chapters as control groups and thus offered the opportunity to investigate the inter-
experiment variance of bioluminescence and 19F magnetic resonance imaging: the 0.9 % 
NaCl group and the vancomycin group (Tab. 6.1). Regarding bioluminescence imaging 
results, the 0.9 % NaCl groups showed in both experiments a signal plateau between d3 and 
d7 p.i. with values of 5.0 x 104 to 1.0 x 105 p/s/cm2/sr and the vancomycin groups had similar 
signals level between day 3 and 5 p.i. of around 1.0 x 104 p/s/cm2/sr. In consequence, similar 
infectious doses led in two independent experiments to similar bioluminescence signals in 
the same murine model for vehicle and vancomycin treatment, demonstrating the benefit 
and reliability of bioluminescence imaging in this model. The 19F accumulation volume and 
signal values were very similar at days 3 and 7 p.i. for both treatment groups in both 
experiment sets. The variation was even weaker than with bioluminescence imaging, 
indicating a highly organized and equivalent immune response. Thus, it suggests that 19F MRI 
with perfluorocarbon emulsions is an interesting and reliable imaging modality to investigate 
the efficacy of promising drug candidates, although the compound’s influence upon the 
inflammatory immune response has to be taken into account. It has to be noted for both 
imaging modalities, that not only the total values were similar in the experiments of both 
chapters, but also the signal reduction caused by vancomycin. In consequence, both 
methods indicated comparable antibacterial capacity of vancomycin by two independent 
experiment sets. 
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In general, the results shown in this chapter were comparable regarding vancomycin efficacy 
and signal magnitude to the results shown in chapter 5. This demonstrates in conclusion that 
both modalities, bioluminescence imaging and 19F magnetic resonance imaging with 
perfluorocarbons, deliver consistent inter-experimental results and are thus suitable and 
applicable to evaluate antibacterial compounds. 
In conclusion, lysostaphin has proven efficacy against S. aureus in two clinically relevant 
murine models, the thigh infection and the catheter-associated infection model. The higher 
dosing of lysostaphin (5 mg / kg body weight / d) resulted in strong reduction of CFU, 
bioluminescence signal and 19F accumulation volume and signal. Similarly efficient was the 
combination of low dose lysostaphin (2 mg / kg) with the β-lactam antibiotic oxacillin. 19F 
MRI with perfluorocarbons visualized the therapeutical effect non-invasively, although the 
results of the oxacillin only and the lysostaphin + oxacillin group were higher than expected 
from bioluminescence imaging and CFU determination. This might be an indication for 
immune-modulation, since perfluorocarbon emulsion accumulates at the site of infection in 
dependence of phagocytic immune cells, but this question has to be addressed by a different 
set of experiments. 
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7. Influence of antibiotic therapy on immune response 
 
The unexpected high values of 19F signal and volume in the oxacillin treated mouse group in 
chapter 6 raised the question about the origin of the discrepancy between CFU counting, 
bioluminescence and 19F magnetic resonance imaging to determine the severity of disease or 
bacterial burden. Experiments in chapter 4 had shown in this regard that perfluorocarbon 
emulsion does not accumulate in bacteria at the site of infection, but in phagocytic immune 
cells, mainly in neutrophils. One obvious explanation for the above-mentioned observation 
might be therefore differences in the migration behavior or perfluorocarbon uptake of 
neutrophils during treatment with oxacillin. Literature research proved in this context an 
increased release of pro-inflammatory cell wall components by the action of β-lactam 
antibiotics like oxacillin (van Langevelde P et al. 1999, Tauber SC, Nau R. 2008). In order to 
investigate whether oxacillin can cause immunomodulatory effects in the S. aureus thigh 
infection model, the cytokine/chemokine response, the activity of the myeloperoxidase and 
the bacterial burden at the site of infection were determined during infection with either 
oxacillin-sensitive S. aureus Xen29 or oxacillin-resistant S. aureus LAC. 
 
7.1. Staphylococcus aureus Xen29 thigh infection model 
 
7.1.1. Reduction of bacterial burden by treatment with either 
vancomycin, oxacillin, linezolid or minocycline 
Female Balb/c mice were challenged with 2.0 x 108 CFU S. aureus Xen29 in the left thigh 
muscle, imaged with bioluminescence imaging every 24 hours and the experiment ended at 
day 5 p.i. with the recovery of the infected thigh muscle. Antibiotic therapy with either 
vancomycin, oxacillin, linezolid or minocycline was initiated 2 hours p.i. and continued every 
12 hours. The bioluminescent signal developed congruent with the experiments from former 
chapters (Fig. 7.1 A). After very high photon emission values immediately after start of 
infection, a strong decrease of signal could be detected after the first 24 hours of infection. 
The bioluminescence signal then recovered to lower values than initially in all groups. The 
0.9 % NaCl group had in this regard at all time points after the first imaging session the 
highest values of all groups. The antibiotic treatment groups started to differ in values at day 
4, with vancomycin showing the highest values, followed by linezolid, minocycline and 
oxacillin. All of them exhibited reduction of bioluminescent signal compared to 0.9 % NaCl 
group, but differences between the groups were small and results overlapping. In 
consequence, bioluminescent imaging demonstrated reduction of bacterial burden at the 
site of infection for all treatment groups, but showed no significant differences between the 
applied compounds. The determination of CFU values at day 5 p.i. showed highest values for 
the 0.9 % NaCl group. Antibiotic treatment led for all groups to significantly reduced 
bacterial burden at the site of infection. Vancomycin treatment reduced the CFU counts in 
 7.1. Staphylococcus aureus Xen29 thigh infection model 141 
this regard with the weakest efficacy, followed by oxacillin and linezolid. Minocycline group 
mice showed strongest reduction of bacterial burden, resulting in no detectable bacteria in 3 
out of 7 mice. 
 
Fig. 7.1: Bioluminescence signal development and bacterial burden in the S. aureus Xen29 thigh 
infection model. Female Balb/c mice (n = 7 per group) were challenged with ca. 2.0 x 108 CFU S. 
aureus Xen29 in the left thigh muscle. Antibiotic treatment started 2 h p.i. and was continued every 
12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 mg/kg/d and minocycline: 20 
mg/kg/d). A. Bioluminescent signal derived from the infected thigh muscle during course of 
infection. First measurement (time point: day 0 p.i.) was performed 5 – 15 min post infection. Mice 
were then imaged every 24 h for development of bioluminescence signal in a manually defined 
region of interest with same geometry and size for all investigated mice. Shown are the means +/- 
SEM for each group. B. Colony-forming unit counts in the infected thigh muscles at day 5 p.i.. 
Muscles were recovered at the end point of the experiment, homogenized and serial dilutions plated 
on B agar plates. Shown are single data points per mouse and the respective medians per group. 
Statistical significant differences are indicated by asterisks (*: P < 0.05, **: P < 0.01). 
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7.1.2. Influence of antibacterial treatment on the levels of various 
cytokines and chemokines at the site of infection 
The recovery of infected thigh muscles enabled additionally to CFU determination the 
quantification of cytokine and chemokine levels at the site of infection. In order to achieve 
this goal, the thigh muscles were homogenized and the homogenization filtered through a 
0.22 µm syringe filter to remove cells. The filtered homogenizate was then used to quantify 
the concentration of various cytokines and chemokines with a flow cytometry bead assay. 
Since we were interested in the state of inflammation and activation of immune cells, the 
antibody-conjugated beads were selected to cover various pro- and anti-inflammatory 
cytokines and chemokines.  
Regarding chemokines, very high amounts of MIP-1α and MCP-1 as well as high amounts of 
RANTES and MCP-3 could be found in the infected thigh muscle at day 5 p.i. (Fig. 7.2). MIP-
1β was detected only at very low levels with similar values for all groups. Especially 
interesting is the fact, that they were found differentially among the treatment groups. MIP-
1α and MCP-3 followed in pattern the efficacy of antibacterial therapy with highest values 
for 0.9 % NaCl group and smallest values for minocycline group. MCP-1 showed this 
gradient, too, but less pronounced than MIP-1α and MCP-3. RANTES in contrast was 
strongest released in minocycline and linezolid groups, and weakest in oxacillin and 0.9% 
NaCl groups.  
 
 
 
 
 
Fig. 7.2 (facing page): Titers of various chemokines and cytokines in the infected thigh muscle of S. 
aureus Xen29 infected mice at day 5 p.i.. Female Balb/c mice (n = 7 per group) were challenged with 
2.0 x 108 CFU S. aureus Xen29 in the left thigh muscle. Antibiotic treatment started 2 h p.i. and was 
continued every 12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 mg/kg/d and 
minocycline: 20 mg/kg/d). Muscles were recovered at day 5 p.i., homogenized, the homogenate 
filtered through a 40 µm cell strainer and the cytokine/chemokine concentration measured with 
either the Mouse Chemokine 6plex FlowCytomix Multiplex or the Mouse Th1/Th2 10plex Ready-to-
Use FlowCytomix Multiplex (both eBioscience). Shown are the titers of A. monocyte chemotactic 
protein-1 (MCP-1), B. monocyte chemotactic protein-3 (MCP-3), C. macrophage inflammatory 
protein 1 alpha (MIP-1α), D. macrophage inflammatory protein 1 beta (MIP-1β), E. regulated on 
activation, normal T cell expressed and secreted (RANTES), F. granulocyte macrophage colony-
stimulating factor (GM-CSF), G. interferone γ (IFNγ) and H. tumor necrose factor α (TNFα). Shown are 
the means +/- SEM per group. Statistical significant differences between different groups are marked 
by asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005, n.s.: not significant). 
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Determination of cytokine values in the infected thigh muscle revealed very high amounts of 
IL-1α at the site of infection and high amounts of IL-6 (Fig. 7.3). The highest concentration of 
IL-1α was measured for the 0.9 % NaCl group, the smallest one for minocycline. The pattern 
of IL-1α concentration among the different treatment groups mirrored thereby the efficacy 
pattern of the different antibiotics. Lower amounts than IL-1α could be detected for virtually 
all other tested cytokines at the site of infection, namely IL-2, IL-4, IL-5, IL-10, IL-17, TNFα 
and IFNγ. GM-CSF, in contrast, delivered no detectable concentration above background 
values at the site of infection. Interestingly, oxacillin treatment led in this experiment with S. 
aureus Xen29 to the highest measured concentrations of TNFα, IFNγ, IL-4, IL-5 and IL-17, all 
of them (with the exception of TNFα and IL-17) significantly higher than those derived from 
0.9 % NaCl group. Other treatments than oxacillin resulted in similar concentrations of this 
cytokines (IL-4, IL-5, IL-17, TNFα and IFNγ) than the 0.9 % NaCl group, indicating no or weak 
influence of treatment or reduction of bacterial burden upon expression and release of 
these cytokines at the site of infection. IL-6 and IL-10 showed with the exception of the 
oxacillin group a concentration pattern that followed the efficacy pattern of antibiotic 
therapy. 0.9 % NaCl with the highest values of bacterial burden and IL-6/IL-10 release, 
minocycline with the smallest values and vancomycin and linezolid groups with intermediate 
ones, while oxacillin treatment caused values comparable to those of 0.9 % NaCl group. IL-2 
was detected at comparable concentrations in all groups. 
 
 
 
 
 
 
Fig. 7.3 (facing page): Titers of various interleukins in the infected thigh muscle of S. aureus Xen29 
infected mice at day 5 p.i.. Female Balb/c mice (n = 7 per group) were challenged with 2.0 x 108 CFU 
S. aureus Xen29 in the left thigh muscle. Antibiotic treatment started 2 h p.i. and was continued 
every 12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 mg/kg/d and minocycline: 
20 mg/kg/d). Muscles were recovered at day 5 p.i., homogenized, the homogenate filtered through a 
40 µm cell strainer and the cytokine/chemokine concentration measured with either the Mouse 
Chemokine 6plex FlowCytomix Multiplex or the Mouse Th1/Th2 10plex Ready-to-Use FlowCytomix 
Multiplex (both eBioscience). Shown are the titers of A. interleukin 1α (IL-1α), B. interleukin 2 (IL-2), 
C. interleukin 4 (IL-4), D. macrophage interleukin 5 (IL-5), E. interleukin 6 (IL-6), F. interleukin 10 (IL-
10) and G. interleukin 17 (IL-17). Shown are the means +/- SEM per group. Statistical significant 
differences between different groups are marked by asterisks (*: P < 0.05, **: P < 0.01, ***: P < 
0.005, n.s.: not significant). 
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In summary, five different patterns of chemokine/cytokine release could be detected at the 
site of infection. First, IL-2 showed similar levels in all groups independently of the applied 
antibiotic treatment. Second, MIP-1α, MCP-3, IL-1α and MCP-1 (the last one less 
pronounced) were detected in a pattern that mirrored the CFU reduction efficacy of the 
different antibiotics with the 0.9 % NaCl group exhibiting the highest, minocycline the 
smallest and the other compounds intermediate values. Third, IL-6 and IL-10 were released 
dependent on the efficacy of the applied antibiotic with the exception of the oxacillin group. 
More precisely, 0.9 % NaCl group showed highest values, minocycline group the lowest ones 
and vancomycin and linezolid intermediate values, while oxacillin led to levels similar to 
those of 0.9 % NaCl although the CFU counts and bioluminescence signal were reduced. The 
fourth group consisted of TNFα, IFNγ, IL-4, IL-5 and IL-17. This group exhibited highest 
amounts for the oxacillin group, while treatment with other antibiotics did not alter the 
concentration of cytokines compared to 0.9 % NaCl group. RANTES showed the fifth pattern 
with the highest amounts for the minocycline and linezolid group and lower, but similar ones 
for oxacillin, vancomycin and 0.9 % NaCl groups. MIP-1β and GM-CSF were detected at very 
low levels. 
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7.2. Thigh infection model with ca-MRSA S. aureus Lac 
(USA300) 
 
S. aureus Xen29, the strain applied in the thigh infection model in chapter 7.1, is oxacillin 
sensitive, thus suited to investigate the effect of oxacillin during therapy, but the results 
could not be differentiated between direct influence of oxacillin on the immune response 
and indirect influence by killing bacteria and thereby releasing pro-inflammatory cell wall 
components that stimulate cytokine release. An oxacillin-resistant strain like S. aureus LAC 
(USA300) provides the possibility to measure potential direct effects of oxacillin and was 
therefore applied in the same infection model to enable the comparison of both results. 
 
7.2.1. Influence of antibacterial treatment with either vancomycin, 
oxacillin, linezolid or minocycline on bacterial burden 
Hence, female Balb/c mice were infected with 2.2 x 108 CFU S. aureus LAC in the left thigh 
muscle and antibiotic treatment started 2 hours later. It was continued every 12 hours until 
the end of the experiment. The infected thigh muscles were recovered at day 5 p.i., 
homogenized and the CFU counts measured. The highest values could be determined for the 
0.9 % NaCl group, although oxacillin treatment resulted in similar, statistically not significant 
different values (Fig. 7.4 D). Vancomycin treatment led to reduction of approximately one 
log 10 unit, while linezolid lowered values by 2 and minocycline by 2.5 log 10 units. Both, 
linezolid and minocycline showed significantly lower values than oxacillin. 
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Fig. 7.4: Bioluminescence signal at the site of infection derived after intra-peritoneal 
administration of luminol sodium salt and bacterial burden in the S. aureus LAC thigh infection 
model at day 5 p.i.. Female Balb/c mice (n = 10 per group) were challenged with 2.2 x 108 CFU S. 
aureus LAC (USA300) in the left thigh muscle. Antibiotic treatment started 2 h p.i. and was continued 
every 12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 mg/kg/d and minocycline: 
20 mg/kg/d). A - C. Bioluminescent signal derived at the site infection after intra-peritoneal of 
luminol sodium salt. Each mouse received 200 mg/kg luminol sodium salt (Alfa Aesar), dissolved in 
0.9 % NaCl solution, via intra-peritoneal injection after a first bioluminescence control image. A 
second image was recorded 5 min after application, the photon emission calculated in a manually 
defined region of interest (same size and geometry for all measurements) and the difference 
calculated with: average radiance (after luminol administration) – average radiance (before luminol 
administration). The resulting mean bioluminescence signal differences +/- SEM per group is shown 
in A – C. D. Colony-forming unit counts in the infected thigh muscles at day 5 p.i.. Muscles were 
recovered at the end point of the experiment, homogenized and serial dilutions plated on B agar 
plates. Shown are single data points per mouse and the respective medians per group. Statistical 
significant differences are indicated with asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005, n.s.: not 
significant). 
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7.2.2. Imaging of myeloperoxidase activity at the site of infection with 
luminol 
Inasmuch as S. aureus LAC does not emit bioluminescent signal, imaging of myeloperoxidase 
activity at the site of infection with luminol was feasible. This method is based on the intra-
peritoneal administration of luminol sodium salt that is cleaved in vivo by the action of 
neutrophilic myeloperoxidase, whereupon light is emitted (Gross S et al. 2009). This photon 
emission was detected by the IVIS in vivo imaging system in a non-invasive manner, thereby 
offering repeated sessions of luminol luminescent imaging. To measure the bioluminescent 
signal derived from luminol cleavage in vivo, first a negative control image was recorded and 
subtracted from an image after luminol application. Repeated imaging after administration 
of luminol at day 1 p.i. proved immediate photon signal that lasted for at least 30 minutes at 
constant signal levels (data not shown). Due to the invariance of photon emission for ca. 30 
min after luminol administration, all following luminol luminescence values in a manually 
defined region of interest were acquired at 2 – 4 minutes post administration. 
Determination of the signal at day 1 p.i. showed highest luminescence signal for the 
minocycline group and lowest ones for 0.9 % NaCl and oxacillin treatment (Fig. 7.4 A - C). The 
difference between these values were statistically significant, the intermediate values from 
linezolid and vancomycin group, in contrast to this, not. The minocycline group delivered in 
this regard at days 3 and 5 p.i. the highest values, too. The 0.9 % NaCl group exhibited the 
second strongest photon emission at day 5 p.i., but the lowest one at day 3 p.i.. Vancomycin 
treatment led to weakest signal at day 5 p.i., but similar values than 0.9 % NaCl group at day 
3 p.i.. Linezolid and oxacillin groups showed at both time points luminol luminescence signal 
at similar levels than the 0.9 % NaCl group. 
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7.2.3. Cytokine and chemokine levels at the site of infection 
The levels of various cytokines and chemokines in the infected thigh muscle were measured 
at the end of infection with a flow cytometry based antibody-conjugated bead kit. The 
infected thigh muscles were therefore homogenized and filtered through a 0.22 µm syringe 
filter to remove cells. The homogenization was then incubated with the cytokine/chemokine 
specific beads and binding was determined via flow cytometry. 
Regarding chemokine levels in the different treatment groups, high amounts of MCP-1, MCP-
3, MIP-1α and RANTES could, in general, be determined in the infected thigh muscles (Fig. 
7.5). In terms of MCP-1, MCP-3 and MIP-1α, a chemokine release pattern could be seen, that 
mirrored the efficacy of the applied antibiotics to reduce CFU counts. In more specific terms, 
this means that 0.9 % NaCl and oxacillin treatment resulted in the strongest release of MCP-
1, MCP-3 and MIP-1α, while the weakest one followed from minocycline treatment. 
Vancomycin and linezolid treatment led to intermediate values. The highest amounts of 
RANTES, in contrast to this, could be measured for the minocycline group. Other treatments, 
in the meantime, resulted in similar values. 
 
 
 
 
 
 
 
Fig. 7.5 (facing page): Titers of various chemokines and cytokines in the infected thigh muscle of S. 
aureus LAC infected mice at day 5 p.i.. Female Balb/c mice (n = 10 per group) were challenged with 
2.2 x 108 CFU S. aureus LAC (USA300) in the left thigh muscle. Antibiotic treatment started 2 h p.i. 
and was continued every 12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 
mg/kg/d and minocycline: 20 mg/kg/d). Muscles were recovered at day 5 p.i., homogenized, the 
homogenate filtered through a 40 µm cell strainer and the cytokine/chemokine concentration 
measured with either the Mouse Chemokine 6plex FlowCytomix Multiplex or the Mouse Th1/Th2 
10plex Ready-to-Use FlowCytomix Multiplex (both eBioscience). Shown are the titers of A. monocyte 
chemotactic protein-1 (MCP-1), B. monocyte chemotactic protein-3 (MCP-3), C. macrophage 
inflammatory protein 1 alpha (MIP-1α), D. macrophage inflammatory protein 1 beta (MIP-1β), E. 
regulated on activation, normal T cell expressed and secreted (RANTES), F. granulocyte macrophage 
colony-stimulating factor (GM-CSF), G. interferone γ (IFNγ) and H. tumor necrose factor α (TNFα). 
Shown are the means +/- SEM per group. Statistical significant differences between different groups 
are marked by asterisks (*: P < 0.05, **: P < 0.01, ***: P < 0.005, n.s.: not significant). 
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Determination of the levels of various cytokines at the site of infection revealed very high 
amounts of IL-1α and IL-6 (Fig. 7.6). The cytokines IL-2, IL-4, IL-5, IL-10, IL-17, TNFα and IFNγ 
could be detected at considerable levels, too. GM-CSF and the chemokine MIP-1β, in 
contrast, could only be measured at very low amounts in the muscle homogenizations. 
Cytokines IL-2, IL-4, IL-5, IL-6 and IFNγ were released at similar levels in all groups, with no 
significant differences between them. This indicates no influence of reduction of bacterial 
burden by antibiotic therapy on release of this group of cytokines during infection. Antibiotic 
treatment led to IL-1α levels that followed the pattern of CFU reduction. In more detail, 0.9 
% NaCl and oxacillin treatment with the highest CFU counts at the site of infection at day 5 
p.i. resulted in the strongest IL-1α levels, while minocycline group with the lowest CFU 
counts had the smallest IL-1α amounts. Vancomycin and linezolid group mice showed 
intermediate levels in both parameters. TNFα and IL-10 levels resembled in pattern the 
reduction of bacterial burden with the exception of the linezolid group. The linezolid group 
mice exhibited similar levels than the oxacillin or 0.9 % NaCl group, although having much 
lower numbers of viable bacteria in their infected thigh muscle. Finally, IL-17 was found at 
comparable levels in all groups with the exception of the minocycline group, which had 
significantly lower levels than 0.9 % NaCl or linezolid group. 
In summary, several different responses to antibiotic therapy could be seen in 
chemokine/cytokine pattern. A first group resembled the pattern of antibiotic efficacy, 
meaning, the lower the CFU counts in the infected thigh muscle, the lower the levels of 
cytokines/chemokines. Members of this group were the chemokines MCP-1, MCP-3, MIP-α 
and the cytokine IL-1α. All of them were released in high amounts. IL-2, IL-4, IL-5, IL-6 and 
IFNγ ranked among the second group, which showed similar levels for all treatments, 
independent of the reduction of bacterial burden by antibiotic treatment. RANTES levels 
showed a third, different pattern with minocycline leading to highest amounts while the 
other treatments resulted in similar levels at the site of infection. For the third group, TNFα 
and IL-10 levels mirrored the pattern of antibiotic efficacy with the exception of the linezolid 
group, which displayed similar values than oxacillin or 0.9 % NaCl group. 
 
Fig. 7.6 (facing page): Titers of various interleukins in the infected thigh muscle of S. aureus LAC 
infected mice at day 5 p.i.. Female Balb/c mice (n = 10 per group) were challenged with 2.2 x 108 CFU 
S. aureus LAC (USA300) in the left thigh muscle. Antibiotic treatment started 2 h p.i. and was 
continued every 12 h (Vancomycin: 30 mg/kg/d, oxacillin: 200 mg/kg/d, linezolid: 15 mg/kg/d and 
minocycline: 20 mg/kg/d). Muscles were recovered at day 5 p.i., homogenized, the homogenate 
filtered through a 40 µm cell strainer and the cytokine/chemokine concentration measured with 
either the Mouse Chemokine 6plex FlowCytomix Multiplex or the Mouse Th1/Th2 10plex Ready-to-
Use FlowCytomix Multiplex (both eBioscience). Shown are the titers of A. interleukin 1α (IL-1α), B. 
interleukin 2 (IL-2), C. interleukin 4 (IL-4), D. macrophage interleukin 5 (IL-5), E. interleukin 6 (IL-6), F. 
interleukin 10 (IL-10) and G. interleukin 17 (IL-17). Shown are the means +/- SEM per group. 
Statistical significant differences between different groups are marked by asterisks (*: P < 0.05, **: P 
< 0.01, ***: P < 0.005, n.s.: not significant). 
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7.3. Discussion 
 
Experiments investigating the accumulation of perfluorocarbon emulsions in the S. aureus 
thigh infection model during antibiotic therapy in chapter 6 raised the question whether 
antibacterial compounds feature an effect on the immune system besides their antibacterial 
action. In more detail, oxacillin treatment resulted in only slightly lower 19F values (overall 
signal and volume) at the abscess area than the 0.9 % NaCl group, although the CFU counts 
in the thigh muscle were reduced strongly. Other antibiotic treatments in the imaging 
experiment to evaluate the efficacy of lysostaphin (chapter 6) did not show likewise results. 
Literature research to explain this observation elucidated that various antibacterial 
compounds can have immunomodulatory effects in addition to the antibacterial activity. Of 
special interest for this work was the discovery that β-lactam antibiotics like oxacillin can 
lead to increased release of pro-inflammatory cell wall components from dying bacteria (van 
Langevelde P et al. 1998, van Langevelde P et al. 1999). Furthermore, macrolides and 
tetracyclines can exhibit distinct effects on the release of cytokines and chemokines or upon 
the migration behavior of phagocytes (Tauber SC, Nau R. 2008). As an example, treatment 
with minocycline, a tetracycline, resulted in a murine brain abscess model with minocycline-
resistant S. aureus to reduce the levels of IL-1β and MCP-1 (Kielian T et al. 2007). 
In order to evaluate immunomodulatory effects of antibiotics in vivo, different antibacterial 
compounds were administered during course of infection in the murine S. aureus thigh 
infection model. Vancomycin, oxacillin and linezolid were used for this series of experiments 
due to the comparability with results from former chapters 5 and 6. Minocycline was added 
to this investigation because of its above-mentioned possible immunomodulatory effects. 
Since oxacillin should receive special attention due to the observations with 19MR imaging in 
the last chapter, two different S. aureus strains were used to infect the animals: S. aureus 
Xen29 and S. aureus LAC (USA300). S. aureus Xen29 is the bioluminescent strain which was 
applied in former experiments of this thesis and should therefore be included in these 
experiments. This strain is oxacillin sensitive and hence should display direct and indirect 
immunomodulatory effects of oxacillin therapy in vivo. S. aureus LAC in contrast is a ca-
MRSA strain and thus oxacillin resistant. Oxacillin should only be able to induce direct 
immunomodulatory effects in the thigh infection model with this strain, but not indirectly via 
its antibacterial activity (which might lead, as shown in former publications (van Langevelde 
P et al. 1998, van Langevelde P et al. 1999), to increased release of pro-inflammatory cell 
wall components). 
The efficacy of the antibiotic treatments to reduce bacterial burden and therefore eliminate 
or reduce the source of immune stimulating pathogens has, of course, to be taken into 
account. In order to determine the efficacy, the infected thigh muscles were recovered at 
day 5 p.i., homogenized and the CFU counts measured. In the MSSA infection experiment 
with S. aureus Xen29 the highest numbers of viable bacteria could be detected for the 0.9 % 
NaCl group, while every antibiotic regimen led to significantly reduced values. The strongest 
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reduction was seen for the minocycline group, the weakest one for the vancomycin treated 
mice. In terms of efficacy pattern, the results are congruent with the experiments in 
chapters 5 and 6 (Tab. 7.1), although linezolid treatment showed much weaker efficacy in 
reducing the CFU counts in the experiments of this chapter (around 1 log10 unit reduction in 
chapter 7 vs. 6 log10 units in chapter 5). Moreover, it has to be stated that vancomycin and 
oxacillin groups showed slightly weaker efficacy in this chapter than in the prior chapters. 
But important for this comparison is that the infected thigh muscles were not recovered at 
the same day p.i.. The thigh infection model in chapters 5 and 6 and, more importantly, the 
antibiotic treatment (twice a day) was continued until day 7 p.i., while the animal 
experiments of chapter 7 were ended at day 5 p.i.. The experiments of these chapters 
deliver moreover no information about the development of bacterial burden during these 
two additional days of infection and therapy. This has to be taken into account when 
comparing CFU results of these chapters. Besides this discrepancy in the time point of 
muscle recovery, the differences in infectious dose should be considered, too. The infectious 
dose was slightly lower than in the former experiments. This resulted in lower CFU counts 
for the 0.9 % NaCl group at the end of the experiment, too, thus maybe impeding the 
efficacy of antibiotics to reduce bacterial burden even stronger. And lastly, different batches 
of antibiotics were employed in chapters 5, 6 and 7, and although they were supplied by the 
same companies, there might have been slight variations in their composition or efficiency. 
 
Tab. 7.1: Comparison of CFU values in the infected thigh muscle at the end of the experiment in the 
different chapters of this thesis. Different antibiotics were applied with the same dosing and 
treatment interval in different chapters and thus results are comparable. All mice were infected with 
S. aureus Xen29 in the left thigh muscle and antibiotic therapy was initiated 2 hours p.i. (then 
continued every 12 hours). The infected thigh muscle was recovered at the indicated time point 
(different between chapters 5/6 and 7), homogenized and the number of viable bacteria determined 
after plating of serial dilutions. Shown are the median values of the respective groups. n.d.: not 
determined, this antibiotic treatment was not included in the experiments of these chapters. 
 chapter 5 chapter 6 chapter 7 
infection: 3.2 x 108 CFU 
muscle recovered: d7 p.i. 
infection: 2.4 x 108 
muscle recovered:d7 p.i. 
infection: 2.0 x 108 
muscle recovered: d5 p.i. 
0.9 % NaCl 2.39 x 10
9 8.84 x 108 6.39 x 108 
Vancomycin  
(30 mg/kg/d) 
2.5 x 107 1.25 x 108 2.76 x 108 
Oxacillin 
(200 mg/kg/d) 
n.d. 5.1 x 107 7.80 x 107 
Linezolid 
(15 mg/kg/d) 
1.2 x 103 n.d. 5.00 x 107 
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Since S. aureus Xen29 is a genetically modified strain and harbors the luxABCDE operon of 
Photorhabdus luminescens, in vivo detection of luciferase activity and thus bacterial burden 
by an optical imaging system was possible (Francis KP et al. 2000). The pattern of photon 
emission over time was congruent with former imaging experiments in this thesis, namely a 
strong signal immediately after injection, that drops strongly within the first 24 hours to 
recover to a lower than initial plateau phase from day 3/4 p.i. until the end of the 
experiment. All antibiotic treatments led to reduction of average radiance signal from day 1 
p.i. on. The degree of signal reduction was dependent on the efficacy of the applied 
antibiotic and followed the outcome of CFU determination. More precisely, minocycline 
resulted in lowest values and vancomycin in the highest ones of the antibiotic treatment 
groups, although all of them entailed significantly lower levels than the 0.9 % NaCl group. In 
this regard, the reduction of bioluminescent signal by antibiotic treatment was in magnitude 
similar to those seen in chapters 5 and 6, indicating consistency of bioluminescence imaging 
as modality to evaluate the efficacy of antibacterial treatment. 
The CFU determination in the S. aureus LAC thigh infection model of this chapter showed, 
with the exception of the oxacillin group, the same efficacy pattern of the applied antibiotics 
than the S. aureus Xen29 thigh infection model. Minocycline treatment reduced the bacterial 
burden strongest, followed by linezolid and vancomycin had the weakest effect. Oxacillin 
showed no significant reduction of CFU values compared to the 0.9 % NaCl group. This had 
to be expected since S. aureus LAC is resistant to this β-lactam antibiotic. Overall, the 
reduction of bacterial burden was slightly stronger than the reduction in the S. aureus Xen29 
infection model, but the overall pattern similar (with the exception of oxacillin due to 
resistance). 
S. aureus LAC does not harbor a luciferase gene and thus does not emit luminescent signal, it 
was possible to apply Luminol based myeloperoxidase imaging, a recently developed in vivo 
method (Gross S et al. 2009, Tseng JC and Kung AL. 2013). Luminol solution was therefore 
administered intra-peritoneally at days 1, 3 and 5 p.i.. Neutrophil derived myeloperoxidase 
cleaves luminol in vivo and this leads to photon emission in the blue light spectrum. This 
luminescent signal can be detected by an optical in vivo imaging system. Administration of 
luminol resulted at all three time points to detectable luminescence signal for all groups. 
Interestingly, the strongest photon emission could be measured for the minocycline group at 
all three days, even though therapy with this antibiotic led to strongest CFU reduction in this 
model. The other groups, including the 0.9 % NaCl group showed variations in their signals, 
but remained at similar levels. This was very surprising, because the activity of 
myeloperoxidase was thought to be connected to the number of neutrophils. But since 
abscesses were much smaller in the minocycline group than, for example, in the 0.9 % NaCl 
group, one would assume that there are higher numbers of neutrophils at the site of 
infection in the 0.9 % NaCl group and thus higher luminol derived luminescence signal. In 
this context, it seems more reasonable that luminol imaging signal is not a benchmark for 
number of neutrophils, but for the activity or myeloperoxidase expression and release of the 
neutrophils. In consequence, these results suggest modulation of neutrophil activity at the 
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site of infection by minocycline, but further experiments are necessary to confirm these 
results and to identify the possible mechanism of modulation. 
Since S. aureus Xen29 expresses a chromosome-located luciferase and thus emits photons in 
the blue light spectrum (overlapping signal with luminol luminescence) by itself, luminol 
imaging of myeloperoxidase activity was not possible with this strain. 
The main focus to determine possible immunomodulatory effects was the release of 
cytokines and chemokines at the site of infection since these molecules are central elements 
in regulation of immune cell attraction, migration and activity. On this account the antibody-
conjugated bead assays were selected to measure the concentrations of various highly 
relevant cytokines/chemokines in the infected thigh muscle. In this context, the chemokine 
bead assays covered: MCP-1, MCP-3, MIP-1α, MIP-1β and RANTES, while the cytokine bead 
assay included beads to measure IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, TNFα, IFNγ and GM-
CSF levels. In order to measure the concentration at the site of infection, the thigh muscles 
were recovered, homogenized and filtered to exclude cells. In general, high amounts of IL-
1α, IL-6, MCP-1, MCP-3, MIP-1α and RANTES could be detected in the infected thigh muscle, 
independently of the applied pathogen. GM-CSF and MIP-1β, in contrast, were found only at 
very low to almost negligible amounts. 
Interestingly, two general patterns of chemokine/cytokine release dependent on the 
antibiotic therapy were found at the site of infection with both S. aureus strains (illustrated 
in Tab. 7.2). The first group of chemokines/cytokines mirrored the efficacy pattern of 
antibiotics. In more detail, the highest amount of release was detected for the 0.9 % NaCl 
group and the lowest values for the minocycline group in both murine models, as both 
groups had either the highest or lowest CFU counts at day 5 p.i. Members of this group in 
models with both pathogens were the cytokine IL-1α as well as the chemokines MCP-1, 
MCP-3 and MIP-1α. All of them were released in the pattern of CFU reduction by antibiotics 
therapy, independently of possible immunomodulatory effects. 
Two variations of this pattern were found in the murine models. First, in the S. aureus Xen29 
model, higher titers of cytokines IL-6 and IL-10 were found for the oxacillin group in the thigh 
muscle homogenizations than expected from CFU determination. In more detail, although 
oxacillin reduced CFU burden efficiently, the titers of these two cytokines were similarly high 
than those of the 0.9 % NaCl group. The second variation of this first general pattern was 
seen in the S. aureus LAC infection model. The linezolid group exhibited similar values of 
TNFα and IL-10 than 0.9 % NaCl and oxacillin groups, although CFU counts were lower. 
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Tab. 7.2: Different patterns of cytokine or chemokine levels at the site of infection at day 5 p.i.. 
Mice were infected either with S. aureus Xen29 (center column) or LAC (right column) and received 
antibiotic or mock therapy during course of infection. Muscles were recovered at day 5 p.i., 
homogenized and the titers of various cytokines/chemokines in the homogenization measured with 
flow cytometry based bead assays (FlowCytomix, eBioscience). The two general patterns of release in 
response to antibacterial therapy and the variations of these general patterns are indicated by the 
multicolored bar charts. 
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The second general pattern of chemokine/cytokine titers showed similar values for all 
treatment groups, independent of the applied antibiotic. IL-2 exhibited this behavior in 
models of both pathogens, while the titers of IL-4, IL-5, IL-6 and IFNγ resembled a similar 
level between all treatment groups in the S. aureus LAC infection model, too. Variations of 
this general pattern were the elevation of distinct cytokine/chemokine titers in either the 
oxacillin or the minocycline group. Interestingly, minocycline treatment led in the 
experiments with both pathogens to increased values of RANTES compared to the other 
groups, suggesting a general phenomenon. Oxacillin treatment led in the S. aureus Xen29 
experiment to higher values of TNFα, IFNγ, IL-4, IL-5 and IL-17 than all other groups. 
In consequence, antibiotic treatment, especially with oxacillin, but also with minocycline or 
linezolid led to variations in the levels of various cytokines and chemokines in the infected 
thigh muscle that did not correspond to the reduction of bacterial burden. The hypothesis, 
the lower the bacterial burden, the lower the level of cytokines and chemokines, especially 
pro-inflammatory ones like TNFα or IL-1, did not fit for all of the antibacterial treatments. It 
might be interesting to study these differences in more detail. It might be especially 
interesting to investigate whether this deregulation of cytokine/chemokine release causes 
beneficial or harmful effects in the case of resistant bacteria. This might, in consequence, led 
to approaches to regulate the immune response during infection in order to achieve an 
increased clearing of the pathogens, more efficient immune response or even accelerated 
wound healing and faster recovery from disease. In conclusion, the cytokine and chemokine 
results indicate that oxacillin treatment induced at least slightly a pro-inflammatory 
environment. This might lead to elevated migration and/or increased level of neutrophil 
activation, which in consequence causes stronger accumulation of perfluorocarbon emulsion 
at the site of infection. Nonetheless, to date, no experiments were performed to elucidate 
the number of neutrophils at the site of infection, therefore this hypothesis has to be 
evaluated in a further set of experiments in future. 
Nonetheless, possible immunomodulatory effects of antibacterial compounds should be 
taken into account for future imaging studies with this platform. On the other hand, this 
observation offers completely new applications for 19F MRI with perfluorocarbons. Since 
several new approaches to fight S. aureus infections are based on the immune system, for 
example passive or active immunization or immunomodulatory peptides (Mookherjee N et 
al. 2007, Ohlsen K and Lorenz U. 2010), it might be interesting and maybe even necessary to 
study the effects in vivo. 19F MRI with perfluorocarbons might be an interesting choice to 
study the migration of neutrophils or, with the help of targeted perfluorocarbon emulsions, 
other immune cell populations. Furthermore, combining this imaging modality with a second 
imaging modality which enables the visualization of the bacterial burden in vivo, like 
bioluminescence imaging, might offer completely new insights into host-pathogen 
interaction. 
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This study comprised two different goals and questions: first, is in vivo imaging in general 
and magnetic resonance imaging in particular useful, maybe even beneficial in preclinical 
evaluation of promising new compounds to fight S. aureus infections? And second, how 
efficient is lysostaphin, a new, promising antibiotic drug candidate, as treatment option 
against S. aureus in clinically relevant murine models? 
The experiments of chapter 4 aimed at the first question, a rather new field of scientific 
investigation. Since bioluminescence imaging of infections in preclinical disease models was 
in principle investigated by several former studies (Contag CH et al. 1995, Francis KP et al. 
2000, Kadurugamuwa JL et al. 2003b, Kuklin NA et al. 2003), the main goal of this thesis was 
the evaluation of magnetic resonance imaging as preclinical infection imaging modality. 
Thus, based on the few MR imaging experiments performed so far to visualize sites of S. 
aureus infection in preclinical models (Marzola P et al. 1999, Kaim AH et al. 2002, Kaim AH et 
al. 2003), different MR methods, native and contrast agent/tracer based, were applied in 
this thesis and evaluated for their infection imaging capability. In the end, 19F MRI with 
perfluorocarbons delivered the best, unobstructed view upon the extend and severity of 
infection. Most of the experiments in this chapter were consequently conducted to 
determine the accumulation mechanism and kinetics in more detail. The perfluorocarbon 
emulsion accumulation was dependent on the number of bacteria in the infected thigh 
muscle and delivered detectable 19F signal at earliest when administered at day 1 or 2 p.i., 
but signal then remained rather stable until the end of the experiment. Interestingly, 
perfluorocarbon emulsion accumulated in all experiments at the rim of the abscess area, in 
the shape of a ‘hollow sphere’. Taken together, this suggested that accumulation is 
connected to a robust immune response. Flow cytometry, cell sorting and histology 
experiments were performed in order to elucidate this hypothesis. They showed that most 
of the perfluorocarbon derived fluorescence could be detected in neutrophils, smaller 
amounts were found in monocytes, macrophages and dendritic cells, too. Most of the 
perfluorocarbon emulsion could be considered as cell associated, proving immune cell 
dependent accumulation and contradicting unspecific cell-independent accumulation. In 
conclusion, 19F MRI of perfluorocarbon emulsion accumulation visualizes the accumulation 
of immune cells, more specific of neutrophils, at the site of infection. This offers, in 
consequence, a completely new perspective for this imaging modality. It might be 
interesting to study differences in the immune response by this modality. For example, since 
S. aureus harbors an extensive amount of factors that interfere with the immune system, it 
might be extraordinarily interesting to study the effects of depletion or overexpression of 
these factors upon the migration of neutrophils in vivo in the mouse model. Furthermore, a 
new, experimental approach to combat infections is the application of compounds that 
modulate the immune response in order to enable a more efficient clearing or inactivation 
of pathogens. 19F MRI with perfluorocarbon emulsion might offer a powerful tool to 
investigate the influence of these compounds upon immune cell activation and migration. In 
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consequence, this imaging modality might give completely new insights into host-pathogen 
interaction and the influence of antibacterial therapy upon the host. 
Nonetheless, the aim of this thesis was to integrate MR imaging into a preclinical small-
animal antibiotic evaluation platform. Therefore, chapter 5 focused on the application of 19F 
MRI with perfluorocarbon emulsion during treatment with clinically relevant antibiotics 
against S. aureus: vancomycin and linezolid. Both antibiotics showed reduction of colony-
forming units and bioluminescence signal, the second imaging modality which was 
integrated into the preclinical testing platform to visualize the photon emission of a 
luciferase integrated into the genome of S. aureus. In consequence, both methods indicated 
efficient antibacterial activity of both compounds, with linezolid being more efficient. 19F 
MRI visualized differences in perfluorocarbon accumulation at the site of infection. 
Treatment with either vancomycin or linezolid led to smaller abscess areas, indicated by the 
‘hollow sphere’ accumulation pattern of the tracer. 19F signal strength and volume were 
reduced for both treatment groups compared to the mock-treated control group, with 
linezolid showing stronger reduction. In conclusion, 19F MRI with perfluorocarbon emulsion 
indicated efficacy of vancomycin or linezolid in the murine S. aureus thigh infection model 
with similar results than colony forming unit determination or bioluminescence imaging. 
In chapter 6, a promising compound against S. aureus infection was tested in the preclinical 
antibiotic evaluation platform established in chapters 4 and 5: lysostaphin. This 
endopeptidase cleaves specifically the cell wall of S. aureus and is currently in preclinical 
testing for application in human disease. Two different clinically highly relevant murine 
models of S. aureus, the catheter-associated and the thigh infection model, were applied to 
evaluate the efficacy of lysostaphin in two concentrations and in combination with oxacillin. 
Lysostaphin showed in both models, dependent on concentration, efficient reduction of 
bacterial burden in terms of colony-forming units and bioluminescence signal. The 
combination of lower dose lysostaphin with oxacillin showed similar efficacy than higher 
dose lysostaphin, being in many parameters superior to vancomycin or oxacillin only. 19F MR 
imaging showed in the thigh infection model clear reduction of both perfluorocarbon 
emulsion accumulation strength and volume, indicating smaller sites of infection and less 
pronounced immune cell immigration than in vancomycin or control groups. Surprisingly, the 
perfluorocarbon emulsion accumulation in oxacillin and oxacillin/lysostaphin treated groups 
was stronger than expected from colony forming unit and bioluminescence signal 
determination. This might indicate a pro-inflammatory modulation of immune response by 
oxacillin, which led to a stronger migration of neutrophils to the site of infection, although 
the bacterial burden was reduced efficiently. 
In order to investigate this possible immunomodulatory effect of antibiotic therapy in vivo, 
the levels of various cytokines and chemokines at the site of infection were measured in 
chapter 7 in order to evaluate differences between different antibiotic treatments. To 
evaluate whether oxacillin shows its potential immunomodulatory effect either indirectly via 
its action against the bacteria or directly by influencing the immune cells, two different 
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strains of S. aureus were applied in the thigh infection model: the oxacillin-sensitive strain 
Xen29 and the oxacillin-resistant strain LAC (USA300). Two principal patterns of cytokine and 
chemokine release could be seen. The first one showed release dependent on the efficacy of 
reduction of bacterial burden at the site of infection. In more detail, the fewer bacteria 
survived the antibiotic treatment, the less cytokines / chemokines could be found. 
Prominent members of this group were the chemokines MIP-1α, MCP-1 and the cytokine IL-
1α. The second pattern showed similar levels of cytokines / chemokines at the site of 
infection independent of the efficacy of the applied antibiotic. This could be seen for the 
cytokine IL-2. Interestingly, some chemokines / cytokines seemed to be differently released 
or regulated in oxacillin, linezolid or minocycline treated mice. RANTES was found in 
minocycline treated mice in higher levels, than in all other groups, who showed a rather 
uniform level. IFNγ, IL-4 and IL-5 showed similar levels for all groups with the exception of 
oxacillin treatment which exhibited in the Xen29 background higher values. Linezolid and 
oxacillin, finally, showed elevated levels of IL-10 dependent on the sensitivity of the S. 
aureus strain. In summary, antibiotic treatment led to differential levels of cytokines and 
chemokines at the site of infection. These differences were not always linked to a reduction 
of bacterial burden, but indicated in some cases direct or indirect immunomodulation. 
Nonetheless, these experiments are only the first steps in the investigation of possible 
immunomodulatory effects of antibiotics in vivo. The effects upon cellular immune response 
as well as on the immune system’s memory were not even addressed by these experiments. 
But in conclusion, 19F MRI with perfluorocarbons might be a very interesting method to 
study the influence of therapy upon immune cell behavior in vivo in more detail. It might 
visualize differences in neutrophil migration behavior and activation during course of 
infection and should be applied in further studies dealing with this subject. 
In conclusion, 19F MRI with perfluorocarbon has proven its value as a platform to image 
both, the course of infection and the efficacy of new promising antibacterial compounds 
non-invasively. It has furthermore been demonstrated, that this imaging modality is prone to 
modulation of the immune response. Although this has to be taken into account during 
antibiotic evaluation, it offers on the other hand a wide field of new applications. The effects 
of immunomodulatory compounds might be visualized in vivo and non-invasively in various 
disease models by this method. It might be used to study the effects of active or passive 
immunization approaches against S. aureus or other pathogens, but it might moreover be 
applied to study immunomodulators or immunization strategies against cancer or disorders 
of the immune system, too. In this study, only untargeted perfluorocarbon emulsions were 
applied as tracer, but the establishment of a protocol to emulsify fluorescently-labeled 
liposomes offers the opportunity to construct surface-functionalized targeted emulsions. 
These particles might aim at either bacteria in order to visualize bacterial burden directly or 
at specific immune cell populations to determine their importance, migration behavior or 
activity during course of infection. Most importantly, the 19F MR sequence applied in this 
study, chemical shift imaging, offers the distinction of different perfluorocarbons in the core 
of the emulsions. Thus, it is possible to target various cell populations, bacteria and immune 
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cells, during course of infection with different targeted perfluorocarbon emulsions and 
visualize and distinguish their accumulation at the same time in the same animal. 
Furthermore, it is possible to study differences in the migration behavior at different phases 
of infection in the same animal by the administration of emulsions with different core 
perfluorocarbons at different time points. These ‘multi – color’ options are superior to, for 
example, gadolinium or iron oxide based MRI, positron emission tomography or classical 
bioluminescence imaging, since it offers the simultaneous acquisition of more than one 
parameter. Moreover, 19F MRI with perfluorocarbon does not interfere with anatomical 1H 
MRI and thus offers unbeatable 3D tissue contrast, which is one of the most important 
advantages of MRI. 
In summary, 19F MRI with perfluorocarbons proved to visualize sites of S. aureus infection by 
accumulation in neutrophils and other phagocytic immune cells. It furthermore proved to be 
useful in evaluating the efficacy of antibiotic compounds and drug candidates in preclinical S. 
aureus infection. Nevertheless, perfluorocarbon emulsion imaging with 19F MRI might offer 
further interesting applications, for example, in the evaluation of immunomodulators or 
immunization approaches, but also in revealing deeper insights of host – pathogen 
interaction by targeting and tracking pathogens or immune cells in vivo. 
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